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Chapter 1
Introduction
Every observation is the result of endless interactions. Constant interactions on all layers,
large and small, are defining the progression of all human beings and are shaping us to be
the individuals we are, or seem to be. Upbringing and social challenges, exposure to various
environments, choices of food and the need to take certain drugs, regular work times or
frequent night shifts, these and many other aspects are relevant for behavior, preferences,
health and disease. They can influence our food preferences and our motivation for physical
activity as well as how we interact with other people. In addition to and in combination
with our inherited genetic background, the above mentioned factors can interact with the
host metabolism. Interactions with environmental factors can, for example, modify our
genome by introducing epigenetic modifications but can also change the composition of
symbiotic bacteria living on the host. Both processes are known to play a crucial role in
physiological and pathophysiological processes and especially the latter will be discussed
in this thesis.
1.1 A brief history on the study of microbes
Going way back in the history of evolution, there is evidence that the first eukaryotes
are a product of interaction, or symbiosis, of single-celled prokaryotes, which includes
bacteria and archaea. This theory of endosymbiosis was first described by Konstantin
Mereschkowski [1, 2] and later enhanced by Lynn Margulis [3]. Briefly, the theory as-
sumes that ancient cyanobacteria and α-proteobacteria invaded archae and transformed
from symbionts to cell organelles like plastids and mitochondria. Only recently, with the
rise of next generation sequencing, new progress was made to uncover the origin of eu-
karyotic cells. A novel archaeal species, Candidatus Lokiarchaeum, was identified, which
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Figure 1.1: The evolution of life; A) Phylogenetic tree, adapted from [5] and B) a brief
history on the evolution of life based on [9, 11, 12, 18];
by: billion years, my: million years, ty: thousand years
the closest living relative to the last eukaryotic common ancestor [4, 5] (Figure 1.1 A).
The nucleus is another cell compartment thought to be developed by interactions, in this
case by evolution of large DNA viruses [6]. This theory recently was backed up by the
discovery that a giant bacteriophage (201φ2-1) assembled a nucleus-like structure after
infection of bacterial cells [7]. Further proof for the lasting interaction between the virus
world and eukaryotic cells can be found in our DNA, of which large parts are of retroviral
origin [8]. Thus, about one and a half billion years ago life started to develop in three
domains: prokaryotes, archae and eukaryotes [9–11] (Figure 1.1 A and B).
Jumping in time for a few hundred million years Homo sapiens appeared, and the history
of the development and distribution of modern humans is also a history of interactions
1 Introduction 3
with bacteria. Bacteria not only accompanied but evolved with us as we developed from
great apes [12], at some point loosing bacteria that are still inhabiting great apes, which
can help to explain “human” diseases like mental disorders and obesity, as many such
diseases are closely linked to alterations in bacteria living in symbiosis with the host
[13–17]. Along with modern humans, bacteria living in symbiosis were spreading from
Africa around the globe, and, similar to humans, constantly adapting to the new en-
vironments [18–20] [Figure 1B]. For example, sequencing analysis of Heliobacter pylori
populations from various geographical and ethnic human grouping revealed a congruent
migration [19]. The majority of studies on the human microbiome, that is “the biotic and
abiotic habitat comprising the community of microorganisms associated with the human
host” [21], was performed by analyzing stool samples, which mostly reflect the microbiome
of the large intestine, as well as samples from the oral cavity and the skin [22]. The large
intestine harbors about 3.8 x 1013 bacteria, by far the greatest amount of bacteria on the
human body [23].
1.2 The human gut microbiome
Coming back to the adaptation of bacteria, it has been acknowledged that in current times
the microbiome of “Western” populations varies greatly from “non-Western” communi-
ties [21]. In general, the microbiome of the latter is more divers, most likely attributed
to the different diet rich on fibers, but with poor content of sugar, fat and meat [24, 25].
Other contributors include differences in medical treatment and hygiene, close contact
with animal or septic environments, the extensive use of antibiotics in early life [26–28]
or, as mentioned before, the divergence of bacteria with the migration of humans [19]. As
the study of the microbiome is a relatively new field of research [29], it was only recently
recognized as a major factor in health and disease by the research community. Although
the discovery of bacteria derived from human samples dates back to the late 17th century,
when van Leeuwenhoek described and drew five “animalcules” (as he referred to bacteria)
[30, 31] and progressed with the work of Pasteur, Koch, Escherich and others [30, 32], the
human microbiome research really took off in the 1990ies when the first studies based on
16S rRNA gene sequencing were published [33, 34]. By transition from culture-dependent
to culture-independent approaches, identification of bacteria became faster and allowed
the detection of non-cultivable bacteria [35]. Until recently, sequencing of the 16S rRNA
gene, the gene of the small ribosomal subunit of bacteria, was the most suitable method, as
this region has nine highly variable regions allowing a proper assessment of the taxonomy
[36, 37]. However, powerful metagenomic approaches are becoming more attractive and
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Figure 1.2: Bacterial diversity, influencing factors and functions of the micro-
biome; based on [42]
The first large comprehensive studies on the human microbiome in health and disease
started in 2008 with the Human Microbiome Project [39, 40] and the metaHit consor-
tium [41] and further research vastly increased the knowledge on the human microbiome
[42–44]. The microbiome starts to form with the delivery of neonates, a theory recently
challenged as controversial studies reported the presence of bacterial DNA in the placenta
of healthy mothers [45] and the amniotic fluid of preterm infants [46]. In the beginning
bacterial diversity is relatively low and its development is dependent on the mode of de-
livery [47–49], breast feeding [49, 50] and diet [51, 52], dietary supplements [51] and drugs
[53], exposure to environmental microbes [54] and compounds [55] as well as infections
[56] and many other factors [42] (Figure 1.2).
The bacterial diversity gradually increases until puberty and decreases with increased age.
A healthy microbiome plays an important role in the host physiology [57]: It provides and
aids in vitamin, folate, cobalamin and steroid hormone biosynthesis [58–60], fermentation
processes as well as diet-related metabolic processes including glutamine and amino acid
degradation [42] (Figure 1.2). Therefore, it is not surprising that alterations of the in-
testinal microbiome are often linked to pathological states and are associated with many
diseases including atherosclerosis [61, 62], asthma [63] and cancer [64, 65]. Likewise, the
reduced prevalence of life style diseases such as obesity in “non-Western” populations and
the strong increase in type 2 diabetes prevalence worldwide is partially transmitted by
our microbiome and alterations in its composition [66, 67].
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1.3 Obesity is a multifactorial disease
Obesity is a major health burden with increasing prevalence worldwide: 2015 about 107
million children and 603 million adults worldwide were obese and prevalence has doubled
in over 70 countries since 1980 [68, 69]. In Germany over 50% of all adults are overweight
and the prevalence of obesity is about 18% [70]. The world health organization (WHO) de-
fines overweight and obesity according to the body mass index (BMI): Overweight ranges
from 25 to 29.9 kg/m2 and obesity begins at 30 kg/m2 [71], but is further divided in three
stages (class I to III) in increments of 5 kg/m2. Obesity is associated with many adverse
effects which is ultimately highlighted by a strong decrease in life expectancy [72]. This
might not only be attributable to obesity itself but to one or more comorbidities like type
2 diabetes, hypertension, dyslipidemia or cardiovascular diseases [72, 73].
In general, obesity results from an imbalance between energy intake and energy expendi-
ture strongly depending on physical activity. However, the physiological coordination of
hunger, nutrient absorption, energy storage and availability is one of the most complex
systems in the human body dependent on many factors, including our genome, epigenome,
environment and microbiome. Ultimately, the development of excess weight is not only
a consequence of these individual but rather of their mutual interactions, as briefly de-
scribed in the following paragraphs.
The genetic influence or heritability on certain phenotypes is usually addressed by twin
studies [74]. Early twin studies on pairs of identical and fraternal twins estimated that
between 40 and 70% of the observed variation in body weight is due to genetic factors [75,
76]. In 1997 Stephen O’Rahilly and Sadaf Farooqi provided first evidence in humans when
they found that mutations in the leptin gene caused obesity in affected children [77]. In
the following years more genes causing monogenic forms of obesity were identified, such
as the leptin receptor, proopiomelanocortin, melanocortin 4 receptor or proconvertase 1
[78, 79]. However, these genes alone cannot explain the large heritability of excess body
weight, only accounting for 7% of children with severe, young onset obesity [80]. With
the advance of high throughput genotyping technologies allowing genome-wide associa-
tion studies (GWAS), in 2007 two independent research groups reported that variants in
the FTO gene contributed to polygenic obesity [81, 82], which represents 90% of obesity
in developed countries like Germany [80]. These and further studies clearly proved, that
multiple genetic variants (e.g. single nucleotide polymorphisms – SNPs) are contribut-
ing to the development of human obesity [80, 83]. The improvement and cost-reduction
of sequencing and computational techniques allowed the identification and imputation
of millions of SNPs, subsequently revealing hundreds of new loci associated with the
development of metabolic diseases [84–87]. In addition to genetic factors, epigenetic mod-
ifications like DNA methylation or histone modifications seem to play a crucial role in
1 Introduction 6


























Figure 1.3: Adipose tissue is an metabolically active endocrine organ; based on
[90-94]
shaping body weight without altering the genome [83]. Ultimately, development of obe-
sity and associated traits is an effect of gene-environment interactions, as people with a
specific genetic background are prone to develop excess body weight only under specific
environmental conditions. Such excess in body weight can be counteracted by modulating
the environment, e.g. by changing diet and increasing physical activity [88].
1.4 Adipose tissue as an endocrine organ
Back to leptin: starting with its discovery in 1995 [89] adipose tissue was “rediscovered”
as an metabolically active endocrine organ with functions beyond energy storage, ranging
from regulating appetite and satiety, energy expenditure, insulin sensitivity and secretion,
glucose and lipid metabolism to an involvement in various inflammatory processes [90].
Most of these functions are linked to proteins produced and secreted by cells in the adipose
tissue (e.g. adipocytes and macrophages) which are called adipokines or adipocytokines
[90, 91] and are often hormones or cytokines transported by the circulatory system thereby
transmitting information to target tissue like the brain, liver or pancreas [92–94] (Figure
1.3). Apart from leptin, other important proteins predominantly expressed by adipose
tissue include, for example, adiponectin (which improves insulin sensitivity and regulates
fatty acid oxidation [95, 96]), or chemerin (which regulates adipogenesis [90, 97]), as well
as the pro-inflammatory cytokines TNF-α and IL-6 [90] (Figure 1.3).
Especially the latter highlight the important role of adipose tissue in inflammatory re-
sponses to obesogenic stimuli [91]. Both TNF-α and IL-6 levels are elevated in individuals
with insulin resistance [98, 99], and expression of TNF decreases with weight loss [100].
Functional evidence supporting a key role of TNF-α in insulin resistance stems from
leptin knockout ob/ob mice, that additionally lacked TNF-α, but had improved insulin
sensitivity compared to controls with sufficient TNF-α [101]. The increased presence of
free fatty acids in obesity is a further process identified to induce insulin resistance by
interacting with toll-like receptor 4 and subsequent activation of the Nf-κB cascade [102].
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Figure 1.4: Adipose tissue inflammation in obesity; based on [106-108]
TNF-a: tumor necrosis factor alpha, IL-6,1β: Interleukin 6 and 1 beta, MCP-1: monocyte chemoattractant
protein 1, MIF: macrophage migration inhibitory factor, CD: cluster of differentiation
accompanied by hypoxia [103], these factors can result in the death of adipocytes and
the recruitment of pro-inflammatory macrophages culminating in a vicious circle further
enhancing insulin resistance [104–108] (Figure 1.4).
Still, many processes involved in low grade adipose tissue inflammation and insulin re-
sistance are poorly understood and novel mechanisms might yet be discovered, as each
of them potentially only partially contribute to the observed phenotype. An example for
a recently discovered mechanisms is the role of microRNAs: microRNA-30 was linked
to metabolic inflammation by regulating Notch signaling [109], whereas microRNA-181b
improved glucose homeostasis [110]. Yet another novel mechanisms involved in adipose
tissue inflammation might be attributable to the microbiome, as described in the next
section.
1.5 Increased intestinal permeability is linked to in-
sulin resistance
A plethora of studies reported associations of compositional and functional changes in the
human gut microbiome with obesity and metabolic diseases [111–113]. Yet, first efforts
to gain insights into underlying mechanisms only emerged in the last decade [114]. Espe-
cially bacterial metabolites and toxins can interact with and influence the host [115, 116].
Already in 1991 Fasano et al. showed that a second enterotoxin of V. cholera reversibly
affects intestinal tight junctions [116] which would allow an influx of bacterial metabo-
lites via the paracellular pathway. The same group later identified a human homologue
to this enterotoxin with similar effects on tight junctions which they named zonulin [117,
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Figure 1.5: The ”tissue microbiota hypothesis”; based on [127]
EPEC: enteropathogenic E. coli, TLR: toll-like receptor, HLA: human leukocyte antigen, bact.: bacterial
(EPEC) [120] as well as food components such as glucose [121] and salt [122] are known to
increase intestinal permeability, which is associated with a number of metabolic disorders
[123–126]. Subsequently, bacteria or bacterial metabolites could enter the host circulation
or lymph system [127, 128], which is supported by increasing evidence for the presence
of bacterial DNA in the circulation, even in healthy subjects [128]. Both the amount of
bacterial DNA and lipopolysaccharide (LPS) are increased in individuals with obesity or
insulin resistance [128–130]. Based on these results, it was suggested that bacteria might
be able to travel to distant host tissues and in 2011 Amar et al. were able to track orally
administered GFP-labeled E. coli to adipose tissue and to quantify adipose tissue bacte-
rial DNA in mice [131]. Subsequently, Burcelin et al. formulated the “tissue microbiota
hypothesis”, suggesting that low concentrations of bacterial components in host tissues
can contribute to inflammatory processes and the development of metabolic diseases [127],
however human studies are scarce and the data is inconsistent [127, 132, 133] (Figure 1.5).
However considering the longtime of coevolution between bacteria and humankind it
would not be surprising, that bacteria not only colonized easy accessible places like the
gut or skin, but influence host physiology more directly by accessing and influencing host
tissues.
1.6 Subject and rationale
During my PhD thesis entitled ‘‘Bacterial translocation to adipose tissue in
metabolic disease’’, I aimed to find evidence for the translocation of bacterial com-
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ponents to human adipose tissue referring to the “leaky gut” hypothesis mentioned above
[134–136], and to study novel mechanisms possibly involved in adipose tissue inflammation
and insulin resistance, such as the role of the adaptive immune system [137, 138]. An ex-
tended rationale builds a preface to each manuscript chapter and is summed up in a larger
context here. The following chapter (Chapter 2 Impaired intestinal barrier: a pathomech-
anism for metabolic diseases?) is a review article summarizing the current knowledge on
causes and consequences of a leaky gut in metabolic diseases. According to a detailed lit-
erature search on the subject of intestinal permeability, bacterial translocation and tissue
bacteria in metabolic disease, zonulin appeared to be the most commonly used biomarker
to measure intestinal permeability [139–141]. As correlation studies of this biomarker with
metabolic traits were lacking sufficient statistical power due to limited sample sizes as well
as adequate statistical adjustments [142–144], circulating zonulin levels were measured in
the present study and analyzed in a large population based cohort [134]. It was contem-
plated to measure zonulin as a marker of intestinal permeability in the cohort used to
analyze bacterial translocation. However discrepancies in previous results and subsequent
experiments uncovered several issues including the fact that the only commercially avail-
able and widely used ELISA kit did not measure zonulin, but most likely properdin [134,
135] (see Chapter 3 Zonulin: a suitable biomarker for intestinal permeability?). Due to the
increased intestinal permeability, bacterial components can enter the host with first entry
points including the mesenteric lymph nodes and the gut capillary system [136]. Addition-
ally, two adipose tissue depots in close proximity to the gastrointestinal tract, mesenteric
and epiploic adipose tissue were considered prime targets for bacterial translocation and
a possible gut – adipose tissue crosstalk. As both tissues have been poorly investigated so
far, they were extensively characterized by measuring inflammatory markers, whole tis-
sue transcriptomics, methylomics and untargeted proteomics and compared to commonly
studied omental and subcutaneous adipose tissue (see Chapter 4 Epiploic adipose tissue:
the watchdog at the gates to insulin resistance?). Mesenteric- and omental-visceral as well
as subcutaneous adipose tissue were thereupon analyzed in regard to the presence of bac-
terial DNA to provide further evidence for the “leaky gut” hypothesis. After an extensive
method optimization to establish contamination-aware methods, bacterial DNA content
was quantified and sequenced. Furthermore, I analyzed functional consequences of the
presence of bacterial DNA in human adipose tissue (see Chapter 5 Bacterial translocation
to human adipose tissue in metabolic disease). Finally, I aimed to study the role of the
human leucocyte antigen (HLA) genomic region in type 2 diabetes, to test the associa-
tion of the adaptive immune system with increased adipose tissue inflammation, insulin
resistance or bacterial translocation as previously suggested [145, 146] (see Chapter 6
Identification of MHC-II alleles contributing to the development of type 2 diabetes).
Chapter 2




The hypothesis, that the translocation of bacteria, bacterial cell wall components, metabo-
lites or DNA into the mammalian circulation and further into distant tissues via an
increased intestinal permeability emerged only recently [127]. Due to the lack of well-
controlled studies in both human and animal models as well as the lack of mechanical
experiments, the validity and impact of this hypothesis is often challenged [127, 147]. This
became evident in the ongoing placenta microbiome debate: 2014 Aagaard et al. provided
data suggesting that the placenta harbors a unique microbiome [45], despite some sup-
port by others [148, 149] it quickly became evident that, when comparing with adequate
controls, the presence of a placenta microbiome might be a false positive result [150, 151].
This debate and the publication of both positive and negative results is still ongoing al-
though recent data by de Goffau et al. strongly suggest the lack of a microbiome but the
presence of potential pathogens in the placenta [152].
The detection of bacterial DNA and components such a lipopolysaccharide, as well as
the measurement of intestinal permeability is highly challenging [139, 147, 151]. Briefly,
this is mostly attributed to the excess of human DNA in tested samples, the need of
adequate controls [151], shortcomings in the measurement of LPS [147] and the lack of
well-established biomarkers for intestinal permeability [139]. Therefore, I performed an
extensive literature search to compile evidence of increased intestinal permeability in
metabolic disease and consequences thereof and focused on studies with state-of the art
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and gold standard methods as well as sufficient negative controls. This immensely helped
in designing and evaluating my own experiments presented in the Chapters 3-6.
The relevant literature search resulted in the publication of a brief review article on the
evidence of a leaky gut in metabolic syndrome [136]. A considerably broader and ex-
tended review on the general causes and consequences of increased intestinal permeability
in metabolic disease was submitted just recently and is included in this thesis (Chapter
2.2).
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2.2.1 Abstract
An intact intestinal barrier, being at the interface of the inner and outer environments, rep-
resents an integral regulator of health. Among several factors, bacteria and their products
have been evidenced to contribute to gut barrier impairment and increased permeability.
Alterations in the normal tight junctions function - caused by both external factors and
host metabolic state - are important for gut barrier and an impairment leads to increased
influx of bacteria or bacterial components (endotoxin or bacterial DNA) into the circu-
lation. Increased systemic levels of bacterial endotoxins and DNA have been associated
with an impaired metabolic host status manifested in increased weight and obesity, in-
sulin resistance, and their associated cardiovascular complications. To this end, bacterial
components and cells are distributed to peripheral tissues via the blood stream, where
they may contribute to metabolic diseases by increasing chronic pro-inflammatory signals
at the tissue and systemic level via toll-like recpetor transduction, increased expression of
pro-inflammatory cytokines and many other, partially unknown mechanisms. Circulating
inflammatory markers can further enhance intestinal permeability leading to a negative
feedback loop. The modulation of gut barrier function through nutritional and other inter-
ventions, including manipulation of gut microbiota, may represent a potential prevention
and treatment target even for cardio-metabolic diseases.
2.2.2 Introduction
While the obesity and T2D pandemics are increasing at alarming rates (1), new factors
relevant to the lack of adaptation towards the increasingly rapid changes in our environ-
ment have been proposed as possible perpetrators. Among those, the intestinal microbiota
and its interactions with host metabolism and immune system have been acknowledged
to influence and contribute to several diseases including gastrointestinal disorders such
as inflammatory bowel diseases (2) and more recently the plethora of metabolic and car-
diovascular diseases (3, 4), although the underlying mechanisms are still unknown (5–7).
One poorly understood feature of metabolic disease is the alteration and dysfunction of
the intestinal barrier accompanied with an increase in intestinal permeability. While the
influx of microbial products has been suggested to underlie chronic inflammation observed
in metabolic disease and more specifically type 2 Diabetes (T2D) (8), clinical features of
metabolic diseases such as hyperglycemia in T2D have been associated with increased mi-
crobial products influx in humans reflective of glucotoxicity (9). First studies in the 1950s
suggested that increased endotoxins, which are lipopolysaccharides of gram-negative bac-
teria in the circulation are a result of an increased intestinal permeability(10). Although
debated, independent studies in mice and humans could confirm these results (11). Ten
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years later, the term “leaky gut” was first introduced when Bjarnason and colleagues re-
ported that patients with increased alcohol consumption developed increased intestinal
permeability (12). In the following years research on intestinal permeability was focused on
autoimmune and inflammatory diseases such as celiac disease (13, 14) or Crohn’s disease
(15). Only recently possible associations between intestinal permeability and character-
istics of a metabolic disease like obesity or type 2 diabetes have emerged as attractive
targets in the field of obesity research.
In this review, we aim to highlight underlying mechanisms of an impaired intestinal barrier
and its possible consequences for an impaired metabolic health. We specifically discuss
recent findings how endotoxemia and bacterial translocation may cause dysfunction of
tissues and organs subsequently contributing to metabolic diseases.
2.2.3 The intestinal barrier
Components of the intestinal barrier
The intestine represents an active interface, where external environmental cues, such as
diet, medication and the billions of symbionts inhabiting our gut co-exist and interact
– usually peacefully – with host factors. The intestinal barrier allows and facilitates the
uptake of nutrients and water from the intestinal lumen whilst at the same time providing
effective mechanisms to combat harmful substances and pathogens and prevent their
translocation into the host circulation and peripheral tissues(16). These checkpoints are
constituted by an intricate network of mechanical and immunological factors including
the mucus, the epithelial layer and the underlying lamina propria (16) as well as as
humoral and immunological factors. The goblet cells produced mucus layer is constituted
by mucin and forms a protective barrier, limiting the amount of bacteria reaching the
epithelial cells (17). Epithelial cells are connected by tight junctions, which hinder the
entry of pathogens while actively regulating the paracellular flow of water, small ions and
nutrients by following local pressure and electrochemical and osmotic gradients (18). Tight
junction complexes mainly consist of occludin and members of the claudin family, the
composition of which defines the kind and function of a specific tight junction. Claudins
and occludin are connected to the cytoskeleton by scaffolding proteins including zonula
occludens proteins (19). Additionally, cells are connected by adherence junctions (for
cell-cell signaling) and desmosomes (for cell stability) (20). The mechanical gut barrier
interacts continuously and is highly impacted by local immune components constituted
of soluble IgA, epithelial and Paneth cell produced and secreted antimicrobial peptides
such as alpha-defensins, lysozyme and C-type lectin providing additional protection to
the epithelial layer and the crypts of Lieberkühn (21, 22), as well as cells belonging
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to the innate and adaptive immunity system such as macrophages, dendritic cells (23),
T- regulatory cells (24) and the highly dense lymphoid tissues inhabiting the lining of
the gut but also highly active in adjunct lymph nodes (25) Disruptions in this intricately
balanced system through toxins, microorganisms, nutrients or food contaminants can lead
to an alteration of the intestinal permeability, mainly by an increased and inadequately
controlled influx via the paracellular pathway. The regulation of this pathway can, under
both physiological and pathophysiological conditions, be altered by various endogenous
and exogenous factors as discussed in the following paragraphs.
Endogenous regulation of the intestinal barrier
A constant challenge for upholding the integrity of the intestinal barrier is the continuous
cell shedding on the tip of the villi, with a turnaround time of about five days (26). Tight
junctions are redistributed to block the gap under involvement of rho kinase (27). Other
signal cascades involved in tight junctions regulation under physiological conditions in-
clude protein kinase C’s (PKC) and mitogen-activated protein kinase (MAPK) pathways,
which regulate protein phosphorylation and expression allowing a selective transport of
molecules (28). Under pathophysiological conditions, increased proinflammatory cytokines
such as interferon-γ (INF-γ) and tumor necrosis factor α (TNF-α) shift the homeostatic
balance (18) by downregulating the expression of claudin-1 (18) and increasing occludin
and claudins 1 and 4 internalization. This leads to an increasingly compromised gut per-
meability, as shown by Bruewer et al. in T84 cells via immunofluorescence microscopy(29).
Further mechanisms of INF-γ induced permeability in T84 cells involve PI3-K/Akt ac-
tivation and a delayed but prolonged NfκB response (30). This is of particular interest,
as metabolic diseases are usually attended by a chronic low grade inflammation (31),
possibly initiating a negative feedback loop.
Exogenous perturbation
Several external factors, including bacteria, alcohol consumption, nutrition and medica-
tion have an impact on the intestinal permeability (21). A high caloric “western” diet
is associated with changes in the microbiome (32) and both are important factors in
the development of metabolic diseases. While pathogenic bacterial species such as en-
teropathogenic E. coli (33–35), H. pylori (36), Salmonella Typhimurium (37) and V.
cholera [38] increase the intestinal permeability, the totality of the gut microbiota con-
tributes equally to upholding the gut barrier health by shaping tolerogenic mechanisms
controlling the responses of resident dendritic cells and macrophages (38). Moreover, ben-
eficial effects were reported for gut bacteria produced short chain fatty acids (39, 40), in
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particular butyrate (41), which has been shown to act as an energy source for colonocytes
(42), regulate HIF1α dependent expression of many probarrier genes in intestinal epithelial
cells (43), facilitates tight junctions assembly (40) and induces colonic regulatory T (Treg)
cells, leading to the suppression of inflammatory and allergic responses (41). Species-wise,
Akkermansia muciniphila (44), Bifidobacterium (45) and lactic acid producing bacteria
like Lactobacillus plantarum (46) and L. reuteri (47) were, among others, also reported
to improve intestinal permeability. Experimental evidence for the effect of food compo-
nents mostly stems from rodent and cell culture experiments. Glucose, well known for
its many adverse effects in metabolic disease (48), is partially transported paracellularly
and enhances small intestinal permeability (49), increases Caco-2 cell permeability and
leads to altered TJ arrangements (50). Recently, Thaiss et al. evidenced a key role for
hyperglycemia in impairing the barrier function by increasing retrograde uptake of glu-
cose into epithelial cells via the GLUT2 transporter, leading to changes in intracellular
glucose metabolism and to a transcriptional reprogramming (9). Further food components
increasing TJ permeability include salt (51) and various fatty acids (52), all of which are
known to contribute to obesity development (53, 54). Another important nutritional fac-
tor affecting the intestinal permeability is gliadin, a component of gluten found in wheat.
In mouse experiments, Lammers and colleagues found that gliadin increased permeability
by binding to the CXCR3 chemokine receptor (55). Beneficial effects on intestinal per-
Figure 2.1 (preceding page): Causes and consequences of increased intestinal per-
meability in metabolic disaese; A) An interplay between environmental factors, nutri-
ents, drugs and the microbiome defines our intestinal lumen and can directly or indirectly
alter permeability of the epithelial cell layer; B) Increased cell shedding under pathophysi-
ological conditions or the reversible interaction with and opening of tight junctions under
allow an influx of pathogens including bacteria or their nucleic acids, metabolites and
lipopolysaccharides as well as further substances and toxins; C) Paracellular transport
via tight junctions is regulated by various kinases and inflammatory cytokines, nutrients
and bacteria can interfere with claudin and occludin expression; D) First entry points of
invading substances are capillaries and lymph vessels of the villi and tissues in close prox-
imity such as mesenteric adipose tissue; E) Endotoxin is rapidly and constantly cleared in
the liver; F) Next to the gut lumen, pathogens could also invade through the oral cavity,
the skin and the lung; G) Under constant interactions and clearance with the immune
system the LPS and bacteria are transported in the circulation, thereby LPS can be bound
to various proteins and cells including erythrocytes and lipoproteins; H) Effected distant
organs include adipose tissue, pancreas tissue and possibly muscle tissue; I) Pathogens
interact with many receptors, i.e. LPS is recruited to TLR-4 leading to increased expres-
sion and secretion of inflammatory cytokines
Abbreviations: LPS: lipopolysaccharide, LBP: LPS-binding protein, TLR: toll like receptors, (V)LDL:
(very) low density lipoprotein, HDL: high density lipoprotein, INF-γ: Interferon gamma, TNF-α: tumor
necrosis factor alpha, rhoK: rho kinase, MAPK: MAP kinase, PKC: protein kinase C
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meability were reported for casein (56) and further cheese peptides (57), vitamin D (58)
as well as polyphenols (59, 60), which is in line with findings that polyphenol rich diet
ameliorated the metabolic disease (61). Furthermore, addition of apple-derived pectin to a
high fat diet (HFD) counteracted some negative effects of a HFD by preventing microbial
shifts and improving barrier function due to increased expression of claudin-1 and abating
metabolic endotoxemia (62).
2.2.4 Intestinal permeability in metabolic disease
Animal studies
An increased intestinal permeability is the key factor for the migration of toxins and
bacterial components to the circulation. First evidence for a link between obesity and
increased permeability was found in mouse studies. Brun et al. used Ussing chambers
– a physiological system to measure the transport of ions, nutrients, and drugs across
epithelial tissues including the gut (63, 64) - to analyze the barrier integrity in leptin-
deficient (ob/ob) and hyperleptinemic, but leptin-receptor mutant (db/db) mice -, which
constitute widely used animal models in obesity-induced T2D (65). They observed a
significantly increased permeability, which was more prominent in db/db mice. This was
accompanied by an increase in portal endotoxemia and systemic inflammation parameters
(66). Later, changes in the microbiome were found to be an important factor linking
intestinal permeability to inflammation (67, 68). It was further shown that the shift in the
intestinal permeability of mice on a high-fat diet could be attributed to claudin switching,
which leads to tight junction restructuring. In this case the expression of claudin-1,-3,-4,-7
and -15 decreased, whereas expression of claudin-2 increased (69). However, as shown in
diabetic mice (db/db) with induced C. rodentium infection, countermeasures are in place
to overcome negative effects. In particular, exogenous IL-22 restored mucosal host defense
as indicated by histological evaluation (70).
Human studies
Although some human studies have linked intestinal permeability with metabolic disease
in humans, they should be seen with caution, as they did not employ reproducible and
robust methods to test for gut permeability such as Lactulose/Mannitol (La/Ma) or sim-
ilar tests and Ussing chambers. In 2012, Teixeira and colleagues showed in 40 patients
that increased permeability is associated with increased BMI and insulin resistance(71).
Further studies followed to confirm these findings and associate intestinal permeability
with increased visceral obesity (72). Damms-Machado and colleagues similarly reported
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a correlation between intestinal permeability and HOMA index in 27 obese individuals
of which 18 suffered from the metabolic syndrome (73). Furthermore, Luther and col-
leagues reported a meta-analysis showing that nonalcoholic fatty liver disease (NAFLD)
increased the intestinal permeability (odds ratio=5.1), which was even more prominent in
nonalcoholic steatohepatitis (NASH) (odds ratio=7.2) (74). Challenging this hypothesis
with interventions has seldom been done: A low-caloric diet of 800 kcal/day was able to
significantly reduce the intestinal permeability, indicating the relevance of nutrition as a
fast acting player influencing intestinal permeability (75). Further interventions leading
to mechanistic insights in the link between metabolism and intestinal permeability are
highly warranted.
2.2.5 Bacterial components in the circulatory system
The role of lipopolysaccharide
The measurement of bacterial components in the circulation allows an indirect verifica-
tion of increased intestinal permeability. This link has emanated from the observation that
sepsis is associated with an acute but reversible state of insulin resistance (76). To this
end, most studies have focused on the measurement of lipopolysaccharide (LPS), or en-
dotoxins, which are molecules on the outer membrane of gram-negative bacteria, leading
the condition of increased exposure to bacterial LPS in the blood in obesity or metabolic
disease to be termed ‘metabolic endotoxemia’. Fat intake is associated with an increase in
postprandial LPS levels (77), which have been shown to be distributed from the gut into
the circulation via the mesenteric lymph nodes using freshly formed chylomicrons (78).
LPS is recognized and bound by both LPS-binding protein (LBP) and sCD14, which can
also be used as marker proteins, and recruited to the TLR4 receptor(79). The highest
proportion of LPS in the circulation is bound to lipoproteins, whereby most of LPS is
bound to high density lipoprotein (HDL) (80). Smaller fractions of LPS are also bound
to platelets (81, 82), monocytes (83) and erythrocytes (84, 85) or are present as free LPS
(86); however this was mostly observed in septic models. Endotoxin and other bacterial
components are taken up by the liver through the portal vein from the gut.
Binding to lipoproteins helps to neutralize LPS activity and to facilitate a rapid clearing
from the circulation (87–89). Clearance mostly takes place in the liver and is done mainly
by hepatocytes and Kupffer cells. In general, LPS is taken up and excreted to the bile.
One way of LPS uptake is via the various lipoprotein receptors, e.g. LDL-R (86). After
LPS stimulation hepatocytes express acute phase protein serum amyloid A which further
promotes LPS clearance (90). However, hepatocytes can also use TLR4 to take up LPS
(91, 92). Moreover since binding of LPS with lipoproteins and chylomicrons has been
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shown to prevent endotoxin induced monocytes activation and secretion of proinflamma-
tory cytokines (93, 94), the redistribution and increased content of phospholipid content
among the different lipoproteins has been suggested as a mechanism for the attenuation
of the immunostimulatory effects of LPS.
Endotoxemia in metabolic diseases
In the same year, it was observed that mice getting a subcutaneous LPS infusion devel-
oped a phenotype comparable to mice on high-fat diet, including increased glucose and
insulin levels as well as whole body and adipose tissue weight gain (77).
LPS is detectable in low concentrations even in healthy human subjects, and already one
meal with high fat content can increase LPS levels (95, 96). In the last years, many stud-
ies in large cohorts reported increased levels of LPS and LBP in patients with metabolic
syndrome or type 2 diabetes (97–100). Pussinen and colleagues analyzed LPS levels of
patients with prevalent diabetes (n=537) and incident diabetes (n=462) and compared
them to a control group (n=6,170), of which about 20% had a metabolic syndrome. En-
dotoxin was significantly increased in individuals with T2D and endotoxin activity was
associated with an increased risk for incident diabetes, independently of other diabetes
risk factors (98). Furthermore, serum endotoxin was linearly associated with the number of
metabolic syndrome traits (98). It was also shown that Roux-en-Y gastric bypass surgery
in patients with obesity and diabetes reduced LPS levels by 20 ± 5% after a 180 days
follow-up period (99), which could also be confirmed for sleeve gastrectomy and duodenal
switch procedures (101, 102). A more recent study by Cox et al. used LPS, LBP as well as
intestinal fatty acid binding protein (iFABP) to calculate a permeability risk score, which
was increased in individuals with type 2 diabetes (100). In secondary complications, such
as NAFLD, even higher endotoxin levels are reported (103). Measurement and interpre-
tation of endotoxin concentrations are complicated, which is reflected by a wide range of
results in healthy as well as subjects with metabolic syndrome (see Limitations).
Verges and colleagues studied LPS kinetics in 30 patients (16 patients with type 2 diabetes
and 14 controls), and although they could not observe differences in total LPS, the distri-
bution was different. Patients with type 2 diabetes had higher LPS-VLDL, LPS-HDL and
free LPS but reduced LPS-LDL. The authors suggested that free LPS transfers first to
HDL and VLDL and the LPS-LDL fraction is mainly a result of VLDL catabolism (104).
Circulating bacterial DNA
In addition to LPS measurement, the amplification and sequencing of bacterial DNA
allows quantification and assessment of the microbial composition. However, both the
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measurement of endotoxin and bacterial DNA do not prove the existence of live bacteria,
for which cultivating techniques and RNA analyses are inevitable. Still, there is increasing
evidence for the presence of bacteria in blood, even in healthy subjects, as discussed in
detail by Castillo and colleagues (105). Briefly, there are multiple studies reporting concur-
rent bacterial phyla in blood with Proteobacteria and Firmicutes being the most dominant
phyla (105). In this chapter, we focused on changes in the blood microbiome characteristic
for the metabolic disease. The first study in this field was published by Amar et al. in
2011, including subjects of the D.E.S.I.R. cohort within a longitudinal study aimed at
better understanding the complex pathophysiology of the metabolic syndrome (106, 107).
The 16S rRNA gene concentration was measured in 3,280 subjects at baseline and after a
nine year follow up. At baseline subjects who developed type 2 diabetes had significantly
higher amounts of bacterial DNA (odds ratio=1.35, p=0.002) and after nine years bacte-
rial DNA was significantly elevated in subjects with abdominal obesity (odds ratio=1.18,
p=0.01). Additionally, pyrosequencing showed that the dominant phylum was Proteobac-
teria(107), whose amount was found to be an independent risk factor of cardiovascular
disease in a subsequent publication in 3,936 participants of the D.E.S.I.R. study(108). In
a small cohort of 58 subjects with obesity who had undergone bariatric surgery, Ortiz et
al. analyzed the translocation of bacterial DNA before and up to 12 month post-surgery.
Bacterial DNA was detected in 32.8% of the patients prior to surgery, but only in 13.8%
and 5.2% of patients after 3 and 12 months, respectively (109). Similarly, blood bacterial
DNA reminiscent of the gut microbiome was found in a Japanese cohort of 100 subjects
of which 50 had type 2 diabetes. In addition, the detection rate was significantly higher
in subjects with type 2 diabetes compared with healthy subjects (28% vs. 4%, p¡0.01)
(110). In line with above mentioned studies, patients with obesity and liver fibrosis seem
to have elevated concentrations of bacterial DNA compared to non-fibrotic patients with
obesity (111). Most recently, Qiu et al. showed that subjects carrying Bacteroides had a
reduced risk and patients carrying Sediminibacterium an increased risk to develop type 2
diabetes (112).
In summary, there is increasing evidence not only for the presence of bacterial DNA and
potentially intact bacteria even in healthy subjects but also for the association between
the amount of bacterial DNA and bacterial composition with obesity and related traits.
However, current methods have considerable limitations (see Limitations) and further,
more elaborative studies are warranted to prove the initial results.
2.2.6 Bacterial translocation to host tissues
The consequence of an increased bacterial load in the circulation in metabolic disease on
other tissues has been scarcely investigated in the past. However, it is currently drawing
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increasingly attention of the respective research field as reviewed and summarized in the
following paragraph.
Mesenteric lymph nodes
Mesenteric lymph nodes (MLN) are situated close to the wall of the small intestine and
are a primary target of bacterial translocation, independent from the distribution via
the circulation. Evidence for bacterial translocation to MLN in metabolic disease mainly
stems from gnotobiotic mice (113–115) and animal models of liver diseases including cir-
rhosis and portal hypertension with a prevalence of translocation being around 40% in
rat models of cirrhosis (116–119). Cirera et al. confirmed translocation of enteric organ-
isms to MLN in patients with advanced cirrhosis (prevalence 30.8%), and also showed
that controls and patients with intestinal contamination had a comparable prevalence of
bacterial translocation (˜ 8%) (120), which has been confirmed by other groups as well
(121). Bacterial DNA was furthermore found in ascitic fluid, where its presence signifi-
cantly increased the production of nitric oxide in peritoneal macrophages (122).
Consequently, it is postulated that immune cells interacting with bacteria are activated in
the MLN after which they are redistributed and spread inflammatory response to other
body sites (118).
Adipose tissue
The human adipose tissue is a metabolically active organ with large heterogeneity in cel-
lular composition, function and expression signatures depending on its anatomic location
(123). First evidence that bacteria are indeed able to translocate from the gut to adipose
tissue stems from mouse experiments. In a pioneering work, Amar and colleagues used,
among other methods, GFP-labeled E. coli to demonstrate the transmucosal passage in
mice on high-fat diet (124). Although first results suggested the presence of bacterial
DNA in human adipose tissue (125), a further study by Zulian et al. could not confirm
these results (126). In this publication, DNA of 14 obese subjects was isolated from whole
adipose tissue and mature adipocytes. Only positive results were observed in the enzy-
matically isolated adipocytes but sequencing revealed that 90% of the bacterial DNA
belonged to Clostridium histolyticum, which is the bacterium used to isolate the collage-
nase enzyme. All other experiments including culturing experiments were negative (126).
In 2017, Udayappan et al. reported the presence of bacterial DNA, mainly stemming
from Actinobacter and Ralstonia, in mesenteric adipose tissue of six patients with obesity.
However, as they did not include negative controls, contamination cannot be excluded
(127). Another noteworthy study was published by Nakatsuji et al., looking at subepi-
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dermal adipose tissue of healthy subjects. Results from six subjects suggest that the skin
microbiome extends to this specific skin-adjacent adipose tissue depot (128). Furthermore
bacterial DNA was found and sequenced in the epicardial adipose tissue on six patients
with acute coronary syndrome and stable angina (129).
2.2.7 Consequences of bacterial presence in organs and tissues
LPS induces immune response in adipocytes and adipose tissue macrophages
Although there are only a few studies proving the existence of bacterial components in
adipose tissue, their potential impact has been demonstrated by cell culture experiments.
Toll-like receptors, especially TLR4 which are needed for the recognition of LPS are ex-
pressed on adipose tissue macrophages as well as adipocytes. Stimulation of adipose tissue
macrophages with LPS induced fibrosis via TLR4 and the induction of the profibrotic fac-
tor TGFβ1 (130). LPS can also act directly on adipocytes, as demonstrated in numerous
studies (131, 132). Creely et al. could show that IL-6 and TNF-α are secreted in response
to LPS in mature subcutaneous adipocytes from lean and obese individuals, whereas in-
hibition of NF-κB reduced the levels of secreted IL-6 after LPS stimulation (131). These
results could be confirmed by Vitseva et al. using subcutaneous abdominal fat from obese
subjects (132).
Effects of LPS on pancreatic cell lines
Endotoxin can exert effects on various pancreatic cells. In 2003, it was shown that en-
docrine cells of the human pancreatic islands express CD14 and TLR4. CD14 was synthe-
sized and secreted by SV40-transformed islet cells (HP62) after treatment with LPS. LPS
was shown to regulate glucose-dependent insulin secretion and induced an inflammatory
response (133). By analyzing isolated human and rodent islets Amyot et al. showed that
LPS impairs insulin expression, whereby human islets are more sensitive to this effect.
LPS further decreases the expression of PDX-1 and MafA and this inhibition is prevented
by blocking NF-κB but not p38 MAPK signaling (134).
LPS effects on hepatocytes
It is assumed that altered TLR4 signaling is a key factor in metabolic liver diseases includ-
ing NAFLD (135). TLR4 is expressed on various liver cell types including hepatocytes,
monocytes, Kupffer cells and stellate cells (136). Using primary human liver biopsies and
human hepatocytes (HepaRG), it was shown that LPS increases NF-κB translocation and
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activity by 2.5 fold , although the observed effect was only partially mediated by TLR4
as demonstrated by siRNA knockdown and chemical blocking of TLR4 (136) . Kheder
and colleagues stimulated macrophages (J774) and HepG2 hepatocytes with LPS which
led to increased TNF-α expression. Co-treatment with increasing doses of vitamin D3
and docosahexaenoic acid (DHA) reduced these effects (137). One year later Lee et al.
used mouse hepatocytes deficient of TLR4, MyD88 and TRIF to show that LPS induces
hepicidin expression, an antimicrobial and iron regulating protein, via TLR4 in a MyD88
dependent manner (138).
2.2.8 Limitations
Compared to patients with sepsis, cancer or severe inflammatory diseases, endotoxin
levels and quantity of bacterial DNA in healthy individuals and subjects with common
metabolic diseases are generally very low. Thus, studies are prone to contamination, false
positive results and misinterpretation. Here, we highlight some concerns which should be
considered in interpretation of relevant literature.
There are various methods to measure the integrity of the intestinal barrier, which how-
ever are heterogeneous. Methods include Ussing chambers (64), histology and electron
microscopy for biopsies and transepithelial/transendothelial electrical resistance (TEER)
for cell culture experiments (139). The gold standard for in vivo studies is the lactu-
lose/mannitol or similar tests, which assess the flow of indigestible sugars from gastroin-
testinal tract to the circulation and the combination of different sugars allows a location
specific measurement (21, 140). In addition, biomarkers such as calprotectin, alpha-1-
trypsin, fatty acid binding protein and zonulin are used. There is extensive literature
on benefits and disadvantages of each method (21, 140–143). However, in our opinion,
studies employing biomarkers are generally lacking in strength due to various reasons:
a) Correlations with dynamic permeability tests such as La/Ma are not present or very
weak; b) most of these markers are also acute phase protein and are therefore increased
in inflammation; c) their actions are not limited to the gut paracellular pathway; d) com-
mercially available ELISAs are often not validated, as we and others could show that the
preferred ELISA for the most commonly used biomarker zonulin is measuring different
products(144, 145). Consequently, relevant literature should be interpreted carefully in
this regard.
Measurement of endotoxin, in particular at low concentrations, is very challenging and
prone to errors. Problems start with sampling, as LPS adheres to plastic walls and there-
fore, blood should be sampled in glass vials for LPS test, which is usually not the case.
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Furthermore, various factors within the blood can interfere with LPS testing, including
bile salts, lipoproteins, EDTA and heparin. There are numerous commercially available
tests, of which only the Limulus amoebocyte lysate test (LAL) is approved by the FDA.
Published data with a huge range of LPS concentrations ranging from 0.01 to 60 EU/ml
in comparable cohorts clearly indicates that this is a major problem which needs to be
considered in studies including LPS measurements. Moreover, using different units im-
pedes the interpretation of findings from different studies (146). Independent from units,
most studies reported a 0.5 to 2-fold increase of LPS in subjects with obesity compared
to subjects with normal weight, as clarified by Boutagy et al. (146). Consequently, they
propose these values as indicator for a metabolic endotoxemia until unified and compara-
ble methods are established.
In studies analyzing bacterial DNA, be it quantification or sequencing, contamination
appears to be the major problem. Contamination can arise starting from sampling, as per
definition a sterile environment can still contain fragments of bacterial DNA(147). The
use of adequate negative controls and suitable bioinformatics approaches is indispensable
(148).
In most works on metabolic endotoxemia it is assumed that LPS is the consequence of
impaired intestinal barrier. However, other locations can contribute to a metabolic en-
dotoxemia as well. For instance, it was shown that oral interventions like extraction of
teeth or periodontal probing but also everyday actions such as chewing and oral hygiene
can lead to an influx of endotoxin into the circulation (149, 150). It was also observed
that subjects with obesity are more likely to suffer from gingivitis, which is most likely
due to increased insulin resistance (151, 152). Considering this, it is likely that LPS and
bacteria from the oral cavity have an underestimated contribution in metabolic endotox-
emia. Additionally, the skin microbiome extends to various compartments beneath, thus
implicating a potential impact (128). However further studies are desirable to support
these findings.
Additionally, LPS is rapidly cleared from the circulation in the liver, which is also the first
organ reached by LPS taken up from the GI tract. Since endotoxin is measurable under
various conditions this points towards a chronic influx and the additional contribution of
other origins like oral cavity, lungs or the skin.
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2.2.9 Conclusion
In summary, we can conclude that an impaired gut barrier contributes to the development
of metabolic diseases and might even provoke them. Increasing evidence supports the
hypothesis that translocation of bacteria or bacterial components to distant organs such as
muscle, adipose tissue and the pancreas is increased in metabolic disease and the relevance
of this data is further supported by first functional studies using endotoxin. However,
findings in this novel field of metabolic research should be treated carefully, as many
studies potentially overrepresented false positive results due to experimental limitations.
The awareness and consideration of increased intestinal permeability in metabolic disease
can help to understand catalysts of such disease but can also help in the identification of
novel, potentially personalized, treatment methods by selectively targeting tight junction
related pathways or by altering the patients microbiome.
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Chapter 3
Zonulin: a suitable biomarker for
intestinal permeability?
3.1 Rationale
The gold-standard technique to determine intestinal permeability in vivo is the Lactu-
lose/ Mannitol or comparable tests [139, 153]. Briefly, the two non-metabolized sugars are
administered orally and their concentration in urine or blood is measured after six hours.
Under healthy conditions lactulose is not taken up, consequently the ration between lac-
tulose and mannitol concentrations can be used as a marker of intestinal permeability.
However, this test is time-consuming, laborious and expensive; hence the use of circulat-
ing biomarkers is often preferred. Zonulin emerged as one of the most commonly used
proteins measured in serum to estimate intestinal permeability.
Zonulin was discovered in the lab of Alessio Fasano, who originally discovered a hu-
man homologue to the second V. cholera endotoxin [116] which corresponded to the
prehaptoglobin-2 [117, 118]. Fasano et al. also showed that it reversibly opens tight junc-
tion using Ussing chambers, and that the increased permeability is reflected by circulating
zonulin levels [117]. A commercial ELISA kit is available since 2009 [154], and circulating
levels have been shown to be increased in patients with obesity and/ or type 2 diabetes
[142–144]. However, the analyzed cohorts were rather small (Nmax < 400). Therefore, I
further evaluated the role of zonulin in metabolic disease by including a preexisting and
metabolically well-characterized, population-based cohort with more than 1,000 individu-
als and correlated the respective zonulin levels with traits of glucose and lipid metabolism.
However, I discovered certain discrepancies in the results. Haptoglobin (HP) is present
in two isoforms (namely HP-1 and -2), which form a dimer resulting in three possible
combinations: homodimers HP-1 and HP-2 or a heterodimer of HP-1/2 [155]. In a Eu-
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ropean population HP-1/1 is present in about 15% of all individuals; HP-1/2 in about
50% and HP-2/2 in about 35% [155]. As zonulin is reported to be prehaptoglobin2, I
expected to observe missing or significantly reduced circulating values in about 15% and
slightly reduced results for half of the sample size of the analyzed cohort, which was not
the case. After confirming the haptoglobin genotype, it became increasingly evident that
there were no differences in circulating zonulin levels. Unfortunately, at this time point,
the used ELISA kit was the only commercially available one. Consequently, I focused on
elucidating the protein(s) bound by this particular ELISA kit and suggested properdin as
one of the potential targets.
A detailed description of this work entitled “Widely used commercial ELISA does not
detect preHP-2, but recognizes properdin as a potential second member of the zonulin
family” and published in Frontiers in Endocrinology in 2018 [134] is provided in the
next paragraph (3.2).
3.2 Publication
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Background: There is increasing evidence for the role of impaired intestinal permeability 
in obesity and associated metabolic diseases. Zonulin is an established serum marker for 
intestinal permeability and identical to pre-haptoglobin2. Here, we aimed to investigate 
the relationship between circulating zonulin and metabolic traits related to obesity.
Methods: Serum zonulin was measured by using a widely used commercial ELISA kit in 
376 subjects from the metabolically well-characterized cohort of Sorbs from Germany. In 
addition, haptoglobin genotype was determined in DNA samples from all study subjects.
results: As zonulin concentrations did not correlate to the haptoglobin genotypes, 
we investigated the specificity of the zonulin ELISA assay using antibody capture 
experiments, mass spectrometry, and Western blot analysis. Using serum samples that 
gave the highest or lowest ELISA signals, we detected several proteins that are likely 
to be captured by the antibody in the present kit. However, none of these proteins 
corresponds to pre-haptoglobin2. We used increasing concentrations of recombinant 
pre-haptoglobin2 and complement C3 as one of the representative captured proteins 
and the ELISA kit did not detect either. Western blot analysis using both the polyclonal 
antibodies used in this kit and monoclonal antibodies rose against zonulin showed a 
similar protein recognition pattern but with different intensity of detection. The protein(s) 
measured using the ELISA kit was (were) significantly increased in patients with diabetes 
and obesity and correlated strongly with markers of the lipid and glucose metabolism. 
Combining mass spectrometry and Western blot analysis using the polyclonal antibodies 
used in the ELISA kit, we identified properdin as another member of the zonulin family.
conclusion: Our study suggests that the zonulin ELISA does not recognize pre-hap-
toglobin2, rather structural (and possibly functional) analog proteins belonging to the 
mannose-associated serine protease family, with properdin being the most likely possible 
candidate.
Keywords: diabetes, lipid metabolism, precursor of haptoglobin2, elisa, intestinal permeability, properdin, 
obesity, metabolic diseases
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inTrODUcTiOn
The “intestinal barrier” is an established term, defined as a func-
tional entity separating the gut lumen from the inner host, and 
consisting of mechanical, humoral, immunological, muscular, 
and neurological elements. Intestinal barrier dysfunction is a 
characteristic feature of pathological states such as inflammatory 
bowel disease, celiac disease, nonalcoholic steatohepatitis, and 
ulcerative colitis (1, 2). There is also emerging evidence for the 
role of impaired intestinal permeability in metabolic diseases 
including obesity and type 2 diabetes (T2D) (3–5). It has been 
hypothesized that gut bacteria and bacterial endotoxins may 
disrupt the intestinal barrier resulting in the so-called “leaky gut” 
(4, 6). The leakage of toxins, bacterial components or even live 
bacteria, and their transfer to target organs such as adipose tissue 
might contribute to the development of obesity and T2D (6, 7). 
Indeed, numerous studies in mouse models have demonstrated 
that changes in the gut microbiota can alter the gut permeability 
and lead to an endotoxemia-induced inflammation in adipose tis-
sue, and ultimately to obesity (3, 8, 9). Results from experimental 
mouse models are supported by studies in humans by showing 
an increase in circulating endotoxin levels and circulating bacte-
rial DNA in obese/diabetic patients, likely due to an increased 
intestinal permeability in affected subjects (10, 11).
Intestinal barrier transport is mainly regulated by structures 
of the paracellular pathway called tight junctions which form 
barriers between epithelial cells and regulate the transport of 
ions and small molecules across the intestinal lumen. Intestinal 
permeability is a functional feature of the intestinal barrier. It can 
be measured by analyzing flux rates of inert molecules across the 
intestinal wall as a whole or across wall components (1). The gold 
standard for assessment of intestinal permeability in vivo is an 
assay combining indigestible large and small oligosaccharides, 
such as lactulose and mannitol; the larger oligosaccharide, lactu-
lose, is only transported via the paracellular pathway, whereas 
the smaller oligosaccharide, mannitol, is taken up freely over 
the intestinal barrier via the transcellular route. However, these 
oligosaccharide assays are expensive, laborious, poorly reproduc-
ible, and time-consuming. Therefore, identifying appropriate bio-
markers for intestinal permeability is highly desirable. Zonulin 
has been identified as a tight junction regulating protein which 
is, functionally, the human counterpart of the Vibrio cholera 
endotoxin zonula occludens toxin (12, 13). Precisely, subsequent 
studies recognized zonulin as the precursor of haptoglobin2 
(pre-HP2) (14). HP is a well-known protein involved in scaveng-
ing hemoglobin, whereas the function of its precursor is largely 
unknown. HP is first synthesized into a single-chain precursor 
protein, which is cleaved into a light N-terminal α-chain and 
heavy C-terminal β-chain. An exon duplication of exons 3 and 
4 of the HP gene differentiates the HP1 from the HP2 allele. 
Due to this exon duplication, the HP2 α-chain is 1.7 kb longer 
than in the HP1 allele. HP is active as tetramer consisting of 2 
α- and 2 β-chains linked by disulfide bonds, resulting in three 
possible genotypes: homozygous HP1/1, homozygous HP2/2, 
and heterozygous HP1/2 (15, 16). About 15% of the Caucasian 
population is homozygous for HP (16, 17). Zonulin as pre-HP2 
reversibly opens tight junctions and is upregulated in diseases 
such as celiac disease and type 1 diabetes (14, 18). Serum zonulin 
concentrations are also increased in T2D and obesity (19–21) and 
strong correlations were observed with various metabolic mark-
ers, including fasting plasma glucose, IL-6, HDL, and triglyceride 
(TG) levels (19–21).
Here, we aimed at characterizing the relationship between 
circulating serum zonulin and traits related to obesity in a 
metabolically well-characterized cohort of Sorbs from Germany. 
To measure zonulin, we used the commercially available ELISA 
kit (Immundiagnostik, Bensheim, Germany). In addition, we 
determined the HP genotypes in the entire cohort. Due to a lack 
of correspondence between the observed circulating zonulin 
concentrations and the HP genotypes in our study cohort, we 
further investigated the possible identity of the product captured 
by the commercial ELISA assay. We found that the ELISA kit used 
in the present study does not detect purified pre-HP2 but rather 
targets one or more proteins from a range of candidate molecules 
possibly structurally and functionally related to zonulin. Our data 
also showed that protein concentrations measured by this ELISA 
correlated with parameters of obesity and related metabolic traits.
MaTerials anD MeThODs
study subjects
All subjects are part of a sample from an extensively clinically 
characterized population from Eastern Germany, the Sorbs 
(22–24). Extensive phenotyping included standardized question-
naires to assess past medical history and family history, collec-
tion of anthropometric data [weight, height, waist-to-hip ratio 
(WHR)], and an oral glucose tolerance test. Glucose was assessed 
by the Hexokinase method (Automated Analyzer Modular, 
Roche Diagnostics, Mannheim, Germany) and serum insulin was 
measured using the AutoDELFIA Insulin assay (PerkinElmer Life 
and Analytical Sciences, Turku, Finland). Total serum cholesterol 
and TG concentrations were measured by standard enzymatic 
methods (CHOD-PAP and GPO-PAP; Roche Diagnostics). 
Serum LDL-C and HDL-C concentrations were determined 
using commercial homogeneous direct measurement methods 
(Roche Diagnostics). All assays were performed in an automated 
clinical chemistry analyzer (Hitachi/Roche Diagnostics) at the 
Institute of Laboratory Medicine, University Hospital Leipzig.
All blood samples were taken in the morning after an overnight 
fast and stored at −80°C until analyses. From the 1,040 Sorbs 
enrolled in the cohort, a subgroup of 376 subjects was genotyped 
for HP and provided blood samples for zonulin measurements 
(Table 1). Main metabolic characteristics of the study subjects are 
summarized in Table 2.
The study was approved by the ethics committee of the 
University of Leipzig and all subjects gave written informed 
consent before taking part in the study.
elisa Measurements
Circulating zonulin was measured by a competitive ELISA 
(Immundiagnostik AG, Bensheim, Germany) in serum samples Abbreviations: HP, haptoglobin; T2D, type 2 diabetes; WHR, waist-to-hip ratio.
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TaBle 2 | Main characteristics of the study participants.
ngT igT T2D
n 191 79 106
Age (years) 45.4 ± 15.6 59.7 ± 29.4** 62.9 ± 11.2**
BMI (kg/m2) 25.8 ± 5 29.7 ± 4.6** 30.97 ± 5.53**
WHR 0.84 ± 0.10 0.92 ± 0.09 0.94 ± 0.09**













HDL (mmoL/L) 1.69 ± 0.40 1.56 ± 0.36* 1.43 ± 0.39**°







HOMA IS (ratio) 1.07 ± 0.76 0.67 ± 0.78** 0.68 ± 1.63**
CRP (mg/L) 2.22 ± 4.20 3.19 ± 4.54 3.87 ± 4.76**
Zonulin (ng/mL) 67.25 ± 25.45 71.88 ± 29.36 81.78 ± 25.31**°°
* p < 0.05 vs NGT; ** p < 0.01 vs. NGT.
° p < 0.05 vs. IGT; °° p < 0.01 vs. IGT.
All data given as mean ± SD. NGT, normal glucose tolerance; IGT, impaired glucose 
tolerance; T2D, type 2 diabetes; CRP, C-reactive protein; HDL, high-density lipoprotein; 
LDL, low-density lipoprotein; FPG, fasting plasma glucose; WHR, waist-to-hip ratio.
TaBle 1 | Composition of the study cohort included in zonulin measurements.
all Female Male
n 376 233 143
Age (years) 53.3 ± 16.2 52.7 ± 15.8 54.2 ± 16.8
BMI (kg/m2) 28.1 ± 5.6 27.9 ± 5.9 28.5 ± 5.1
NGT 191 (50.8%) 124 (53.2%) 67 (46.8%)
IGT 79 (21.0%) 49 (21.0%) 30 (21.0%)
T2D 106 (28.2%) 60 (25.8%) 46 (32.2%)
Age and BMI are mean ± SD, NGT, IGT, and T2D as absolute number (percentage). 
NGT, normal glucose tolerance; IGT, impaired glucose tolerance; IFG, impaired fasting 
glucose.
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of 376 individuals according to the manufacturer’s protocol. Inter-
assay coefficient of variation was 6.5%. When purified proteins 
zonulin and properdin and the synthetic peptide AT1001 were 
tested by the ELISA, they were resuspended in PBS and diluted in 
Diluent buffer (IDK kit) to reach a final concentration of 5 µg/mL.
genotyping
Haptoglobin genotypes were determined by PCR using a method 
adapted from Koch et al. (17). Briefly, the following two primer 
pairs were used: A (5′-GAGGGGAGCTTGCCTTTCCATTG-3′) 
and B (5′-GAGATTTTTGAGCCCTGGCTGGT-3′), as well as C 
(5′-CCTGCCTCGTATTAACTGCACC AT-3′) and D (5′-CCGAG 
TGCTCCACATAGCCATGT-3′). For primer pair A/B, a 95°C initial 
denaturation was done for 5 min followed by 35 cycles of 95°C 
(20  s) denaturation, 58°C (30  s) primer annealing, and 69°C 
(3.5 min) elongation. A terminal elongation of 7 min at 72°C was 
included at the end. For the primer pair C/D, conditions were as 
follows: 95°C for 5 min; 35 cycles of 95°C for 30 s and 69°C for 2 
min; and 7 min at 72°C.
The primer pair A/B generates two bands: a 1,757-bp allele-1 
specific band and a 3,481-bp allele-2 specific band. The primer 
pair C/D produces one allele-2 specific band of 349  bp. The 
combination of the bands allows a reproducible typing of the two 
common HP genotypes HP1 and HP2. In contrast, no band is 
detectable for the rare HP deletion genotype, present in ~0.1% 
Caucasians (16).
antibody capturing experiment
We aimed to isolate the target protein of the ELISA antibody 
from serum samples utilizing the immobilized anti-zonulin 
antibodies on the ELISA plates to perform antibody captur-
ing experiments. Based on the manufacturing information, 
these polyclonal antibodies were raised against an octapeptide 
sequenced from the zonulin molecule (25). Equal amounts of 
undiluted serum samples with highest and lowest concentra-
tions of zonulin, as measured using the same ELISA kit, were 
transferred to separate wells, incubated, and washed according to 
the manufacturer’s protocol. Afterward, we eluted the captured 
protein(s) by incubation with 50 µL of hot (95°C) SDS sample 
buffer with β-mercaptoethanol for 5 min. The captured protein 
of high- or low-zonulin serum samples were pooled [N = 8 for 
high (two pooled groups) and low (one pooled group); measured 
protein concentrations using the zonulin ELISA of the serum 
samples is given in Table S1 in Supplementary Material]. In 
addition, 20 µL of these elution samples (high or low zonulin) 
were separated by SDS-PAGE using precast Bolt 4–12% Bis-Tris 
Plus gels (ThermoFisher, Waltham, MA, USA). Proteins were 
stained using the Pierce silver stain for mass spectrometry 
(ThermoFisher) or detected by Western Blot.
Mass spectrometry
To identify proteins isolated from serum samples as described 
above, bands were excised from silver-stained gels and in-gel 
digested with trypsin following a standard protocol (26). After 
enzymatic digestion, the peptide mixtures were immediately 
analyzed by LC/MS/MS on an U3000 RSLC nano-HPLC system 
(Thermo Fisher Scientific) coupled to an Orbitrap Fusion Tribrid 
mass spectrometer (Thermo Fisher Scientific). Samples were 
loaded onto a pre-column (RP-C8, 300 µm * 5 mm, 5 µm, 100 Å, 
Thermo Fisher Scientific) and washed with water containing 
0.1% (v/v) TFA for 15 min, before the peptides were separated on 
the separation column (RP-C18, 75 µm * 250 mm, 2 µm, 100 Å, 
Thermo Fisher Scientific) using gradients from 1 to 40% (v/v) B 
(45 min) and 40 to 85% (v/v) B (5 min) followed by 85% B (5 min), 
with solvent A: 0.1% (v/v) formic acid (FA) in water and solvent 
B: 0.08% (v/v) FA in acetonitrile. Data were acquired using data-
dependent MS/MS mode where each high-resolution full-scan 
in the orbitrap (m/z 198–1,500; R  =  120,000) was followed by 
high-resolution product ion scans in the orbitrap [higher energy 
collision-induced dissociation (HCD), 27% normalized collision 
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FigUre 1 | Distribution of zonulin ELISA values according to haptoglobin 
genotypes. Data are presented as boxplots with Turkey–Whiskers and 
outliers.
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energy, R = 15,000, isolation window 2 Th] within 5 s, starting 
with the most intense signal in the full-scan mass spectrum.
Data analysis was performed using the Proteome Discoverer 
2.1 (Thermo Fisher Scientific). MS/MS data of precursor ions (m/z 
range 350–5,000) were searched against the Swissprot Database 
(version 11/2016, taxonomy human, 20,082 entries) and a con-
taminant database using Sequest HT. Mass accuracy was set to 
5 ppm and 20 mmu for precursor and fragment ions, respectively. 
Carbamidomethylation of cysteines was set as fixed modification, 
oxidation of methionines and N-terminal acetylation were set as 
variable modifications, and two missed cleavages of trypsin were 
allowed. Results were filtered for non-contaminant proteins iden-
tified by at least three unique highly confident peptides (peptide 
FDR ≤ 1%).
Western Blot analysis
Western blot experiments were performed to validate the results 
of mass spectrometric data analysis and to compare the serum 
target proteins identified by the polyclonal antibodies used by 
this ELISA kit compared with monoclonal anti-zonulin anti-
bodies. Gels were blotted on a PVDF membrane and Western 
blots were probed with anti-C3 β-chain (1:2,000) (Biozol, 
Eching, Germany), anti-HP (1:1,000) (Abcam, Cambridge, 
UK), polyclonal anti-zonulin (1:500) (kindly provided by 
Immundiagnostik), and monoclonal anti-zonulin (1:5,000) 
(BioRad, Hercules, CA, USA) antibodies. Purified C3c from 
plasma (Athens Research, Athens, GA, USA) and recombi-
nant zonulin were used as positive controls. Properdin (R&D 
Systems, Minneapolis, MN, USA) was also used to validate the 
potential protein candidate identified by the ELISA. Incubation 
with primary and secondary antibodies (HRP-conjugated) was 
done for 90 min at room temperature. Blots were visualized 
by enhanced chemiluminescence using Pierce ECL Western 
Blotting Substrate (ThermoFisher Scientific).
statistical analysis
Statistical analysis was performed using SPSS 24 (IBM). All non-
normally distributed metric parameters were log transformed 
to generate a Gaussian normal distribution. Spearman’s rank 
correlation method was used to assess the relationship between 
metabolic traits. To test for significant differences in distribution 
for ordinal values, the Kruskal–Wallis test was used. Exact differ-
ences between two groups were tested by both the Mann–Whitney 
U test and unpaired Student’s t-test. In addition, multiple linear 
regression analyses were done to assess the linear relationship 
between continuous variables and genotypes. For all tests, a value 
of p < 0.05 was considered to be statistically significant.
resUlTs
haptoglobin genotype
Haptoglobin genotype HP1/1 was present in 15.8% of the sub-
jects, HP1/2 in 47.6%, and HP2/2 in 36.6%. These frequencies 
are comparable with the distribution of HP genotypes in cohorts 
of European ancestry reported by others (16, 17). We tested the 
association of the HP genotypes with various anthropometric 
and metabolic traits in all study subjects. The analysis revealed 
that blood hemoglobin levels significantly increase with the 
presence of at least one HP2 allele (p  =  0.004 over all three 
groups, p  =  4.2  ×  10−4 between HP1 homozygote and HP2 
carriers). Furthermore, we observed that the total protein 
concentration in the urine significantly differed between the 
three groups, with an increase in the HP2 carriers (p = 0.027). 
Interestingly, mean triiodothyronine (fT3) levels were lower 
in the HP1/1 group than in the HP2/2 group (p = 0.012) and 
in accordance, an increase in administered thyroid gland hor-
mones (p = 0.023) was observed.
Zonulin elisa Data not Matching hP 
genotype Distribution
Strikingly, there were no significant differences in levels of the 
zonulin ELISA signal between the three HP genotype groups 
(Figure  1; p  =  0.153 using ANOVA, p  =  0.07 for the t-test 
comparing log-transformed zonulin signals between HP1/1 
vs. HP1/2  +  HP2/2). Assuming that the protein measured 
by the kit is zonulin (i.e., pre-HP2), subjects with the HP1/1 
genotype were expected to have no detectable zonulin levels. 
As the zonulin concentrations measured in patient sera using 
the zonulin ELISA kit clearly did not reflect the HP genotype 
distribution, we therefore concluded that the protein measured 
by the kit is not identical to zonulin as pre-HP2 or that, beside 
pre-HP2, the kit detects other unrelated proteins. Consequently, 
we aimed at identifying the protein(s) detected by the alleged 
zonulin ELISA kit.
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FigUre 2 | (a) Silver stain of immunoprecipitated ELISA products and (B) Western blot analyses using an anti-C3 β-chain antibody. Commercially available C3c 
protein isolated from human plasma was run as positive control. High: pooled IP samples of sera that gave highest ELISA signals; low: pooled IP samples of sera 
that gave lowest ELISA signals; neg: negative control using dilution buffer from the ELISA kit; tracer: competitive tracer reagent from the ELISA kit. Letters in (A) 
indicated bands analyzed by MS after tryptic in gel digestion (Table S2 in Supplementary Material).
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The Zonulin elisa Does not Detect 
recombinant pre-hP2, but Targets 
Multiple Proteins
To attempt identifying proteins bound and quantified by the 
capturing antibody deployed in the zonulin ELISA kit, we 
performed an immune-capturing experiment using patient sera 
and the immobilized antibody of the ELISA kit as supplied. After 
incubation of the immobilized ELISA kit antibodies with selected 
patient sera representing the highest and lowest measured ELISA 
signals in the cohort, the captured proteins were separated by 
SDS-PAGE. Notably, we could not measure the protein content 
of the eluted samples, but given that equal amounts of serum were 
used, that the same washing and elution procedure was performed 
for all samples, and that 20 µL of the pooled elution samples were 
used for SDS-PAGE and Western blot, the detected amount of 
“captured” protein should resemble the amount of protein that 
was present in the initial serum sample.
Silver staining revealed multiple bands, with the most intense 
band at ~70  kDa and further prominent bands at ~55, ~180, 
and  >180  kDa (Figure  2A). This band pattern was incompat-
ible with a band pattern that would be expected for pre-HP2 
or HP-derived proteins and further supported the results dem-
onstrating the lack of correspondence of the captured protein 
with HP genotypes. To further characterize major proteins 
captured by the ELISA kit, protein bands were cut (Figure 2A) 
and subjected to MS analysis after tryptic digestion (Table S2 in 
Supplementary Material). Mass spectrometry demonstrated that 
bands 1 (>180 kDa), 2 (~150 kDa), and 3 (~70 kDa) were all very 
likely representing the C3 protein or cleavage products derived 
from the C3 protein, such as the C3 precursor (187 kDa), C3c 
(144 kDa), and the C3 β-chain (71 kDa). Furthermore, the 55 kDa 
band was identified as properdin or factor P (MW 53 kDa). To 
validate results from mass spectrometry, we performed Western 
blot analyses. The major band at 70 kDa was clearly detected by 
an anti-C3 β-chain antibody (Figure 2B).
Consequently, we tested several C3c proteins from different 
suppliers (Abcam, Cambridge, UK; Athens Research, Athens, 
GA, USA; mybiosource, San Diego, CA, USA), in a range from 
0.1 mg/mL to 0.1 ng/mL under native and denatured conditions, 
as well as diluted in serum, with the respective ELISA kit. All 
results were negative (data not shown), indicating that C3 might 
represent a contaminant only. Additionally, we tested C3, recom-
binant zonulin, HP1, and HP2 at increasing concentrations (range 
1–50 µg/mL), along with sera from celiac patients (both HP1-1 
and HP2-2), healthy controls (both HP1-1 and HP2-2), and our 
standard control (AF, HP2-2). The results showed in Figure  3 
demonstrated that while this kit does not recognize C3, zonulin, 
or mature HP (both HP1 and HP2), it does recognize protein(s) 
both in HP1-1 and HP2-2 genotype subjects, irrespective of their 
disease status.
anti-zonulin Monoclonal antibodies and 
immundiagnostik Polyclonal antibodies 
recognizing the same Target Proteins in 
Western Blot
Our ELISA results clearly showed that this kit does not detect 
zonulin (alias, pre-HP2 as originally claimed by the manufac-
turer) or complement C3, the protein captured by our experi-
ments described above. In order to further characterize the target 
protein(s) of this kit, we performed Western blotting analysis of 
sera from an HP2-2 subject either under baseline condition or 
after deglycosylation as we have previously described (14), using 
recombinant zonulin as control. As anticipated, the zonulin 
monoclonal antibodies recognized recombinant zonulin as well 
as a variety of bands in the serum sample, including bands with a 
MW of ~70, 52, 37, 27, and 16 kDa (Figure 4A). Based on similar 
patterns we detected when zonulin was originally cloned (14), we 
predicted that the ~72 kDa corresponded to the glycosylated HP 
β-chain, the 52 kDa zonulin, and the 16 kDa the HP2 α-chain. 
To confirm this interpretation, we performed deglycosyla-
tion experiments showing the shift of the 72-kDa β-chain to a 
lower MW, while, as anticipated, the zonulin band and the HP2 
α-chain remained unchanged (Figure 4A). Interestingly enough, 
the Immundiagnostik polyclonal antibodies raised against the 
zonulin synthetic peptide inhibitor GGVLVQPG (AT1001) (25) 
recognized the same main bands detected by the monoclonal 
antibodies but with different intensity, being the recombinant 
zonulin and serum α-chain bands fainter compared with the 
monoclonal antibody signal, while the serum β-chain and serum 
zonulin-like signals stronger (Figure 4A). When combined to our 
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FigUre 4 | Western blot analyses of a prototype human serum sample (AF HP2-2) using both anti-zonulin monoclonal antibodies and Immundiagnostik polyclonal 
antibodies. (a) Prototype serum sample of an HP2-2 homozygous subject, either untreated (lane 1) or after deglycosylation (lane 2) was resolved and then 
immunoblotted using either anti-zonulin monoclonal antibodies (left panel) or Immundiagnostik polyclonal antibodies (right panel). Recombinant zonulin was added 
as control (lane 3). As anticipated, zonulin monoclonal antibodies recognize the recombinant protein as well as a serious of serum bands, with the strongest signal 
being related to the 16-kDa zonulin α2-chain. The Immundiagnostik polyclonal antibodies also recognize recombinant zonulin but with a much weaker signal 
compared with the monoclonal antibodies. These antibodies also recognize the same serum bands detected by the zonulin monoclonal antibodies, with the 
~70- and 52-kDa bands being highlighted with the strongest signal. Sample’s deglycosylation showed the shift of the 70-kDa band to a lower MW, suggesting that 
this may represent the zonulin β-chain as we have previously shown (14). (B) Prototype serum samples of an HP1-1 and an HP2-2 homozygous subject were 
resolved and immunoblotted using the Immundiagnostik polyclonal antibodies. Recombinant zonulin and properdin were added as control. The antibodies also 
detect properdin that migrated at the same molecular weight of zonulin and serum bands recognized by the antibodies in both HP2-2 and HP1-1 subjects.
FigUre 3 | Mean zonulin ELISA values obtained by testing specific candidate target proteins and patients’ serum samples. This ELISA kit did not detect increasing 
concentrations (range 1–50 µg/mL) of complement, recombinant zonulin (pre-HP2), mature HP1 or mature HP2. Conversely, a strong signal was detected in sera of 
both celiac disease patients (CD) and healthy controls (non-CD, internal control AF with HP2-2), irrespective of their HP genotype. All samples were measured in 
technical triplicates; kit controls are shown for comparison.
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3 Zonulin: a suitable biomarker for intestinal permeability? 48
FigUre 5 | (a) Mean zonulin ELISA values according to glucose tolerance groups (B) mean ELISA values according to BMI groups. ** p < 0.01; *** p < 0.001. 
NGT, normal glucose tolerance; IGT, impaired glucose tolerance; T2D: type 2 diabetes.
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ELISA results, these data suggest that while the zonulin monoclo-
nal antibodies specifically detect in serum samples only zonulin 
at its predicted molecular weight, most likely the polyclonal 
antibodies used in this kit are possibly detecting “zonulin-like” 
protein(s) (as suggested by the much more intense signal of the 
~52-kDa band compared with the monoclonal antibodies) with 
similar molecular weight, structure, and possibly function.
immundiagnostik Polyclonal antibodies 
recognizing both Pre-hP2 and Properdin 
as an additional Target in Western Blot
Among all the proteins we identified with our mass spec analy-
sis, properdin fulfills the structural–functional characteristics 
mentioned above and, therefore, may represent the most likely 
candidate target detected by this ELISA kit. To explore this 
hypothesis, we performed both Western blotting analysis using the 
Immunodiagnostik polyclonal antibodies and ELISA test using 
commercially available properdin. The Western blot showed that 
beside recombinant zonulin, the Immunodiagnostik polyclonal 
antibodies also detect properdin (Figure 4B) that migrated at the 
same molecular weight of zonulin and serum bands recognized 
by the antibodies in both HP2-2 and HP1-1 subjects (Figure 4B). 
Similar results were obtained with polyclonal antibodies raised 
against recombinant zonulin (data not shown). The same samples 
used for Western blotting analysis, including zonulin, properdin, 
and AT1001 at a concentration of 5 µg/mL were tested using the 
ELISA kit. The results showed that properdin and AT1001 were 
both detected by the ELISA test; however, their amounts were 
substantially underestimated by 914- (5.47 ng/mL) and 40-folds 
(126.04 ng/mL), respectively. However, despite zonulin being 
detected in Western blot, it was not detected with the ELISA kit 
(Figure 3). In comparison, serum from subjects with HP1-1 and 
HP2-2 genotype were measured at a concentration of 67.54 and 
56.41 ng/mL, respectively.
correlations of Measured Protein 
concentrations Using the elisa with 
Metabolic Traits
In a sample of 376 subjects tested using the purchased zonulin 
ELISA, the product was measured in a mean concentration of 
72.2 ± 27.2 ng/mL (mean ± SD), ranging from 17.8 to 207.1 ng/
mL. The ELISA signal was significantly increased in subjects with 
T2D (81.78 ± 25.31 ng/mL) compared with subjects with normal 
glucose tolerance (67.25 ± 25.45 ng/mL, Mann–Whitney U test; 
p = 2.1 × 10−8) or impaired glucose tolerance (71.88 ± 29.36 ng/
mL, p  =  0.0017) (Figure  5A). Additionally, lean subjects had 
significantly lower values (65.64 ±  25.23 ng/mL) than subjects 
with overweight (74.20 ±  30.68 ng/mL, p =  0.0082) or obesity 
(76.24 ± 24.17 ng/mL, p = 7.0 × 10−5) (Figure 5B). We observed 
no gender differences or any correlations with age (data not 
shown). The ELISA signal correlated with traits related to glucose 
and lipid metabolism (Spearman’s rank correlation test, adjusted 
for age, sex, and BMI; Table 3). It was positively correlated with 
BMI, HOMA-IR and -IS, and fasting plasma glucose (Table 3). 
Strong correlations were also observed for lipid metabolism 
parameters, such as TG levels, total cholesterol, LDL, and apoli-
poprotein B (Table 3). Correlations were tested for a total of 95 
accessible traits. After Bonferroni correction for multiple testing 
(adjusted value for significance at p <  5.2 ×  10−4), correlations 
for BMI (p = 1.2 × 10−5), fasting glucose (p = 9.0 × 10−6), TG 
(p = 4.2 × 10−10), total cholesterol (p = 3.3 × 10−5), and apolipo-
protein B (p = 2.3 × 10−5) remained statistically significant.
DiscUssiOn
The role of impaired intestinal permeability in metabolic diseases 
including obesity and T2D has recently been acknowledged in 
multiple studies (3, 4, 27). The tight junction regulator zonulin, 
which was identified as pre-HP2 by Tripathi et al. (14), is an estab-
lished circulating marker of intestinal permeability in humans 
(28, 29). Here, we aimed to investigate the relationship between 
intestinal permeability, represented by circulating zonulin, and 
metabolic traits related to obesity and T2D. We set out to measure 
zonulin with a widely used commercially available ELISA kit in a 
metabolically well-characterized cohort of Sorbs from Germany. 
Considering the identity of zonulin as pre-HP2, we also genotyped 
the HP gene in DNA samples from all subjects. The genotype 
frequency of the HP1/1 genotype corresponded to previously 
reported frequencies of 15% in populations of European ancestry 
(16, 17). Assuming that the measured zonulin is identical with 
pre-HP2 as reported previously (13), we expected subjects with 
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TaBle 3 | Correlation of ELISA signal with metabolic phenotypes.
non-adjusted adjusted for age,  
sex, BMi
r p-value r p-value
anthropometric trait
Age 0.31 0.55 – –
Sex −0.005 0.93 – –
BMI 0.221 1.2 × 10−5 – –
WHR 0.172 7.3 × 10−4 0.118 2.1 × 10−2
glucose metabolism
Glucose (0 min) 0.294 6.6 × 10−9 0.227 9.0 × 10−6
Glucose (120 min) −0.039 0.45 −0.046 0.38
Insulin (0 min) 0.173 7.7 × 10−4 0.079 0.13
Insulin (120 min) −0.039 0.46 −0.044 0.39
HOMA IR 0.244 2.0 × 10−6 0.149 4.0 × 10−3
HOMA IS −0.243 2.0 × 10−6 −0.145 4.9 × 10−3
lipid metabolism
Triglycerides 0.370 6.5 × 10−14 0.312 4.2 × 10−10
Total cholesterol 0.219 1.5 × 10−5 0.211 3.3 × 10−5
LDL 0.182 3.4 × 10−4 0.160 1.7 × 10−3
HDL −0.136 7.7 × 10−3 −0.063 0.22
Apolipoprotein B 0.247 9.9 × 10−7 0.215 2.3 × 10−5
adipokines
Adiponectin −0.215 2.2 × 10−6 −0.176 5.4 × 10−4
Progranulin 0.151 3.0 × 10−3 0.129 1.1 × 10−2
Vaspin 0.027 0.6 0.05 0.33
Chemerin 0.103 4.3 × 10−2 0.065 0.21
FGF21 0.165 2.1 × 10−3 0.152 4.7 × 10−3
Other
C-reactive protein 0.232 4.0 × 10−6 0.166 1.1 × 10−3
Total protein 0.124 1.5 × 10−2 0.134 8.6 × 10−3
Hemoglobin 0.201 7.4 × 10−5 0.143 5.1 × 10−3
Uric acid 0.176 5.2 × 10−4 0.110 3.1 × 10−2
Bold, significant correlations after adjustment; underlined, significant after Bonferroni 
adjustment for multiple testing (p < 5.2 × 10−4).
r, Spearman’s rank correlation coefficient; p, significance level; BMI, body mass index; 
HDL, high-density lipoprotein; LDL, low-density lipoprotein; WHR, waist-to-hip ratio; 
FGF21, fibroblast growth factor 21; HOMA-IR/IS, Homeostasis Model Assessment 
Insulin Resistance/Insulin Sensitivity.
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the HP1/1 genotype to have no detectable, or if taking into 
account cross-reactions, at least significantly lower zonulin levels. 
However, concentrations measured in the HP1/1 homozygous 
subjects were comparable with those found in HP2/2 and HP1/2 
carriers.
The epitope used to generate the capture antibody in the 
zonulin ELISA is based on the sequence GGVLVQPG (AT1001) 
published by Wang et  al. (25) (communication with customer 
support; Immundiagnostik AG, Bensheim, Germany), which 
was initially thought to represent the N-terminal sequence 
of fetal zonulin (25). However, this sequence is not present in 
pre-HP2, which has since been identified to be zonulin (14). The 
discrepancies between the previously reported zonulin sequence 
and the pre-HP2 sequence may be due to intraspecies variability 
associated with a high zonulin mutation rate or due to sequencing 
errors at that time (14). In summary, the commercially available 
competitive ELISA does very likely not detect pre-HP2 or zonulin, 
but rather unknown targets bound by the antibody raised against 
the sequence reported by Wang et al. (25).
Based on database searches, the epitope could correspond 
to Glu-Rich2, a protein which shares seven out of eight amino 
acids. The zonulin/pre-HP2-binding partner CD163 shows 
some conformity with the epitope (30). Our antibody capture 
experiment and subsequent mass spectrometry analysis did not 
provide any evidence for either protein. The most abundant 
protein identified by MS, C3, is evidently an unspecific product 
overshadowing the real targets. Indeed, the respective ELISA 
kit did not detect any complement C3 proteins obtained from 
different suppliers when tested under native and denatured 
conditions, as well as diluted in serum. Also, the same kit did 
not detect recombinant zonulin, mature HP1 or mature HP2. 
Considering the additional MS hits, a few proteins stand 
out, although, without further validation, we interpret these 
data with caution, since only more abundant proteins may 
be identified by MS analysis, while our protein(s) of interest 
may be in low abundance in serum samples and, therefore, 
not identifiable with this approach. The van Willebrand factor 
(vWF, band A, Figure  2) is involved in the intrinsic coagula-
tion pathway and the acute phase response and known to be 
increased in inflammatory bowel disease and bacterial diarrhea 
(31). Inter-alpha-inhibitor heavy chain 4 (band B, Figure 2) is a 
large glycoportein cleaved into smaller fragments by Kallikrein 
which is also involved in the intrinsic coagulation pathway. One 
of these fragments, called urinary trypsin-inhibitor, attenuates 
LPS-induced endothelial barrier dysfunction by upregulation 
of vascular endothelial-cadherin expression (32). Complement 
component 9 (C9, band C, Figure 2) is an important component 
of the membrane attacking complex within the complement 
cascade and is required for complement-mediated lipopolysac-
charide release and outer membrane damage in bacteria (33). 
Protein S100-A8, or Calprotectin (band D, Figure 2), is a cal-
cium- and zinc-binding protein which plays a prominent role in 
the regulation of inflammatory processes and immune response 
(34). However, based on the data presented in Figure  4, our 
most likely candidate(s) should be in the ~50-kDa range, where 
the polyclonal antibody signal was stronger. Therefore, the most 
interesting candidate protein we have identified is properdin 
or factor P (band D, Figure 2), a member of the complement 
alternative pathway that has a molecular weight (53 kDa), within 
the range of those proteins recognized by the Immundiagnostik 
anti-AT1001 polyclonal antibodies (Figures 4A,B) and serum 
levels (~25 ng/mL) (35) similar to the range of detection of the 
kit. Our combined Western blot analysis (Figure 4B) and ELISA 
test confirmed that the polyclonal antibodies raised against 
AT1001 detect properdin among other proteins. However, when 
purified proteins/peptides, including the AT1001 peptide used 
to raise the polyclonal antibodies and which serves as internal 
control in the ELISA kit, were tested by ELISA, they were highly 
underestimated by the test. One possible explanation for these 
results is that zonulin and also properdin are not the main tar-
gets detected by the ELISA; however, the fact that even AT1001 
was underestimated seems to suggest that this hypothesis can-
not entirely explain our results. Alternatively, it is possible that 
tertiary and quaternary (multimers) structure arrangements 
present in sera samples but not in recombinant proteins are nec-
essary in order to properly detect both zonulin and properdin 
3 Zonulin: a suitable biomarker for intestinal permeability? 50
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by this ELISA. This is the case and/or that the main target of this 
ELISA is/are additional proteins in the ~50 kDa range present in 
human serum remains to be established.
Once released from neutrophils, T cells, and macrophages in 
response to acute microbial exposure, properdin causes produc-
tion of chemotactic anaphylatoxin C3a and C5a with subsequent 
formation of immune complexes that cause increased endothelial 
permeability (35). Intriguingly, zonulin as pre-HP2 also causes 
generation of C3a and C5a, with subsequent increased vascular 
permeability in several districts, including the lung, with subse-
quent onset of acute lung injury (36). Another striking similarity 
between zonulin and properdin is the fact that both are associated 
with viral respiratory tract infections (37, 38).
Notably, the peptide sequence used for the generation of the 
antibody is also not present in any of the discussed proteins. 
The five proteins mentioned above, including properdin, have 
~50% similarity to this epitope. Zonulin as preHP-2 is a member 
of a larger family of tight junction regulating proteins. Indeed, 
phylogenetic analyses suggest that HPs evolved from mannose-
associated serine protease (MASP), a complement-associated 
protein (like properdin), with their α-chain containing a comple-
ment control protein (CCP) (this domain activates complement 
similar to properdin), while the β-chain is related to chymot-
rypsin-like serine proteases (SP) domain (39, 40). However, the 
SP domain of HP lacks the essential catalytic amino-acid residues 
required for protease function; structure-function analyses have 
implicated this domain in receptor recognition and binding (41). 
Although not an SP, zonulin shares approximately 19% amino-
acid sequence homology with chymotrypsin, and their genes both 
map on chromosome 16. Alignment of the β-chain sequence of 
zonulin to that of several SPs is remarkably consistent except for 
an insertion of 16 residues in the region corresponding to the 
methionyl loop of the SPs. Comparison of the zonulin α–β junc-
tion region with the heavy–light–chain junction of tissue-type 
plasminogen activator strengthens the evolutionary homology 
of zonulin and SPs. The active-site residues typical of the SPs, 
His57 and Ser195, are replaced in zonulin by lysine and alanine, 
respectively. Because of these mutations, during evolution zonu-
lin most likely lost its protease activity despite that zonulin and 
SPs evolved from a common ancestor (18). Therefore, zonulin 
and the SPs represent a striking example of homologous proteins 
with different biological functions but with the common char-
acteristic of complement activation. In addition to zonulin and 
properdin, other members of the MASP family include a series 
of plasminogen-related growth factors [epidermal growth factor 
(EGF), hepatocyte growth factor (HGF), etc.] involved in cell 
growth, proliferation, differentiation and migration, and disrup-
tion of intercellular junctions. In light of these considerations, 
other MASP members identified in our capturing experiments 
in general, and properdin in particular, are intriguing possible 
targets (36).
Analyzing the protein concentrations measured using this 
ELISA in subjects who have been extensively characterized for 
metabolic phenotypes, our data suggest that it is upregulated 
both in diabetic and obese patients. This is in line with previously 
reported findings using this ELISA kit (19–21). Our data show that 
the ELISA target is potentially involved in the lipid metabolism 
by showing in various linear stepwise regression models that tri-
glyceride levels and fasting glucose are the strongest independent 
available variables explaining the observed variance in measured 
protein concentrations (Table S3 in Supplementary Material).
It is important to note that our study, as it has not been initially 
designed to address the question of ELISA specificity, has clear 
limitations. To obtain amounts of isolated protein in the antibody 
capture experiments, we needed to change the experimental 
protocol provided by the manufacturer. We used undiluted 
serum samples instead of a 50-fold dilution, which very likely 
increased the risk of non-specific binding. Yet, we used sera from 
patient that exhibited the highest and the lowest concentrations 
measured by the ELISA kit using the manufacturer’s protocol. 
Thus, any non-specific binding should be detected as equally 
strong bands in the silver-stained gels after the antibody capture 
experiment. Yet, we observed band intensities of affinity purified 
protein that clearly correlated with the concentrations measured 
using the ELISA, in the silver-stained gels (total protein) and in 
the Western blot using the anti-C3-β-chain antibody, indicating 
a specific isolation of proteins recognized by the kit antibody. 
Nevertheless, ELISA results that failed to recognize C3 disputed 
the notion that complement C3 is the target of this kit. Also, we 
have performed this experiment using two different Lot nos. of 
the ELISA, using sera from eight different patients of each high 
and low concentration and obtained the same results.
In conclusion, based on our data we suggest that the 
Immun diagnostik ELISA kit supposedly testing serum zonulin 
(pre-HP2) levels could identify a variety of proteins structurally 
and possibly functionally related to zonulin, suggesting the exist-
ence of a family of zonulin proteins as previously hypothesized 
(42), rather than a single member of permeability-regulating 
proteins. Along these lines, studies that have used this ELISA 
kit for zonulin/preHP2 as a marker for intestinal permeability 
need to be interpreted with these findings in mind (see Table 
S4 in Supplementary Material for a list of publications using 
the respective ELISA kit). Additional studies are necessary to 
establish the primary target proteins (zonulin, properdin, and/or 
other structurally similar proteins) detected by this commercially 
available ELISA.
eThics sTaTeMenT
The study was approved by the ethics committee of the University 
of Leipzig and all subjects gave written informed consent before 
taking part in the study.
aUThOr cOnTriBUTiOns
LS, PK, and JH conceived the study, designed and conducted 
experiments, analyzed data, and wrote the paper. AT recruited 
patients. CI performed mass spectrometry experiments. AC, HH, 
DS, and MS interpreted and analyzed data. RF performed the 
zonulin ELISA test. MF performed the Western blotting analysis. 
AF critically revised the manuscript, contributed to the study 
design of some of the performed experiments, and provided 
critical interpretation of the data. All authors discussed results, 
edited, and commented on the manuscript. All the authors have 
3 Zonulin: a suitable biomarker for intestinal permeability? 51
10
Scheffler et al. Zonulin ELISA Detects Also Properdin
Frontiers in Endocrinology | www.frontiersin.org February 2018 | Volume 9 | Article 22
accepted responsibility for the entire content of this submitted 
manuscript and approved submission.
acKnOWleDgMenTs
We thank all those who participated in the studies, in particular 
our study subjects. We thank Dr. Ingo Bechmann for helpful 
advice and discussions.
FUnDing
This work was supported by the German Research Council (SFB-
1052 “Obesity mechanisms” B03, C01, and C07) and the German 
Diabetes Association and from the DHFD (Diabetes Hilfs- und 
Forschungsfonds Deutschland). IFB Adiposity Diseases is 
supported by the Federal Ministry of Education and Research 
(BMBF), Germany (grant number FKZ: 01EO1501, grant number 
AD2-060E, and grant number AD2-6E99) and by the National 
Institutes of Health (NIH), USA (grant number R01-DK104344 
and grant number P30-DK040461).
sUPPleMenTarY MaTerial




1. Bischoff SC, Barbara G, Buurman W, Ockhuizen T, Schulzke J-D, Serino M, 
et al. Intestinal permeability––a new target for disease prevention and therapy. 
BMC Gastroenterol (2014) 14:189. doi:10.1186/s12876-014-0189-7 
2. Arrieta MC, Bistritz L, Meddings JB. Alterations in intestinal permeability. 
Gut (2006) 55:1512–20. doi:10.1136/gut.2005.085373 
3. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, et al. 
Changes in gut microbiota control metabolic endotoxemia-induced inflam-
mation in high-fat diet-induced obesity and diabetes in mice. Diabetes (2008) 
57:1470–81. doi:10.2337/db07-1403 
4. Teixeira TF, Collado MC, Ferreira CL, Bressan J, Peluzio Maria do C. 
Potential mechanisms for the emerging link between obesity and increased 
intestinal permeability. Nutr Res (2012) 32:637–47. doi:10.1016/j.nutres. 
2012.07.003 
5. Frazier TH, DiBaise JK, McClain CJ. Gut microbiota, intestinal permeability, 
obesity-induced inflammation, and liver injury. JPEN J Parenter Enteral Nutr 
(2011) 35:14–20. doi:10.1177/0148607111413772 
6. Harris K, Kassis A, Major G, Chou CJ. Is the gut microbiota a new factor 
contributing to obesity and its metabolic disorders? J obes (2012) 2012:879151. 
doi:10.1155/2012/879151 
7. Burcelin R, Serino M, Chabo C, Garidou L, Pomie C, Courtney M, et  al. 
Metagenome and metabolism: the tissue microbiota hypothesis. Diabetes Obes 
Metab (2013) 15(Suppl 3):61–70. doi:10.1111/dom.12157 
8. Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O, et al. 
Changes in gut microbiota control inflammation in obese mice through a 
mechanism involving GLP-2-driven improvement of gut permeability. Gut 
(2009) 58:1091–103. doi:10.1136/gut.2008.165886 
9. Turnbaugh PJ, Backhed F, Fulton L, Gordon JI. Diet-induced obesity is linked 
to marked but reversible alterations in the mouse distal gut microbiome. Cell 
Host Microbe (2008) 3:213–23. doi:10.1016/j.chom.2008.02.015 
10. Ortiz S, Zapater P, Estrada JL, Enriquez P, Rey M, Abad A, et al. Bacterial DNA 
translocation holds increased insulin resistance and systemic inflammatory 
levels in morbid obese patients. J Clin Endocrinol Metab (2014) 99:2575–83. 
doi:10.1210/jc.2013-4483 
11. Sato J, Kanazawa A, Ikeda F, Yoshihara T, Goto H, Abe H, et al. Gut dysbiosis 
and detection of “live gut bacteria” in blood of Japanese patients with type 2 
diabetes. Diabetes Care (2014) 37:2343–50. doi:10.2337/dc13-2817 
12. Fasano A, Baudry B, Pumplin DW, Wasserman SS, Tall BD, Ketley JM, et al. 
Vibrio cholerae produces a second enterotoxin, which affects intestinal 
tight junctions. Proc Natl Acad Sci U S A (1991) 88:5242–6. doi:10.1073/
pnas.88.12.5242 
13. Fasano A, Fiorentini C, Donelli G, Uzzau S, Kaper JB, Margaretten K, et al. 
Zonula occludens toxin modulates tight junctions through protein kinase 
C-dependent actin reorganization, in  vitro. J Clin Invest (1995) 96:710–20. 
doi:10.1172/JCI118114 
14. Tripathi A, Lammers KM, Goldblum S, Shea-Donohue T, Netzel-Arnett S, 
Buzza MS, et al. Identification of human zonulin, a physiological modulator 
of tight junctions, as prehaptoglobin-2. Proc Natl Acad Sci U S A (2009) 
106:16799–804. doi:10.1073/pnas.0906773106 
15. Peretti de Albuquerque Wobeto V, Zaccariotto TR, Fátima Sonati MD. 
Polymorphism of human haptoglobin and its clinical importance. Genet Mol 
Biol (2008) 31:602–20. doi:10.1590/S1415-47572008000400002 
16. Langlois MR, Delanghe JR. Biological and clinical significance of haptoglobin 
polymorphism in humans. Clin Chem (1996) 42:1589–600. 
17. Koch W, Latz W, Eichinger M, Roguin A, Levy AP, Schomig A, et al. Genotyping 
of the common haptoglobin Hp 1/2 polymorphism based on PCR. Clin Chem 
(2002) 48:1377–82. 
18. Fasano A. Zonulin and its regulation of intestinal barrier function: the bio-
logical door to inflammation, autoimmunity, and cancer. Physiol Rev (2011) 
91:151–75. doi:10.1152/physrev.00003.2008 
19. Zhang D, Zhang L, Zheng Y, Yue F, Russell RD, Zeng Y. Circulating zonulin 
levels in newly diagnosed Chinese type 2 diabetes patients. Diabetes Res Clin 
Pract (2014) 106:312–8. doi:10.1016/j.diabres.2014.08.017 
20. Żak-Gołab A, Kocełak P, Aptekorz M, Zientara M, Juszczyk Ł, Martirosian G, 
et  al. Gut microbiota, microinflammation, metabolic profile, and zonulin 
concentration in obese and normal weight subjects. Int J Endocrinol (2013) 
2013:9. doi:10.1155/2013/674106 
21. Moreno-Navarrete JM, Sabater M, Ortega F, Ricart W, Fernandez-Real JM. 
Circulating zonulin, a marker of intestinal permeability, is increased in asso-
ciation with obesity-associated insulin resistance. PLoS One (2012) 7:e37160. 
doi:10.1371/journal.pone.0037160 
22. Tonjes A, Zeggini E, Kovacs P, Bottcher Y, Schleinitz D, Dietrich K, et  al. 
Association of FTO variants with BMI and fat mass in the self-contained pop-
ulation of Sorbs in Germany. Eur J Hum Genet (2010) 18:104–10. doi:10.1038/
ejhg.2009.107 
23. Tonjes A, Koriath M, Schleinitz D, Dietrich K, Bottcher Y, Rayner NW, et al. 
Genetic variation in GPR133 is associated with height: genome wide associ-
ation study in the self-contained population of Sorbs. Hum Mol Genet (2009) 
18:4662–8. doi:10.1093/hmg/ddp423 
24. Veeramah KR, Tönjes A, Kovacs P, Gross A, Wegmann D, Geary P, et al. Genetic 
variation in the Sorbs of eastern Germany in the context of broader European 
genetic diversity. Eur J Hum Genet (2011) 19:995–1001. doi:10.1038/ejhg.2011.65 
25. Wang W, Uzzau S, Goldblum SE, Fasano A. Human zonulin, a potential 
modulator of intestinal tight junctions. J Cell Sci (2000) 113(Pt 24):4435–40. 
26. Shevchenko A, Tomas H, Havlis J, Olsen JV, Mann M. In-gel digestion for mass 
spectrometric characterization of proteins and proteomes. Nat Protoc (2006) 
1:2856–60. doi:10.1038/nprot.2006.468 
27. Damms-Machado A, Louis S, Schnitzer A, Volynets V, Rings A, Basrai M, 
et al. Gut permeability is related to body weight, fatty liver disease, and insulin 
resistance in obese individuals undergoing weight reduction. Am J Clin Nutr 
(2017) 105:127–35. doi:10.3945/ajcn.116.131110 
28. Sapone A, de Magistris L, Pietzak M, Clemente MG, Tripathi A, Cucca F, 
et al. Zonulin upregulation is associated with increased gut permeability in 
subjects with type 1 diabetes and their relatives. Diabetes (2006) 55:1443–9. 
doi:10.2337/db05-1593 
29. Drago S, El Asmar R, Di Pierro M, Grazia Clemente M, Tripathi A, Sapone A, 
et al. Gliadin, zonulin and gut permeability: effects on celiac and non-celiac 
intestinal mucosa and intestinal cell lines. Scand J Gastroenterol (2006) 
41:408–19. doi:10.1080/00365520500235334 
3 Zonulin: a suitable biomarker for intestinal permeability? 52
11
Scheffler et al. Zonulin ELISA Detects Also Properdin
Frontiers in Endocrinology | www.frontiersin.org February 2018 | Volume 9 | Article 22
30. Thomsen JH, Etzerodt A, Svendsen P, Moestrup SK. The haptoglobin- 
CD163-heme oxygenase-1 pathway for hemoglobin scavenging. Oxid Med 
Cell Longev (2013) 2013:11. doi:10.1155/2013/523652 
31. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev 
Biochem (1998) 67:395–424. doi:10.1146/annurev.biochem.67.1.395 
32. Chen J, Wang J, Su C, Qian W, Sun L, Sun H, et al. Urinary trypsin inhibitor 
attenuates LPS-induced endothelial barrier dysfunction by upregulation of 
vascular endothelial-cadherin expression. Inflamm Res (2016) 65:213–24. 
doi:10.1007/s00011-015-0907-9 
33. Tegla CA, Cudrici C, Patel S, Trippe R, Rus V, Niculescu F, et al. Membrane 
attack by complement: the assembly and biology of terminal complement 
complexes. Immunol Res (2011) 51:45–60. doi:10.1007/s12026-011-8239-5 
34. Yui S, Nakatani Y, Mikami M. Calprotectin (S100A8/S100A9), an inflam-
matory protein complex from neutrophils with a broad apoptosis-inducing 
activity. Biol Pharm Bull (2003) 26:753–60. doi:10.1248/bpb.26.753 
35. Kouser L, Abdul-Aziz M, Nayak A, Stover CM, Sim RB, Kishore U. Properdin 
and factor H: opposing players on the alternative complement pathway 
“See-Saw”. Front Immunol (2013) 4:93. doi:10.3389/fimmu.2013.00093 
36. Rittirsch D, Flierl MA, Nadeau BA, Day DE, Huber-Lang MS, Grailer JJ, 
et  al. Zonulin as prehaptoglobin2 regulates lung permeability and activates 
the complement system. Am J Physiol Lung Cell Mol Physiol (2013) 304:72. 
doi:10.1152/ajplung.00196.2012 
37. Shirey KA, Lai W, Patel MC, Pletneva LM, Pang C, Kurt-Jones E, et al. Novel 
strategies for targeting innate immune responses to influenza. Mucosal 
Immunol (2016) 9:1173–82. doi:10.1038/mi.2015.141 
38. Ahout IM, Brand KH, Zomer A, van den Hurk WH, Schilders G, Brouwer ML, 
et  al. Prospective observational study in two Dutch hospitals to assess the 
performance of inflammatory plasma markers to determine disease severity 
of viral respiratory tract infections in children. BMJ Open (2017) 7:e014596. 
doi:10.1136/bmjopen-2016-014596 
39. Wicher KB, Fries E. Haptoglobin, a hemoglobin-binding plasma protein, is 
present in bony fish and mammals but not in frog and chicken. Proc Natl Acad 
Sci U S A (2005) 103:4168–73. doi:10.1073/pnas.0508723103 
40. Kurosky A, Barnett DR, Lee TH, Touchstone B, Hay RE, Arnott MS, et  al. 
Covalent structure of human haptoglobin: a serine protease homolog. Proc 
Natl Acad Sci U S A (1980) 77:3388–92. doi:10.1073/pnas.77.6.3388 
41. Nielsen MJ, Petersen SV, Jacobsen C, Thirup S, Enghild JJ, Graversen JH, 
et al. A unique loop extension in the serine protease domain of haptoglobin 
is essential for CD163 recognition of the haptoglobin-hemoglobin complex. 
J Biol Chem (2007) 282:1072–9. doi:10.1074/jbc.M605684200 
42. Fasano A. Regulation of intercellular tight junctions by zonula occludens toxin 
and its eukaryotic analogue zonulin. Ann N Y Acad Sci (2000) 915:214–22. 
doi:10.1111/j.1749-6632.2000.tb05244.x 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2018 Scheffler, Crane, Heyne, Tönjes, Schleinitz, Ihling, Stumvoll, Freire, 
Fiorentino, Fasano, Kovacs and Heiker. This is an open-access article distributed 
under the terms of the  Creative Commons Attribution License (CC BY). The use, 
distribution or reproduction in other forums is permitted, provided the original 
author(s) and the copyright owner are credited and that the original publication in 
this journal is cited, in accordance with accepted academic practice. No use, distribu-
tion or reproduction is permitted which does not comply with these terms.
3 Zonulin: a suitable biomarker for intestinal permeability? 53
Chapter 4
Epiploic adipose tissue: the watchdog
at the gates to insulin resistance?
4.1 Rationale
As summarized in Chapter 2, there is compelling evidence for an increased intestinal per-
meability in metabolic disease. The available data also provides arguments for an influx of
bacteria, bacterial metabolites and other compounds via the paracellular pathway. First
entry points in the host are hypothesized to be the capillary system of the gastrointesti-
nal tract as well as the mesenteric lymph nodes (see Chapter 2). Additionally, two major
white adipose tissue depots were identified as prime targets for bacterial translocation due
to their close proximity to the small and large intestine, namely mesenteric and epiploic
adipose tissue [156, 157]. Mesenteric adipose tissue was previously mainly examined in
the context of inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis.
Although some genes involved in the pathogenesis like NOD2 or IL23R have been iden-
tified, Crohn’s disease is a heterogeneous disorder with multifactorial etiology, and many
of the underlying factors and gene-environment interactions have yet to be understood
[158]. One of its typical characteristics is the presence of hyperplastic and hypertrophic
mesenteric adipose tissue, which in this context is also called “creeping fat” [159]. This is
accompanied by an increased inflammation [159] and altered gene expression of various
adipokines in this particular fat depot [160, 161]. Moreover, Peyrin-Biroulet et al. also
showed that both mesenteric lymph nodes and adipose tissue were invaded by gut bacte-
ria in the context of Crohn’s disease [162]. Epiploic adipose tissue, or rather appendices
epiploicae, are small chunks of fat directly attached to the colon. Apart from the rare but
benign inflammatory process of epiploic appendagitis due to torsion or venous thrombosis,
little is known about epiploic adipose tissue which has been poorly investigated in the
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past and is commonly described as cushioning layer for the large intestine [156, 163].
To the best of my knowledge, there are only two reports on mesenteric and one on epiploic
adipose tissue in the context of obesity or metabolic disease [164–166]. All three studies
have a rather small sample size, are limited to gene expression results of preselected
candidate genes and lack a characterization of important features like adipocyte size or
macrophage infiltration [164–166]. Therefore, to better classify and interpret the role of
different adipose tissue depots in bacterial translocation to different adipose tissue more
easily, I aimed to provide an in-depth characterization of mesenteric and epiploic adipose
tissue in comparison with commonly sampled omental and subcutaneous adipose tissue.
This included the measurement of adipokine and cytokine mRNA levels, adipocyte diam-
eter and macrophage infiltration in human adipose tissue samples of 70 patients (note:
the same cohort was included in studies aimed at characterization of bacterial translo-
cation to adipose tissue, see Chapter 5 Bacterial translocation to human adipose tissue
in metabolic disease). Furthermore, an age, sex and BMI matched sub cohort consist-
ing of patients with and without insulin resistance was used for untargeted “multiomics”
approaches including transcriptomics, methylomics and proteomics to identify molecular
pathways characteristic for epiploic adipose tissue and involved in insulin resistance.
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4.2 Abstract
Context: Human white adipose tissue is a diverse and metabolically active endocrine or-
gan with many depot specific differences. Mesenteric and epiploic adipose tissue are fat
depots in close proximity to the gastrointestinal tract which have been scarcely analyzed
so far in the context of metabolic diseases. I hypothesized that they play a crucial role in
mediating gut-related signals to target tissues and organs.
Methods: Mesenteric and epiploic, along with subcutaneous and omental adipose tissue of
70 patients undergoing Roux en-Y gastric surgery was collected. The samples were sub-
jected to an extensive characterization including adipocyte size, macrophage infiltration
and gene expression profile of adipokines and inflammatory markers. The cohort included
nine insulin sensitive patients matched with 15 patients with insulin resistance for age,
sex and BMI and subsequently analyzed in an untargeted approach in regard to their
transcriptome, proteome and methylome profile.
Results: Epiploic adipose tissue manifested characteristic features distinguishing it from all
other fat depots. Adipocyte size was comparable, but the expression of various adipokines
and markers of lipid metabolism was significantly increased, as documented for leptin,
PPAR-γ and progranulin. Furthermore, an increase in caspase-1 expression was observed,
but no increase in recruitment of adipose tissue macrophages. Proteome and transcrip-
tome data allowed a clear discrimination of patients with insulin resistance in all tissues,
but this difference was most prominent in epiploic adipose tissue. In line with this, various
metabolic and inflammatory pathways were upregulated in epiploic fat when compared
with other fat depots.
Conclusions: The data suggests an important role of epiploic adipose tissue in the devel-
opment of insulin resistance, possibly associated with its exposed location on the colon.
4.3 Introduction
Gut-derived signals, mainly connected to the human gut microbiome, are well estab-
lished factors in the progression of various metabolic diseases such as type 2 diabetes
[167, 168]. Increasing evidence from both correlation and mechanistic studies suggests an
active crosstalk between the gut and other organs including the brain [169], liver [170],
pancreas [171] and adipose tissue [172]. First insight in the connection between gut mi-
crobes and adipose tissue metabolism stems from experiments with germ-free mice that
exhibited strongly increased fat mass after treatment with microbiota harvested from
wild-type animals [173]. In the last decade further studies in both rodents and humans
could strengthen evidence of the “gut-adipose tissue axis” [172, 174, 175], however most
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of the underlying mechanisms remain unknown. A recent study linked an increased ex-
pression of miR-181 in white adipose tissue with a reduction of tryptophan metabolism
derived metabolites in the circulation [176], thereby providing evidence for the important
role of the gut microbiota regulated tryptophan metabolism in the development of dis-
eases associated with a “Western” lifestyle [168]. Further bacterial metabolites linked to
host metabolic regulation are short-chain fatty acids (SCFA) like butyrate or propionate
[115]. It is known that established target receptors are expressed in adipose tissue [177]
and stimulation with SCFA suppresses adipose-specific insulin signaling and leads to an
inhibition of fat accumulation [115, 178].
To study the gut-adipose tissue connection in humans, mesenteric and epiploic adipose
tissue, two adipose tissues in close proximity to the small and large intestine, are of par-
ticular interest. Both have only recently drawn attention as novel players in metabolic
diseases [164–166], however to the best of my knowledge an in depth characterization of
these adipose tissues in patients with obesity or type 2 diabetes is still lacking. Especially
the adipose tissue of the appendices epiploicae, 50 to 100 small fat chunks with a size of
2-5 cm directly attached to the colon [156], could play an important role in the gut-adipose
tissue crosstalk as the colon harbors most of the microbes in our body [23].
This study aims to characterize epiploic adipose tissue by employing immunohistochem-




70 patients with obesity had undergone Roux-en Y gastric bypass surgery at the University
of Leipzig Medical Center in Germany were recruited between 2017 and 2019. All patients
gave written informed consent before taking part in the study, which was approved by the
ethics committee of the University of Leipzig (017-12-23012012). Routinely assessed clini-
cal phenotyping included anthropometric, metabolic and inflammatory markers as well as
medication (Table 4.1). The cohort contained nine insulin sensitive patients (HOMA-IR
< 2.5, Hba1c < 5.8%, no diabetes medication), who were matched with 9 patients with
type 2 diabetes for proteome and methylome analysis and additional 6 patients with type
2 diabetes for transcriptome analysis (matched for age, sex and BMI).
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Parameter No T2D n T2D n p
Age [years] 44.8 ± 11 39 51.9 ± 11.4 31 0.01
Sex [female/male] 29/10 39 22/9 31 0.75
BMI [kg/m2] 47.0 ± 5.7 39 49.2 ±7.3 31 0.15
Glucose markers
FPG [mmol/l] 5.4 ±1.1 39 7.3 ± 2.0 31 2.7 x 10-5
FPI [pmol/l] 124.3 ± 102.7 36 185.7 ± 167.8 29 0.09
HOMA-IR 4.4 ± 3.8 36 9.7 ± 12.1 29 0.03
HbA1c [%] 5.5 ± 0.5 38 6.7 ± 1.1 30 3.0 x 10-6
Lipid markers
HDL
[mmol/l] 1.2 ± 0.4 37 1.0 ±0.3 29 0.17
LDL [mmol/l] 3.0 ± 0.9 37 2.4 ±0.8 29 0.01
Triglycerides [mmol/l] 1.3 ± 0.7 37 2.1 ± 2.0 29 0.03
Body fat [%] 48.5 ± 9.1 37 44.8 ± 9.4 25 0.12
Blood cells
Leucocytes [Gpt/l] 7.9 ± 2.3 39 8.3 ± 2.2 31 0.38
Erythrocytes [Tpt/l] 4.8 ± 0.4 39 4.7 ± 0.5 31 0.15
Thrombocytes [Gpt/l] 279.0 ± 66.2 39 264.5 ± 68.7 31 0.38
Inflammation
LBP [µg/ml] 11.5 ± 3.9 34 13.6 ± 5.6 30 0.09
TNF-α
[pg/ml] 1.4 ± 0.5 35 2.0 ±1.1 30 0.005
IL-6 [pg/ml] 3.3 ± 3.1 35 5.0 ± 4.2 30 0.06
CRP [mg/l] 7.3 ± 7.1 39 13.6 ± 12.8 30 0.02
Life style
Tobacco [ever/never] 20/9 29 11/2 13 0.29
Alcohol [yes/no] 20/9 29 5/5 10 0.28
Table 4.1: Cohort characteristics; all values are given as mean ± standard deviation, all com-
parisons: Student’s t-test, except sex, tobacco, alcohol: Chi2 test BMI: body mass index, FPG: fasting
plasma glucose, FPI: fasting plasma insulin, HOMA-IR: homeostatic model assessment for insulin resis-
tance, HbA1c: glycated hemoglobin A1C, HDL/LDL: high/ low density lipoprotein, LBP: lipopolysac-
charide binding protein, TNF-α: tumor necrosis factor alpha, IL-6: interleukin 6, CRP: C-reactive protein,
Alcohol: any consumption of alcoholic beverages during the past six months
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4.4.2 Circulating parameters
Tumor necrosis factor alpha (TNF-α) and interleukin 6 (IL-6) were measured by ELISA
(R&D Systems, Minneapolis; HSTA00E, HS600B and HSLB00D) using undiluted serum
and lipopolysaccharide binding protein (LBP) was measured by ELISA (Hycult Biotech,
Uden, Netherlands, #HK315-02) using diluted plasma (1:1000) according to the manu-
facturer’s protocols. Circulating adipokines and apolipoproteins were measured by mass
spectrometry in the matched cohort as previously described [179].
4.4.3 Tissue collection, storage and preparation
Adipose tissue biopsies were collected during laparoscopic Roux-Y gastric bypass surgery.
Subcutaneous tissue was taken from the incision of the first trocar in the left paramedian
mid abdomen, omental tissue from the mid of the pars libera of the greater omentum,
mesenteric tissue from the mesenterium of the mid jejunum close to the bowel wall and
epiploic tissue was sampled from the appendices epiploicae of the transverse colon. Biop-
sies were immediately transferred into sterile vials and kept on ice before of approximately
100 mg each were instantly snap-frozen in liquid nitrogen and transferred to long-term
storage at -80°C. Extraction of nucleic acids was performed with Qiagens RNeasy lipid
tissue and DNeasy mini kits following the kit manufacturer’s protocol.
4.4.4 Immunohistochemistry
Sample aliquots for immunohistochemistry (IHC) were incubated in 4% paraformalde-
hyde in PBS for 24 h and embedded in paraffin. 6 µm slices were used and treated with
DAKO retrieval solution (pH=9) for 30 minutes by applying hot steam. Adipocytes were
stained with anti-perilipin-1 (goat, 1:200) and macrophages with anti-Iba1 (rabbit, 1:500)
at 4°C overnight. Supervised automated analysis was performed using CellSens software
(OLYMPUS Life Science, Shinjuku, Japan) to assess adipocyte count and diameter as
well as counts of macrophages and crown like structures in adipose tissue.
4.4.5 Gene expression
All qRT-PCR experiments were run on a LightCycler 480 platform using TaqMan probes.
Nine commonly used reference genes were tested for stable mRNA expression within
a wide range of insulin sensitivity/ resistance in all tested adipose tissues in repeated
duplicates. Based on expression stability scores calculated by geNorm [180], NormFinder
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[181], ΔΔCt [182], BestKeeper [183] and RefFinder [184]. GAPDH, B2M and 18S were
chosen as reference genes for further analysis.
4.4.6 Transcriptome
Transcriptome analysis was performed in a sub cohort of 24 patients. Nine insulin sensitive
patients (HbA1c < 5.8%, HOMA-IR < 2.5, no diabetes medication) and 15 manifesting
insulin resistance were matched for age sex and BMI (see Appendix A.1). Transcriptome
analysis was performed using human HT-12 v4 Expression BeadChips (Illumina, Cali-
fornia, USA) with an established routine protocol in the Core Unit DNA technologies
according to the company’s guidelines.
4.4.7 Methylome and proteome
DNA-methylation and proteome was analyzed in 18 patients who were also part of the
transcriptome cohort (9 vs. 9, see Appendix A.1) using Infinium MethylationEPIC arrays
(Illumina) and untargeted proteomics. Methylation experiments were performed in the
Core Unit DNA technologies using a routine protocol in accordance to the company’s
guidelines. Abundance of proteins was determined by the group of Prof. von Bergen at
the Helmholtz Center for Environmental Research Leipzig. Briefly, proteins in each sample
were fractionated and divided into five fractions which were subsequently proteolyticaly
cleaved with trypsin. All samples were analyzed using reverse phase chromatography and
high resolution mass spectrometry.
4.4.8 Data analysis and statistics
All data was analyzed using R3.6.1 [185] and SPSS25 (IBM, New York, USA) and
all figures were generated using ggplot2 [186] and formatted in Adobe Illustrator 2020
(Adobe, California, USA). Continuous variables were tested for normal distribution using
Kolgomorov-Smirnov test. Consequently, for normally distributed parametrical tests were
employed to compare means (Student’s t-test) or test correlations (Pearson). Majority of
the studied traits showed traits no normal distribution and accordingly Mann-Whitney-U
test was used to compare median values and Spearman’s Rank correlation test was used
to assess correlations. Chi2 test was used to compare dichotomous categorical variables.
Differentially expression of qRT-PCR was calculated according to the ΔCt method [187].
All results were adjusted for multiple testing using a Benjamini-Hochberg approach [188],
and unless stated otherwise, pFDR<0.05 was considered statistically significant.
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Illumina HT12 data was analyzed in R using the lumi package [189], employing back-
ground correction, log2 transformation and quantile normalization. Gene names were
annotated using the package “illuminaHumanv4.db” [190]. Differential gene expression
was calculated using the limma package by using a linear model (lmFit) and empirical
bayes statistics [191]. Methylation was analyzed in R using minfi [192] and methylumi
[193] by employing background correction and swan normalization [194] and SNPs on
CpG interrogations were dropped using addSNPinfo. Proteome data was analyzed using
Qiagens IPA tool1 (QIAGEN Inc., Hilden, Germany) [195]. Gene set enrichment analysis
was performed using the GSEA tool from the BROAD institute [196] using the KEGG2
database [197]. Analysis was run with default parameters and 1000 phenotype permuta-
tions. All gene sets with pFDR <0.1 after permutations were considered significant in all
pathway analysis.
4.5 Results
4.5.1 Epiploic adipose tissue exhibits high adipokine expression
An initial characterization of adipose tissue and inflammation hallmark genes revealed
an increased expression of various adipokines and markers of lipid metabolism in epiploic
adipose tissue compared to all other analyzed tissues (Fig. 6, Table S3, see Appendix A.1).
Particularly high differences were observed for leptin, progranulin, chemerin, PPARG
and CEBPA (all p<10-6). Inflammatory markers with increased expression in epiploic
adipose tissue included caspase-1 and TLR9 but no increased expression of inflammatory
cytokines IL6 and TNFA was observed (Fig. 4.1 A-F, Table S3, see Appendix A.1). The
amount of adipose tissue macrophages was similar to subcutaneous and slightly lower
compared to omental adipose tissue (Fig 4.1 I). The observed mean adipocyte size was
similar to omental-visceral adipose tissue, albeit with less adipocytes in the range of 40
to 70 µm, and smaller compared to subcutaneous adipose tissue. Epiploic adipose tissue
had the most amount of very small adipocytes, and differences to the other tissue were
especially large in the group of patients with T2D (Fig 4.1 G and H). Correlation between
macrophage infiltration and adipocyte size with both expression of IL6 and TNF in the
respective tissue and circulating protein levels were observed in omental and subcutaneous
but not epiploic adipose tissue (Fig. 4.1 J).
1https://www.qiagenbioinformatics.com/products/ingenuitypathway-analysis
2https://www.genome.jp/kegg/pathway.html
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4.5.2 Epiploic adipose tissue has a distinct mRNA profile
On transcriptome level, epiploic adipose tissue was distinctly different compared to all
other adipose tissues, however mesenteric adipose tissue was very similar to omental-
visceral fat (Fig. 4.2A-F). Based on the first two components of a comparative PCA,
epiploic fat was placed between subcutaneous and the other visceral depots (Fig. 4.2 H).
Highest p-values between tissues were observed comparing to mesenteric and omental
adipose tissue, and the same top three genes were HOXA10, HOXA11A and HOXA9,
contrary, highest fold changes were observed when comparing to subcutaneous adipose
tissue (Fig. 4.2 A-C). Trancriptome profile of most differently expressed genes allowed
a clear discrimination of adipose tissue, however an intermediary profile was observed
for some samples while comparing epiploic to omental adipose tissue and this effect was
independent from subjects sex or diabetes status. Candidate genes were identified based
on p-values, fold changes and an extensive literature search (Table 4.3), and validated by
qRT-PCR in the large cohort (Fig. 4.2 G).
Gene set enrichment analysis results showed that significantly different regulated path-
ways are selectively enriched in epiploic adipose tissue compared to the other three depots
(Fig. 4.2 I). The only KEGG pathways differently abundant versus all other three depots
was Mtor-signaling. Proteasome as well as amino and nucleotide sugar metabolism were
upregulated compared to both visceral depots and type 2 diabetes pathways were upreg-
ulated compared to mesenteric and subcutaneous adipose tissue. In addition, tryptophan,
β-alanin, arginine and proline metabolism were upregulated versus subcutaneous adipose
tissue and pyruvate metabolism versus omental-visceral adipose tissue (Fig. 4.2 I).
4.5.3 DNA-Methylation and proteomics underline inimitability
of epiploic adipose tissue
The tissues were furthermore compared based on their methylation level and differently
methylated CpG sites partially reflected the differentially expressed genes (Fig 4.3). To
Figure 4.1 (preceding page): Fundamental characterization of epiploic adipose tis-
sue; A-F) Gene expression of selected adipokines and proinflammatory markers given as
normalized z scores, G) relative distribution of adipocyte diameter in increments of 10 µm,
H) mean adipocyte diameter, I) amount of macrophages per 100 adipocytes, J) heatmap
showing correlations between adipocyte diameter and adipose tissue macrophages with
parameters of inflammation and insulin resistance as well as adipokine expression, color in-
dicated correlation coefficient and a nominal p-value<0.5, *: pFDR<0.05, ***: pFDR<0.001
Epi: Epiploic, Mes: Mesenteric, Om: Omental, Sc: Subcutaneous, circ.: circulating, FPG: fasting plasma
glucose, HbA1c: glycated hemoglobin A1c, BMI: body mass index
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Epiploic vs Subcutaneous Epiploic vs Omental Epiploic vs Mesenteric
gene correlation P gene correlation P gene correlation P
TCF21 -0.86 8.6-6 HOXA9 -0.87 4.3-6 HOXA9 -0.89 2.8-7
PRRX1 -0.81 4.3-5 MAB21L2 -0.85 8.4-6 HOXA4 -0.85 2.5-6
HLX -0.80 0.00011 GARNL3 -0.76 0.00085 EBF3 -0.82 1.9-5
HOXC9 -0.77 0.00018 CHST15 -0.75 0.0015 HOXB5 -0.74 0.00042
PTGDS -0.76 0.00034 NR2F1 -0.74 0.0015 HOXA2 -0.74 0.00043
VEGFC -0.72 0.0013 GATA6 -0.73 0.0022 MN1 -0.72 0.00065
ISL1 0.81 4.3-5 EMX2OS 0.72 0.0024 TWIST1 0.77 0.00015
WT1 0.82 4.3-5 PRKCZ 0.73 0.0022 HOXA10 0.81 2.4-5
IRX2 0.84 1.3-5 C10orf90 0.75 0.0013 WNT5A 0.81 2.4-5
EN1 0.85 8.5-6 HOXA10 0.80 0.00015 HOXA13 0.87 7.1-7
PITX2 0.90 4.2-7 HOXA13 0.88 2.7-6
NKX2-3 0.93 1.7-8 BARX1 0.93 3.4-8
Table 4.2: Genes with correlating observations of differentially methylated re-
gions and differntially expressed genes
strengthen the results, differently methylated regions (DMRs) were determined and cor-
related with differentially expressed genes, and the most significant overlaps included,
for example, several HOX genes (HOXA9, A4, B5, A10, A2 ), WNT5A, or ISL1 (Table
4.2). In total, 31 DMRs were associated with gene expression compared to mesenteric (21
positively/ 10 negatively), 59 compared to subcutaneous (31/ 28) and 46 compared to
visceral adipose tissue (23/ 23). In contrast, 119 DMRs overlapped with gene expression
comparing subcutaneous with omental adipose tissue (73/ 46) and 13 comparing omental
to mesenteric adipose tissue (8/ 5).
Proteome pathway analysis revealed that IL-8, β-adrenergic, CXCR4, phospholipase C,
CDK5, ephrin receptor and proteinkinase A signaling as well as NRF2-mediated oxida-
tive stress response were upregulated and glycolysis and rhoA signaling downregulated in
epiploic adipose tissue compared to both omental and subcutaneous adipose tissue (all
PFDR<0.05).
Figure 4.2 (preceding page): Transcriptome analysis comparing epiploic adipose
tissue with reference tissues; A-C) Volcano plots showing differentially expressed
genes, positive fold change: upregulated in epiploic fat, 15 most significant genes are an-
notated, D-F) Heatmaps showing tissue clustering of the 100 most significant, differentially
expressed genes, red indicates higher expression in epiploic fat, G) qRT-PCR replication
of the candidate gene MMP9 between tissues, H) PCA showing tissue clustering based
on transcriptomics, I) visualization of KEGG pathway analysis, ***: p(FDR)<0.001
vs: versus, T2D: type 2 diabetes, NES: normalized enrichment score
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5
Figure 4.3: Differentially methylated CpG sites between epiploic and omental
adipose tissue; top hits per chromosome are annotated
4.5.4 Multiomics profile between patients is largely different in
epiploic adipose tissue
Transcriptome
Patients were classified into being insulin sensitive or insulin resistant (see Methods) and
both transcriptome and proteome profile were compared between patient groups. Based
on mRNA levels, epiploic adipose tissue showed the strongest separation between these
groups, with 27 genes being differentially expressed, of which the most significant were
RNASE4 (PFDR=0.01, logFC=0.7) and ADHFE1 (PFDR=0.01, logFC=0.65). Top hits
and candidate genes (Table 4.3) were subsequently validated by qRT-PCR in the original
cohort and the large differences observed in the strictly matched, small cohort diminished
in the large cohort, indicating a role in insulin resistance but not type 2 diabetes in
general (Figure 4.4). Epiploic adipose tissue was followed by mesenteric adipose tissue
which showed nine differentially expressed genes between patients with and without insulin
resistance, followed by omental (n=1) and subcutaneous (n=0) adipose tissue. SLC27A2
was a gene commonly found in all comparisons. Considering differentially enriched KEGG
3 pathways in epiploic adipose tissue, most were found to be more abundant in the insulin
sensitive group, including fatty acids metabolism (pFDR= 0.017, NES=-1.98) and pyruvate
metabolism (pFDR=0.017, NES=-1.89). In total, 18 pathways reached an adjusted p-value
3https://www.genome.jp/kegg/pathway.html
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Gene PFDR log(2) FC Described function
Epiploic adipose tissues
RNAS4 0.01 0.7 Same locus as ANG; angiogenetic [228]
ADHFE1 0.01 0.65 Needed for adipocyte phenotype in WAT and BAT, increased in diabetic mice [229]
CIDEA 0.02 1.27 CIDEA-/- have lean phenotype, resistant to obesity [230]
DAPK2 0.02 1.06 Specific for mature adipocytes, downregulation in obesity independent from sex and diabetes [231]
SPTBN1 0.02 1.02 Involved in pathogenesis of obesity [232]
ANG 0.02 0.54 Related to obesity [228, 233]
FAM13A 0.02 0.75 Impaired in obesity, protects IRS1 from proteasomal degradation, activation improves IS [234]
Mesenteric adipose tissues
MMP9 0.01 -2.25 Marker of adipogenesis, but no inflammation, related to IS [235]
SLC27A2 0.03 1.12 Confounding: decreased in peripheral blood of children with obesity and AT of overfed rats,
but overexpression in rats on “cafeteria”-diet [236]
Table 4.3: Candidate genes
FC: fold change, BAT/ WAT: brown/ white adipose tissue, IS: insulin sensitive
< 0.1 (Table 4.4). Similar to differentially expressed genes, fewer enriched gene sets were
found in the other three adipose tissue depots (Table 4.4).
Proteome
Proteome analyses further supported the findings obtained by transcriptomics. Consis-
tently, epiploic adipose tissue showed a strong discrimination of insulin sensitive and
resistant subjects, which was in this case similar to omental adipose tissue (Figure 4.5
A-C).
The proteins with the highest significance and fold change in epiploic adipose tissue in-
cluded CLTC, NCL and VPS13C (Figure 4.5 D). Many proteins overlapped with dif-
ferentially expressed genes manifesting correlation coefficients > 0.7 for all comparisons.
Subsequently, weighted correlation network analysis was performed to identify key drivers
explaining tissue dependent variances between patient groups. Biological processes as well
as correlations of certain protein clusters with phenotype groups are shown in Figure 4.5
G. In general, proteins involved in fatty acid oxidation and the tricarboxylic acid cycle are
significant positively associated with epiploic fat in patients with insulin sensitivity and
cell aging and cell-cell signaling proteins are negatively correlated with insulin resistance
in epiploic fat. Additionally, in epiploic adipose tissue proteins of the integrin-mediated
Figure 4.4 (preceding page): Transcriptome analysis comparing insulin sensitive
and resistant individuals; A-D) Top 25 differentially expressed genes, significant genes
after FDR correction are highlighted, E) volcano plot showing differentially expressed
genes in epiploic fat, the 15 most significant genes are annotated, positive fold changes
indicates higher expression in the sensitive group, F,G) qRT-PCR replication of candidate
genes in the matched (F) and large cohort (G), *: p(FDR) <0.05, ***: p(FDR) <0.001
FDR: false discovery rate
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Kegg pathway ES NES p pFDR
up regulated in insulin resistant epiploic adipose tissue
LYSOSOME 0.49 1.91 0.01 0.05
up regulated in insulin sensitive epiploic adipose tissue
FATTY ACID METABOLISM -0.59 -1.98 0.00 0.02
LYSINE DEGRADATION -0.52 -1.94 0.00 0.01
PYRUVATE METABOLISM -0.55 -1.89 0.00 0.02
PEROXISOME -0.53 -1.89 0.00 0.01
PROPANOATE METABOLISM -0.62 -1.77 0.01 0.04
AMINOACYL TRNA BIOSYNTHESIS -0.38 -1.76 0.01 0.04
VALINE LEUCINE AND ISOLEUCINE DEGRADATION -0.56 -1.75 0.03 0.04
HISTIDINE METABOLISM -0.55 -1.74 0.01 0.03
BUTANOATE METABOLISM -0.60 -1.68 0.01 0.05
RNA POLYMERASE -0.48 -1.68 0.05 0.05
RIBOSOME -0.41 -1.65 0.05 0.06
ONE CARBON POOL BY FOLATE -0.53 -1.62 0.04 0.07
GLYCOLYSIS GLUCONEOGENESIS -0.38 -1.61 0.00 0.07
BIOSYNTHESIS OF UNSATURATED FATTY ACIDS -0.58 -1.59 0.05 0.08
PPAR SIGNALING PATHWAY -0.45 -1.59 0.00 0.08
CITRATE CYCLE TCA CYCLE -0.51 -1.59 0.06 0.07
GLYOXYLATE AND DICARBOXYLATE METABOLISM -0.57 -1.57 0.03 0.08
up regulated in insulin resistant mesenteric adipose tissue
LYSOSOME 0.45 1.88 0.00 0.13
VIBRIO CHOLERAE INFECTION 0.38 1.85 0.00 0.09
Table 4.4: Differentially abundant pathways between patients with and without
insulin resistance
(N)ES: normalized enrichment score
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signaling and extracellular matrix disassembly pathways are oppositional regulated in
the patient groups. Two exemplary key driver analyses are shown in Figure 4.5 H and
I. Among them ECHDC3, PECR, PPA2, LETM1 and MAP4 were identified as proteins
with strong effects on insulin sensitivity in epiploic adipose tissue (Figure 4.5 H and I).
Proteome pathway analysis revealed that consistently with transcriptome analyses, in
epiploic adipose tissue IPA pathways such as oxidative phosphorylation and fatty acid
oxidation were upregulated in insulin sensitive patients and leukocyte and IL-8 signaling
were upregulated in the insulin resistant group (Figure 4.6).
4.6 Discussion
In this part of my thesis in aimed to characterize two adipose tissues which have been
rarely investigated in the context of metabolic diseases. Mesenteric adipose tissue, which
is located in close proximity to the small intestine, was extensively characterized for its
role in inflammatory bowel diseases like Crohn’s disease [198, 199]. Contrary, the fat
of the appendices epiploicae of the colon was previously only considered as cushioning
layer [156]. Based on a standard characterization of adipocyte size and adipose tissue
macrophages (only epiploic) no major differences were observed, expect the in general
larger adipocytes in subcutaneous adipose tissue as expected [200]. This indicates that
epiploic adipose tissue is a white adipose tissue, with a comparable ability to store
excess energy. It furthermore showed no increased inflammation, at least in regard
to adipose tissue macrophages. Gene expression of inflammatory genes TNF and IL6
was also not increased, however I observed an increased expression of CASP1 and
TLR9. TLR9 is known to be activated by unmethylated viral or bacterial DNA and
downstream signaling activates both IL-6 and TNF-α. Considering that I did not observe
increased levels of bacterial DNA, and IL6 as well as TNF expression other binding
targets or mechanisms are possible. For example Nishimoto et al. reported low grade
tissue inflammation mediated by cell-free DNA from dying adipocytes which activates
TLR9 ultimately leading to and increased release of chemoattractant protein MCP-1 [201].
Figure 4.5 (preceding page): Untargeted proteomics comparing insulin sensitive
and resistant individuals; A-C) PCA showing clustering of patient groups and, D-F)
the volcano plot for the respective comparison underneath, significant hits after colored
and hits with high p value and fold change are annotated, G) WGCNA for patient and
tissue group comparisons, significant results are indicated by correlation coefficient and p
value, related biological processes are annotated H, I) two examples for WGCNA related
key driver analysis, *: pFDR<0.05, **: pFDR<0.01, ***: pFDR<0.001
IS: insulin sensitive, IR: insulin resistant, FA: fatty acid, ER: endoplasmatic reticulum
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Striking findings were obtained in case of adipokine and lipid marker gene expression.
Overall, epiploic adipose tissue showed an increased expression of nearly all tested genes,
with particularly elevated levels for leptin and PPARG expression. These results suggest,
that epiploic adipose tissue is highly metabolically active, although ir remains elusive
wheter the adipokines exert their effects locally or centrally. It is of note however, that
the increased leptin expression was accompanied by an increased expression of leptin
receptor, albeit on a smaller scale, which could point to an increased leptin signaling in
epiploic adipose tissue. Mesenteric adipose tissue exhibited expression levels comparable








































Epiploic adipose tissue: insulin resistant vs sensitive:
Figure 4.6: Co-regulation of proteins and
mRNA; Blue hue indicates upregulation in
insulin sensitive and red in insulin resistant
individuals
To further investigate the differences be-
tween epiploic and other adipose tissues,
a small but well-matched cohort was ana-
lyzed using transcriptome and methylation
arrays as well as untargeted proteomics. As
expected, all fat depots including the epi-
ploic adipose tissue showed differentially
expression of many developmental genes
[202], HOXA9 and HOXA10 being the
most prominent ones in epiploic fat. The
selectively upregulated lipopolysaccharide
binding protein (LBP) and olfactomedin 4
(OLFM4 ) in epiploic adipose tissue might
be linked to increased intestinal permeabil-
ity or an inflamed colon, as OLFM4 is
known to be associated with an increased
inflammation and OLFM4-/- mice exhibit
an increased immunity against E. coli and
S. aureus infections [203, 204]. Subsequent
pathways analysis supported the data ob-
tained from adipokine gene expression: that epiploic adipose tissue shows an increased
metabolic profile compared to other adipose tissues as various metabolic pathways were
upregulated selectively in this depot, among them tryptophan, sphingoliplid, β-alanine,
arginine, proline, pyruvate and amino sugar metabolism. Additionally, many inflamma-
tory pathways were upregulated on both mRNA and protein level that involved T-cell
and chemokine signaling as well as IL-8 and toll-like receptor signaling. Taken together,
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these results point to the presence of various processes involved in immune cell migration
and inflammation in epiploic tissue, which might be attributable to its location on the
large intestine. However, as mentioned above, these pathways were not associated with in-
creased expression of TNF and IL6 or an increased macrophage infiltration. It is possible,
that rather bacterial metabolites or colonic macrophages due to altered microbiota than
increased infiltration of bacteria per se are playing a role. Kawano et al. demonstrated
that the colon is the first tissue exposed and responding to a high-fat diet by increased
MCP1 expression in colon epithelial cells, which leads to adipose tissue inflammation and
insulin resistance [205].
This process is thought to involve the activation of the NLRP3 inflammasome, character-
ized by an increased CASP1 expression, which I could likewise observe in epiploic adipose
tissue [205]. Activation of the NLRP3 inflammasome was further associated with a mas-
sive increase in CXCR4 expression [205], which was also reflected on both mRNA and
proteome level in epiploic adipose tissue in the present cohort. Another mechanism might
involve SCFA, as Smith et al. report that gut microbiota-derived fermentation products
leads to increased levels of CD4+ T-cells in the colon [206] and it is well documented that
SCFA alter many metabolic processes including lipolysis, gluconeogenesis and insulin sen-
sitivity [207, 208] and that SCFA receptors GPR109A, GPR41 and GPR43 are expressed
in white adipose tissue [207].
An additional mechanism might involve GLP-1 related pathways: Grasset et al. showed
that enteric GLP-1 production is increased upon gut dysbiosis which is further linked to an
excessive amino acid metabolism [209] reflected by enriched pathways in epiploic adipose
tissue. Furthermore, GLP-1 receptor agonists were reported to modulate the enteric im-
mune response via the intestinal intra-epithelial lymphocyte GLP-1 receptor [210]. More
targeted functional studies will be necessary to identify the processes involved leading to
the observed increased metabolic profile of epiploic adipose tissue.
Based on both proteome and transcriptome data, separation of patient groups according
to the insulin sensitivity/ resistance status was distinct in all visceral depots, except for the
subcutaneous adipose tissue. According to the expression profiles, most significant results
were surprisingly observed in epiploic adipose tissue, suggesting an active role of epiploic
adipose tissue in the development in insulin resistance, possibly linked to gut microbiome
alterations in the colon in patients with diabetes [211, 212] or in patients taking antidia-
betic drugs [53, 213]. Noteworthy, when validating target genes in the large cohort (type 2
diabetes vs non diabetes), containing individuals with insulin resistance but no diabetes,
results were attenuated, suggesting a strong role of these genes (RNASE4, ADHFE1,
MMP9 ) in mediating insulin resistance. Pathways associated with insulin resistance in
epiploic adipose tissue included leukocyte, IL-8 and Mtor signaling, and pathways associ-
ated with insulin sensitivity included oxidative phosphorylation and fatty acid oxidation
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as well as ethanol degradation. Again, this points to an active metabolic involvement of
epiploic adipose tissue in insulin sensitive patients, which shifts to an upregulation of
inflammatory pathways in insulin resistance.
Overall, characterization of epiploic adipose tissue provides novel findings which war-
rant further investigations including gut microbiota and functional studies to identify
key drivers of the characteristic metabolic features of epiploic adipose tissue. Due to its
exposed location on the colon wall, it might be the first adipose tissue (or an organ in gen-
eral) to sense gut microbiota alterations and to provide a metabolic response by increased
inflammation and adipokine signaling.
Chapter 5
Bacterial translocation to human
adipose tissue in metabolic disease
5.1 Rationale
As depicted in the Introduction and Chapter 2, there is increasing evidence that the in-
testinal microbiota is altered in both composition and function in obesity. This shift is
associated with chronic low-grade inflammation and metabolic pathologies. Further evi-
dence from rodent models suggests a mechanism contributing to the obesity development
and adipose tissue inflammation: Increased intestinal inflammation due to changes in mi-
crobiota or nutrition lead to an impairment of intestinal barrier integrity and a subsequent
translocation of bacteria into the host circulation and mesenteric adipose tissue [131, 146].
The mechanism of microbial contribution to disease pathogenesis has not been adequately
explored in humans and contradicting data has been published [127, 132, 146] (see Chap-
ter 2 Impaired intestinal barrier: a pathomechanism for metabolic diseases?).
The focus of this part of the thesis was on a contaminant-aware identification of bacteria or
bacterial components in human adipose tissue and its possible link with inflammation and
insulin resistance. Emphasis was put on establishing a pipeline to keep contaminations to
a minimum and to include appropriate negative controls as well as state of the art bioin-
formatic tools to control for the latter (such as decontam [214]). The results are mainly
based on 16S rRNA gene sequencing data, which allow an easy and robust identification
of the present genera, but cannot determine if “alive” bacteria are present. Nevertheless,
the viability of bacteria was addressed using immunohistochemistry approaches. It has to
be acknowledged as well, that only adipose tissue of 75 patients with obesity undergoing
Roux-en Y gastric bypass was included and no lean and evidently healthy subjects were
available for the analyses. Therefore, patients with obesity but without type 2 diabetes
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were taken as a reference for contrasting with adverse metabolic states associated with
obesity. The results could help to determine if mechanisms of microbial-induced pathology
similar to the one reported in experimental models by Amar et al. [131] exist in humans
and if specific taxa might have a key role. Together with results from further replication
cohorts or other studies verifying these findings, investigating adipose tissue bacteria may
lead to novel, more specific and effective treatments for obesity and metabolic disease.
The manuscript has been submitted and is currently in revision in the journal Gut.
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5.2.1 Abstract
Objective: The “leaky gut hypothesis” has been suggested as a mechanism for bacterial
translocation to various organs, but bacterial transfer to human adipose tissue (AT) re-
mains poorly understood and its impact on metabolism elusive. We hypothesized that, I)
bacterial DNA is highly tissue specific, II) related in composition and quantity to immune
inflammatory and metabolic burden.
Design: We quantified and sequenced the bacterial 16S rRNA gene in blood and AT sam-
ples (omental, mesenteric, subcutaneous) of 75 subjects with obesity with or without type
2 diabetes (T2D).
Results: Under stringent experimental and bioinformatic control for contaminants, bacte-
rial DNA was detected in blood and omental, subcutaneous and mesenteric AT samples
in the range of 0.1 to 5 pg/µg DNA isolate. Bacterial composition was reminiscent of the
gut microbiome with Proteobacteria and Firmicutes being the predominant phyla. Mesen-
teric AT was identified as a primary site of bacterial translocation reflected in the highest
bacterial diversity across tissues. Bacterial quantity was associated with immune cell in-
filtration, inflammatory and metabolic parameters in a tissue specific manner. Moreover
similarly differentially abundant bacteria between subjects with and without T2D were
associated with anthropometric measures such as age and BMI, insulin resistance such as
HOMA-IR and local and systemic immune markers such as IL-6 and bacterial quantity.
Conclusions: Our study provides contaminant aware evidence for the presence of bacte-
rial DNA in several ATs in obesity and T2D, and suggests an important role of bacteria
in initiating, and sustaining local AT subclinical inflammation and therefore impacting
metabolic sequelae of obesity.
5 Bacterial translocation to human adipose tissue in metabolic disease 79
5.2.2 Introduction
There is compelling evidence that the intestinal microbial composition and function can
be altered by a western diet, and that these alterations result in host pathologies, includ-
ing obesity, inflammation, insulin resistance and type 2 diabetes (T2D), phenotypes which
are transmissible via microbiota transfer [1–5]. Studies in animal models revealed “leaky
gut” as a mechanism whereby diet-induced intestinal microbiota shifts contribute to these
metabolic disease states: Intestinal microbiota alterations in high-fat diet (HFD)-fed mice
associate with intestinal inflammation, increased intestinal permeability, bacterial intesti-
nal mucosal adherence and transmucosal bacterial translocation to mesenteric AT and
blood [6–9]. These events correlate with increases in adiposity and weight gain, mesen-
teric AT inflammation, systemic and tissue inflammatory markers leading to metabolic
dysregulation and insulin resistance in mice [6–9]. Antibiotics intervention significantly
improves these abnormalities, including intestinal integrity, even under high fat diet chal-
lenge [9, 10]. Combined, these results advocate for a contributing role of bacterial translo-
cation to obesity, inflammation and metabolic dysfunction in mouse models. Moreover,
differences in bacterial translocation may contribute to the large variance in obesity-
related pathologies. However, it remains to be determined whether similar mechanisms of
microbial-induced pathology exist in humans, and whether specific bacterial taxa might
have a key role [11, 12]. Few human studies have demonstrated that intestinal permeabil-
ity is associated with visceral adiposity [13] and metabolic syndrome in obese individuals
[14], is increased in patients with T2D, and is significantly correlated with serum CRP
levels [15]. Moreover, the amount of circulating bacterial DNA has been shown to play a
role in the development of cardiovascular events [16] and T2D [17]. Based on these results
it was hypothesized that bacteria in the circulation might also migrate into other organs
such as AT, contributing to the commonly observed chronic low grade inflammation in
insulin resistance and T2D. Yet, the pathological process leading thereto is ill-defined in
humans.
Therefore, we aimed to investigate whether bacterial DNA is present in different AT de-
pots of subjects with obesity and if the amount and composition of these bacteria can be
attributed to their metabolic and/or inflammatory state.
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5.2.3 Methods
Study subjects
For the present study, 75 patients with obesity undergoing laparoscopic Roux-en-Y gas-
tric bypass surgery were recruited at the University of Leipzig Medical Center, Germany.
All patients gave written informed consent before taking part in the study, which was
approved by the ethics committee of the University of Leipzig (017-12-23012012). Exclu-
sion criteria included chronic or acute inflammatory disease as defined by white blood cell
counts and/or high sensitive C-reactive protein (hsCRP) alongside clinical symptoms,
antibiotics treatment within 2 months prior to surgery, pregnancy and/or nursing. All
subjects underwent routine clinical phenotyping including oral glucose tolerance test, col-
lection of anthropometric (age, sex and body mass index (BMI)) and metabolic parameters
such as fasting plasma glucose (FPG), fasting plasma insulin (FPI), high density lipopro-
tein (HDL) cholesterol, Homeostasis model assessment for insulin resistance (HOMA-IR),
hemoglobin A1c (HbA1c) as well as blood cell count.
Assessment of inflammatory status
hsCRP and white blood cell count were measured according to local laboratory routine
practice. Circulating levels of tumor necrosis factor alpha (TNF-α) and interleukin 6 (IL-
6) were measured by high-sensitive ELISA (R&D Systems, Minneapolis; HSTA00E and
HS600B) using undiluted serum according to the manufacturer’s protocol. Lipopolysac-
charide binding protein (LBP) was measured by ELISA (Hycult Biotech, Uden, Nether-
lands, #HK315-02) using diluted plasma (1:1000) according to the manufacturers’ proto-
col.
Sample preparation
AT biopsies (abdominal subcutaneous, omental- and mesenteric-visceral) were collected
before opening the intestine to prevent spill-over contamination during the surgery. Sub-
cutaneous AT was taken from the incision of the first trocar in the left paramedian mid
abdomen, omental tissue was taken from the mid of the pars libera of the greater omen-
tum and mesenteric tissue was taken from the mesenterium of the mid jejunum close to
the bowel wall and immediately put on ice. Prior to processing of the tissues in a pre-PCR
lab, the laminar flow-hood as well as the required lab ware were pretreated with UV for
at least 90 minutes. After transferring and aliquoting, samples were immediately frozen
in liquid nitrogen and stored at -80°C.
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DNA was isolated using Qiagen DNeasy Kit with an additional lysozyme degradation
step at a 0.25 mg/mL dilution (L7615, Sigma-Aldrich, Missouri, USA). A negative con-
trol (UV-treated PBS) was included for each isolation and included in all subsequent
steps. RNA was isolated using Qiagen RNeasy Lipid tissue mini kit and was reversely
transcribed using Super Script III (ThermoFisher Scientific, Massachusetts, USA).
Immunohistochemistry
Sample aliquots for immunohistochemistry (IHC) were incubated in 4% paraformaldehyde
in PBS for at least 24 h and embedded in paraffin. Paraffin blocks were sliced into 6 µm
slides and treated with DAKO retrieval solution (pH=9) for 30 minutes by applying hot
steam. Adipocytes were stained with anti-perilipin-1 (goat, 1:200; Abcam, Cambridge,
UK) and macrophages with anti-Iba1 (rabbit, 1:500; Fujifilm Wako Chemicals, Tokio,
Japan). Donkey serum was used as blocking buffer and the primary antibody was incu-
bated at 4°C overnight. As secondary antibodies, donkey anti-goat with Alexa Fluor 488
(1:200) and donkey anti-rabbit with Alexa Fluor 568 (1:200; both Invitrogen, California,
USA) were used for one hour at RT. Supervised automated analysis was performed using
CellSens software (OLYMPUS Life Science, Shinjuku, Japan) to assess adipocyte count
and diameter as well as counts of macrophages and crown like structures in AT.
Gene expression
Gene expression was measured using TaqMan probes with 2x PCR mastermix (Applied
Biosystems, Foster City, USA) on a LightCyler 480 (Roche, Basel, Switzerland) in a 384
well format. Plates were pipetted on a Pipetmax platform (Gilson, Wisconsin, USA). For
optimal normalization nine reference genes were tested for their stability over all analyzed
tissues between insulin sensitive and insulin resistant subjects. Two genes, GAPDH and
B2M were chosen as final reference genes. PCR efficiency was calculated using a duplicated
standard curve in each run. Analysis was done according to the ΔΔCt method [18].
Quantification of bacterial DNA
Quantification of bacterial DNA in blood and AT was performed according to Amar et al.
(16). The primers (5’- CGGTGAATACGTTCCCGG-3’ and 5’- TACGGCTACCTTGT-
TACGACTT -3’) were used accordingly with optimized PCR conditions (98°C for 2 min.;
42 cycles of 95°C/15 sec., 60°C/30 sec., 72°C/20 sec.) with a High Resolution Melting
master mix (Roche, Basel, Switzerland 04909631001). A duplicated standard curve using
purchased E. coli JM 109 DNA dilutions (Promega, Madison, USA) was used for quan-
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tification. Results were in concordance with a commercially available kit (Zymoresearch,
California, USA) (n=13, r=0.74, p=0.004) and proved more sensitive (ΔCt=3.9).
Amplification and sequencing of V4V5 region of 16S rRNA
A variety of 16S primers were tested, however nonspecific human DNA amplification was
observed for most due to very low amounts of bacterial DNA in the samples. Consequently,
primers adapted from the Ribosomal Database Project (RDP) [19] and Claesson et al. [20]
amplifying the V4/V5 region (V4-F: 5’-actgggcgtaaagcg-3’; V5-R: 5’-ccgtcaattcctttgagttt-
3’) were used. After extensive testing of various polymerases, the high fidelity Q5 proof
reading polymerase was chosen for amplification (New England BioLabs, Ipswich, USA).
A detailed summary of all tested primers and polymerases can be found in Table S4
and S5. All negative controls as well as additional PCR-negative controls for each run
were included, amplified and sequenced. Paired-end sequencing was performed by BGI
Genomics (Shenzhen, Guangdong, China) on a HiSeq 2500 platform with an average of
2x 157,045 (± 68,730) raw reads.
Statistics
All statistics were performed in R 3.5.1 (R Core Team, 2018) and SPSS 24 (IBM,
Armonk, New York). All figures were generated in R 3.5.1 using ggplot2 v3.1.1 [21],
phyloseq v1.26.1 [22], vegan v2.5-4 [23] and circlize v0.4.7 [24] and were relabeled using
Adobe Illustrator (Adobe Inc., CA, USA). Spearman’s rank correlation test was used
for correlation analyses of non-normally distributed data. Student’s t-test and Wilcoxon
signed-rank-test/ Mann-Whitney U test were used for group comparisons based on data
distribution, which was tested by Kolmogorov–Smirnov test.
Analysis of 16S Data
Preprocessed and quality-filtered paired end sequencing data (avg. 112,973 ± 48,825
reads) were obtained from BGI Genomics. Preprocessing included removal of reads with
a certain proportion of low quality (20) bases (20% of read original length), removal of
reads contaminated by adapter (5 bases overlapped by reads and adapter with maximal
3 bases mismatch allowed), removal of reads with ambiguous bases and removal of reads
with low complexity (reads with 10 consecutive same base). Data was imported to
Qiime2 v2018-11 [25] with all subsequent steps performed using QIIME2 plugins for the
cited software packages. Paired-end joining and denoising was performed with DADA2
[26] leaving 3,663 features in 370 samples (including negative controls) with a median
frequency of 77,601 [40,141 - 103,152] reads and a mean length of 325.6 ± 15.1 base
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pairs. A rooted tree was generated using the align-to-tree-mafft-fasttree [27]. Taxonomic
assignment was performed using the q2-feature-classifier [28] which was trained for the
used primers using the 99% OTU data set of the SILVA 132 release [29]. Subsequently,
taxonomy and generated feature tables were imported to phyloseq v1.26.1 [22] for
further analysis. All features not assigned to bacteria, as well as mitochondrial and
chloroplast features were excluded (∑ = 193). Decontam v1.2.1 [30] was used to filter
out features on genus level with a high chance of being contaminants using sequenced
negative controls. Prevalence based contaminant identification was used with a threshold
score of 0.5, filtering out 41% of features as potential contaminants and leaving 309
genera. Additionally, samples with only contaminants were excluded, resulting in 317
samples taken forward for further analysis. Comparison of alpha diversity (Observed,
Shannon) was done in phyloseq and ordination analysis including calculating Bray-Curtis
dissimilarity [31], multivariate homogeneity of Groups dispersions and distance based
redundancy analysis (db-RDA) were performed using vegan v2.5-4 [23]. Differential
abundance was calculated with DESeq2 v1.22.2 [32], applying poscount type for size
factor estimation, followed by a Wald significance test employing a local fit. Correlation
of genera with markers of interest was performed using the microbiome package for R
v1.4.2 [33] employing Spearman’s rank correlation.
5.2.4 Results
Inflammatory burden and metabolic impairment in the study cohort
75 patients undergoing bariatric surgery were recruited for this study, whereof 33 had
T2D. Parameters of glucose metabolism including fasting plasma glucose, HOMA-IR and
HbA1c and circulating inflammatory markers such as TNF-α, IL6 and CRP were sig-
nificantly higher in subjects with T2D compared to individuals without T2D (Table 1).
Subjects with T2D were significantly older (45.2 ± 11.0 vs. 52.5 ± 11.3 years, p=0.006).
As expected, measures of inflammation correlated positively with HOMA-IR and HbA1c
and negatively correlated with HDL-cholesterol.
Furthermore, circulating inflammatory parameters such as TNF-α (ρ=0.29, p=0.02) and
CRP (ρ=0.32, p=0.01) correlated significantly with LBP levels, which in turn were corre-
lated positively with BMI (ρ=0.32, p=0.01) and fasting plasma insulin (ρ=0.28, p=0.03)
and increased in patients with T2D albeit not significantly (11.5 ± 3.9 vs 13.4 ± 5.7 ng/µl,
p=0.12) (Table 1).
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Bacterial DNA is detectable in AT
We detected bacterial 16S rRNA gene in human AT as well as blood in a range of 0.1-5
pg per µg total DNA. All biological samples had significantly higher amounts of bacterial
DNA compared to negative controls carried through the whole experimental process in-
cluding DNA isolation (Figure 2A). Highest values were observed in blood with 1.12 [0.58
– 1.84] pg/µg total DNA, followed by mesenteric AT (0.65 [0.49 – 1.02] pg/µg and subcu-
taneous (0.64 [0.25 -1.62] pg/µg). Omental AT had only slightly higher values compared
to the negative controls (0.24 vs. 0.21 pg/µg, p=0.04). 88.0% of all blood samples, 78.7
% of mesenteric, 69.3 % of subcutaneous, and 46.7% of omental AT samples had higher
amounts of bacterial DNA when compared to the mean quantity of the negative controls
(Figure 1A). As a positive reference, DNA isolated from stool samples was included which
contained 0.39 [0.20 – 0.72] µg/µg total DNA bacterial DNA (Figure 1B). Using the E. coli
genome (4.6 Mbp) as reference, up to 0.7% of the cells were estimated to be of bacterial
origin in adipose tissue.
Quantity of bacterial DNA correlates with markers of inflammation
In a fat depot-specific manner, bacterial DNA load correlated with markers of inflamma-
tion including the expression of TNFA (ρ=0.25, p=0.04 in subcutaneous AT) and IL1B
(ρ=0.34, p=0.007 in mesenteric AT) as well as macrophage infiltration in omental AT
(ρ=0.46, p=2.0 x10-4; Figure 1C). Subgroup analyses revealed, that some of the observed
correlations were driven by T2D status with strong correlations, for example between
tissue macrophages and bacterial load in omental AT (ρ=0.62, p=3.1 x 10-4) in subjects
with T2D (Figure 1C). However, the quantity of bacterial DNA in AT did not correlate
with any anthropometric, glucose or lipid metabolism parameters, except for a negative
correlation between mesenteric AT and BMI (ρ=-0.32, p=0.01). Moreover, the amount of
bacterial DNA in AT did not differ between subjects with and without T2D.
Mesenteric AT exhibits highest bacterial diversity
Observed bacterial richness as well as Shannon distance, were significantly higher in stool
compared to blood and AT depots combined (17.9 ± 4.0 vs 4.9 ± 3.2, p=2.8x10-43 and
1.3 ± 0.3 vs 0.6 ± 0.52, p=3.3x10-7, respectively) (Figure 2A). Considering AT depots
and blood, mesenteric AT showed the highest alpha diversity in both observed diversity
and Shannon distance (5.7 ± 0.3 and 0.82 ± 0.06, respectively), which was significantly
higher compared to blood and visceral AT (p<0.001). Subcutaneous AT also had a slightly
higher alpha diversity compared to blood and omental AT (p<0.01). Measures of alpha
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diversity were not different between subjects with and without T2D (Figure S1).
Inflammation and insulin resistance determine the compositional dissimilarity
between tissues
Bray-Curtis dissimilarity was used to assess compositional dissimilarity between the tis-
sues of interest. There was no homogeneity of the dispersion among the tissues, i.e. vari-
ances between the different tissues were significantly different (Figure 2B). Distance based
redundancy analysis on Bray-Curtis dissimilarity was used to estimate the impact of col-
lected variables on the ordination and therefore bacterial community composition. In
all three ATs bacterial load, inflammatory markers like tissue macrophages, TNF-α and
IL-6 as well as markers of insulin resistance such as HOMA-IR represented parameters
significantly shaping community composition (Table S1, Figure 2C-E). In blood, only
inflammation markers (circulating TNF-α and IL-6, CRP and LBP) and the age of the
subjects accounted for the clustering of the samples (Table S1, Figure 2F).
Proteobacteria and Firmicutes are the predominant phyla in AT
Taxonomy on phylum level was dominated by Proteobacteria and Firmicutes in all AT
depots. Other prominent phyla common to all adipose depots included Actinobacteria
and Patescibacteria (Figure 3A). Chloroflexi and Planctomycetes were mostly observed in
blood (average pFDR=0.001 and pFDR=0.01, respectively; Figure 3D). Both mesenteric
and subcutaneous AT had a large portion of phyla with a mean abundance below 1%
which, among others, included Bacteroidetes and Tenericutes. In contrast, omental AT
had a smaller fraction of low abundant phyla. Tested tissues displayed specific taxonomic
signatures (displayed on genus level in Figure 3B-D, Table S2).
Bacterial composition reflects unique blood and adipose tissue signatures on
genus level
In general, fewer genera were differentially abundant between the analyzed ATs (avg.
5.3) and with 12 differentially abundant genera most differences were observed between
subcutaneous AT and blood. Among those genera, Acinetobacter showed significantly
higher (avg. log(2)FC=6.7, pFDR=2.2x10-8) and Tahibacter significantly lower (avg.
log(2)FC=-20.7, pFDR=1.7x10-3) abundance in all AT compared to blood. Another gen-
era which was more present in blood compared to both visceral AT depots was Delf-
tia (avg. log(2)FC=-27.7, pFDR=7.5x10-20) (Figure 3D). Both genera dominantly found
in blood were associated with diabetes status, Thahibacter positively (log(2)FC=26.8,
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pFDR=1.1x10-18) whereas Delftia negatively (log(2)FC=-27.3, pFDR=3.3x10-19) (Fig-
ure 4A). Among the AT, omental and mesenteric AT were more similar and showed
more differentially abundant genera compared to subcutaneous AT. Among them En-
terobacter (avg. log(2)FC=28.9, pFDR=1.6x10-22) and Gemella (avg. log(2)FC=25.0,
pFDR=3.6x10-22) were significantly increased in subcutaneous AT (Figure 3D).
Bacterial composition and its differential abundance in AT is related to
metabolic disease
Out of 309 analyzed genera, 18 were found to be differentially abundant between
subjects with or without T2D. Most differences were observed in blood and mesen-
teric AT. For three genera, directionally consistent overlaps between tissues were ob-
served: Rhodoferax was less abundant in subjects with diabetes in subcutaneous and
mesenteric AT (log(2)FC=-27.0, pFDR=1.2x10-18; log(2)FC=-8.0, pFDR=0.03), Lacto-
coccus in blood and subcutaneous AT (log(2)FC=-30.0, pFDR=8.9x10-23; log(2)FC=-
30.0, pFDR=2.3x10-22) and Lactobacillus in blood and omental AT (log(2)FC=-30.0,
pFDR=8.9x10-23; log(2)FC=-27.3, pFDR=7.6x10-19)(Figure 4A). Corresponding associ-
ations with related clinical markers were also observed for those genera (Figure 4B).
Amounts of Lactococcus correlated negatively with HOMA-IR in blood and BMI in sub-
cutaneous AT. Most correlations were observed in subcutaneous tissue, especially with
age, bacterial DNA quantity and HOMA-IR. Least correlations were observed in blood,
where genera mostly correlated with circulating IL-6 and the amount of circulating bac-
terial DNA.
5.2.5 Discussion
There is emerging yet controversial evidence for the presence of bacteria in the circulation
and AT [7, 11, 12, 16, 34, 35]. In the present study, under stringent experimental condi-
tions focusing on sterile handling and bioinformatic control for contaminants, we detected
bacterial DNA, which was correlated with macrophage infiltration in various human fat
depots. Moreover we evidenced tissue specific quantitative, taxonomic as well as com-
positional bacterial signatures driven by and significantly associated with inflammatory
markers and metabolic traits in a tissue dependent manner.
Despite the appealing evidence for the presence of bacteria in AT in animal studies [7],
validation in human AT remains challenging. Burcelin et al. presented first exploratory
data, when they proposed the “tissue microbiota” hypothesis [35], which however, has
never been further supported or confirmed in independent studies. In contrast, in 2016
Zulian et al. failed to amplify bacterial DNA from human AT and declared the subject an
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open issue [34]. Taking into account the inconsistencies in previous studies, one would ex-
pect that, if present at all, bacterial DNA in AT would be of very low abundance, making
its experimental validation highly challenging. Predominantly present human DNA is one
of the major factors hindering a successful amplification of the bacterial 16S rRNA gene.
Reagents, handling and cross-contamination can introduce further noise, largely affecting
the outcome of experimental procedures. Thus, experimental optimization and controlling
for contaminants represent two major issues to be addressed in studies aimed at bacterial
detection in human tissues [36]. Here, we used high fidelity Q5 proof reading polymerase
and a primer pair for the V4/5 16S region which did not tend to amplify human 18S
or other related genes in the abundance of genomic human DNA. The selection of the
adequate polymerase and primer pairs seems crucial, as most of the tested primer pairs
and polymerases did not amplify bacterial DNA (Table S3, S4). To reduce contaminations
all steps were performed under a laminar flow hood in a pre-PCR room and it appeared
essential to have all utensils UV treated for at least 90 minutes [36]. In addition, nega-
tive controls (with UV treated PBS) were carried through the whole protocol for each
run including sequencing. We also accounted for potential contamination by employing a
bioinformatical statistical approach largely based on the carried through negative controls
[30]. After rigorous experimental and bioinformatic control for high risk contamination in
our low bacterial biomass samples, our results still provide clear evidence for the presence
of low amounts of bacterial DNA in AT of subjects with obesity and T2D. Admittedly,
we can only speculate about the origin of the detected bacterial DNA. Measurements of
intestinal permeability such as lactulose/mannitol test, which could indicate the translo-
cation of bacteria from gut into AT were not available for our study cohort. Moreover,
we have recently shown that the commonly used biomarker for intestinal permeability,
zonulin (pre-haptoglobin 2), was not an adequate option, since commercially available
ELISA kits do not detect pre-haptoglobin 2, but rather unspecifically measure other pro-
teins potentially related to the “zonulin family” [37] with unclear role in gut leakiness and
bacterial translocation.
One of our most compelling findings was that mesenteric AT harbored the highest bac-
terial quantity and diversity among tested ATs. Mesenteric AT could be a “gate keeper”
between the gut and systemic exposure to bacteria, clearing bacterial components before
they reach other tissues. In support of our data, experiments in mouse models show that
bacterial DNA can be robustly tracked along the intestine into AT in mice with diet in-
duced obesity [7]. This has also been corroborated in human studies where hyperglycemia
has been shown to be associated with intestinal barrier impairment [38] and the influx of
bacterial components such as LPS [39] and bacterial DNA in the circulation [7]. A con-
tradictory finding was that blood had the highest amount of bacterial DNA underlining
the relevance of other sources of bacterial DNA in the blood, such as oral cavity [40, 41]
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and skin [42].
The most commonly observed phyla in tissues tested in the present study were Firmicutes
and Proteobacteria, followed by Actinobacteria. This is in line with data by Burcelin et
al. who reported bacterial DNA in the stromal vascular fraction of human AT [35]. Sim-
ilar bacterial composition have been shown for the blood microbiome [43, 44] where a
bacterial signature has been associated with pathologies in obesity such as liver fibrosis
[44] but also with systemic inflammation in subjects with liver cirrhosis [45]. Consistent
with the “leaky gut” hypothesis and low grade inflammation of AT caused by bacterial
translocation, both quantity and distribution of bacteria were closely linked to the pa-
tients’ systemic inflammation as well as the tissue specific inflammation in our study. Our
data are, in this aspect, in line with the published literature devoted to the leaky gut
hypothesis and low grade systemic and tissue inflammation in AT. For instance, the po-
tential role of bacterial components was demonstrated by stimulation of AT macrophages
and adipocytes with LPS, which led to an increased inflammation via TLR2 and 4 and
a higher expression of TNF-α and IL-6 [46, 47]. Consequently bacterial inflammatory sig-
nature was linked to metabolic changes, whereas blood bacterial composition was mostly
related to inflammation without variation in circulatory metabolic parameters.
There are several strengths and weaknesses of the study, which have to be acknowledged.
To the best of our knowledge, this is the first contamination aware study to provide ev-
idence for the presence of bacterial DNA in human AT, and to suggest its link to the
metabolic and inflammatory status of obese patients. The relatively large sample size
with 75 metabolically well-characterized subjects and three AT depots did not only allow
for generating robust and reproducible data on bacterial DNA, but also testing for cor-
relations between the bacterial load, AT immune cell infiltration and clinical phenotypes.
On the other hand, the presence of bacterial DNA in AT does not necessarily deliver a
proof for the presence of live bacteria. Preliminary attempts to cultivate bacteria from AT
were negative (data not shown), and although our data do not rule out the presence of
live bacteria in AT, it definitely warrants further experimental work to ultimately prove
this hypothesis. It may also be desirable in the future to include lean subjects with a
healthy metabolic phenotype to be compared with patients with obesity.
In conclusion, our study provides evidence for the presence and depot-specific differences
in the amount and composition of bacterial DNA in AT of obese patients, and suggests
an important role of bacteria in molecular signatures of various AT depots potentially
contributing to metabolic sequelae of obesity.
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5.2.9 Table and Figures
all No diabetes T2D p
n 75 33 42
Age (years) 48.4 ± 11.6 45.2 ± 11.0 52.5 ± 11.3 0.006
Sex (f/m) 54/21 22/11 32/10 0.36
BMI (kg/m2) 47.9 ± 6.6 47.2 ± 5.8 48.8 ± 7.4 0.28
Glucose parameter
FPG 6.3 ± 1.9 5.4 ± 1.0 7.4 ± 2.1 0.001
FPI 153.6 ± 134.9 126.6 ± 99.5 188.7 ± 165.7 0.06
HOMA 6.9 ± 8.7 4.5 ± 3.7 9.9 ± 11.9 0.01
HbA1c (%) 6.0 ± 1.0 1.1 ± 0.2 5.5 ± 0.5 2.9x10-8
Inflammatory markers
TNF-α(pg/ml) 1.7 ± 0.9 1.4 ± 0.5 2.0 ± 1.0 0.002
IL6 (pg/ml) 4.2 ± 3.8 3.3 ± 3.0 5.3 ± 4.4 0.04
CRP 10.2 ± 10.3 7.5 ± 70 13.7 ± 12.7 0.01
LBP 12.6 ± 4.9 11.4 ± 3.9 13.9 ± 5.7 0.12
Table 5.1: Cohort characteristics
Related to Methods - Cohort characteristics
All values as mean ± standard deviation; p: Significance based on student’s t-test
T2D: type 2 diabetes, BMI: body mass index, FPG: fasting plasma glucose, FPI: fasting plasma insulin,
CRP: C-reactive protein, HbA1c: glycated hemoglobin A1c, HOMA-IR: homeostatic model assessment for
insulin resistance, IL6: interleukin 6, LBP: Lipopolysaccharide binding protein, TNF-α: Tumor necrosis
factor alpha
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Figure 5.1: Bacterial DNA quantity; A) Amount of bacterial DNA in pg/µg DNA iso-
late in all adipose tissues and blood compared to all negative controls and B) comparing
all adipose tissues with stool samples on a logarithmic scale (ng/µg DNA isolate), Box-
plots with Tukey-Whiskers and mean (black rhombus); C) Spearman’s rank correlation
plot of bacterial quantity with adipose tissue macrophages (ATM) (sc, om), tissue spe-
cific gene expression (mes, sc, om) and circulating inflammatory markers (all). Significant
values are indicated: *: p<0.05, **: p<0.01, ***: p<0.001
NC: negative control, Om: Omental, Mes: Mesenteric, Sc: Subcutaneous, bact.: bacterial, NGT: nor-
mal glucose tolerance, IGT: impaired glucose tolerance, T2D: type 2 diabetes, ATM: adipose tissue
macrophages, ADIPOQ: Adiponectin, LEP: Leptin, PPARG: Peroxisome proliferator-activated receptor
γ, CEBPA:CCAAT enhancer-binding protein alpha, IL1B and 6: Interleukin 1β and 6, TNFA(-α): Tumor
necrosis factor α, LBP: Lipopolysaccharide binding protein
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Figure 5.2: Bacterial diversity; A) Observed diversity and Shannon index in all adi-
pose tissues, blood and stool after controlling for contaminants based on genus level,
B) PCoA on Bray-Curtis dissimilarity with indication of group variances (betadisper);
C-F distance based redundancy analysis (dbRDA) with fitting of explanatory variables;
significantly impactful variables after permutation analysis are shown in red; complete ex-
planatory variables included (if applicable): Lipopolysaccharide-binding protein (LBP),
tumor necrosis factor (TNF)-α, interleukin (IL)-6, age, body mass index (BMI), C-reactive
protein (CRP), homeostatic model assessment for insulin resistance (HOMA-IR), glycated
hemoglobin (Hb) A1c, adipocyte size, adipose tissue macrophages (ATM) and bacterial
load
Om: Omental, Mes: Mesenteric, Sc: Subcutaneous
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A) Taxonomy - Phyla B) C)
D)
Figure 5.3: Taxonomy; relative distribution of phyla; A) and relative distribution of
genera belonging to Proteobacteria (B) and Firmicutes (C); D) circularized plot showing
genera and phyla with significant differential abundance (inner track) between tissues
sorted by phyla; color indicates increased presence in the respective tissue; outer circle
shows mean abundance of all present genera on a log scale
Om: Omental, Mes: Mesenteric, Sc: Subcutaneous
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Figure 5.4: Tissue bacteria and their metabolic links; A) Differential abundant
genera between subjects with and without diabetes for all AT and blood; B) correlation
analysis between presence and amount of genera with inflammatory, anthropometric and
metabolic parameters
Adip.: Adipocyte, ATM: adipose tissue macrophages, bact.: bacterial, BMI: body mass index, CRP: C-
reactive protein, HbA1c: glycated hemoglobin A1c, HOMA-IR: homeostatic model assessment for insulin
resistance, IL6: interleukin 6, LBP: Lipopolysaccharide binding protein, TNF-α: Tumor necrosis factor
alpha
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5.2.10 Supplementary Information titles
Table S1: Statistics for fit of db-RDA per tissue
Related to Results - Inflammation and insulin resistance determine the compositional
dissimilarity between tissues and Figure 2
Distance-based RDA and envfit (environmental fit) calculated on Bray-Curtis dissimilarity
using vegan, values based on 1000 permutations
Table S2: Results for differential abundance analysis using DESeq2
Related to Results - Proteobacteria and Firmicutes are the predominant phyla in AT and
Figure 4
Table S3: Tested primers and amplification combinations thereof
Related to Methods and Discussion
Table S4 Tested polymerases and results for low bacterial biomass samples
Related to Methods and Discussion
Figure S1: Alpha diversity between patients with and without T2D per tissue
AT: adipose tissue
Related to Results - Mesenteric AT exhibits highest bacterial diversity and Figure 2
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5.3 Addendum
5.3.1 Rationale
Experiments in the above-mentioned manuscript do not allow the interpretation of func-
tional consequences of bacterial DNA in adipose tissue nor do they allow addressing the




Conditionally immortalized human subcutaneous preadipocytes from a non-diabetic, 30 to
40 year old male donor (LONZA Walkersville, MD, USA) were used to analyze the effects
of bacterial DNA on adipocytes. Preadipocytes were grown in SkBM-2 medium (LONZA)
supplemented with human epidermal growth factor, dexamethasone, l-glutamine, fetal
bovine serum and gentamicin/ amphotericin-B. Preadipocytes were split onto 6-well plates
and cultured until reaching 95% confluency in 5 ml growing medium at 33°C with 5%
CO2 and 90% humidity before starting differentiation. Differentiation medium contained
DMEM with 4.5 g/L glucose and was supplemented with L-glutamine, fetal bovine serum,
gentamicin/ amphotericin-B, dexamethasone, insulin, isobutyl-methyl xanthine and in-
domethacin. Culture conditions in differentiation medium changed to 37°C with 5% CO2
and 90% humidity and preadipocytes were differentiated for 10 days. At this point, wells
contained about 380.000 viable cells. All cell culture experiments described below were run
in triplicates. Considering the quantification results in the above-mentioned manuscript
concentrations of bacterial DNA equivalent to 1% of human cells was used as lowest treat-
ment condition. The respective concentration was calculated based on the typical E. coli
genome size of 4.7 mega base pairs and consequently 0.014 ng E. coli DNA per well were
used. Additionally, 10 and 100-fold higher concentrations were used as positive controls
and cells were incubated for 4, 24 or 72 hours. An equivalent volume of water was used
as negative control for each time point. After identifying the most optimal time point
(4 hours, see Results), adipocytes were treated with same concentrations of E. coli and
human DNA as well as a combination of both in ten-fold dilutions (0.014 to 14 ng) for 4
hours. Furthermore, 400 ng of genomic human from 12 analyzed patients with and without
insulin resistance as well as a negative control (UV-treated water) were depleted of human
DNA using the NEBNext Microbiome DNA Enrichment Kit (NEB #E2612L) according
to the manufacturer’s instructions and eluted in 100µl UV-treated water. Thereof, 25 µl
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per well were used to incubate differentiated adipocytes for 4 hours.
Protein and RNA preparation
Before the cells were washed wish PBS and shock frozen, the supernatant was collected
and stored at -80°C for further experiments. For downstream analysis, RNA and pro-
teins were isolated using Qiagens AllPrep DNA/RNA/Protein Mini Kit according to the
manufacturers’ protocol. RNA was eluted in 30 µl RNAse-free water and proteins were
dissolved in 100µl of supplied buffer ALO. RNA was reverse transcribed with SuperScript
IV reverse transcriptase (Invitrogen, California, USA) using both oligo(dT) and random
primers. The final cDNA was diluted 1:6 with water for downstream qRT-PCR.
Gene expression analysis
Gene expression of genes involved in TLR signaling, inflammasome activity and insulin
resistance were measured using TaqMan probes (Applied Biosystems, California, USA;
for a complete list see Appendix). All reaction mixes contained 0.5µl probe, 5µl 2x gene
expression master mix, 1.5 µl water and 3µl cDNA dilutions. Pipetting was automated
using a pipetting robot (PIPETMAX, Gilson, Wisconsin, USA) and all experiments were
run as duplicates on a LightCycler480® (Roche, Basel, Switzerland). GAPDH, B2M and
18S were used as housekeeping genes, after testing for reference gene stability as described
in Chapter 4.4.5. Fold changes compared to the respective negative controls included in all
experiments were calculated using efficacy corrected ΔΔCt methods according to Pfaffl
et al. [187].
Catalyzed Reporter Deposition (CARD)- Fluorescence In Situ Hybridization
(FISH)
In cooperation with the group of Niculina Musat at the Umweltforschungszentrum (UFZ)
Leipzig and Shirin Tabei, adipose tissue slides were analyzed using CARD-FISH to stain
living bacteria with RNA probes. Therefore, paraffin embedded sections of 6 µm thin-
ness prepared as described in Chapter 5.2.3 for immunohistochemistry approaches were
collected on polylysine coated glass slides (3 per each slide) and further used for cell vi-
sualization by CARD-FISH using the following protocol: tissue sections were incubated
3X 5 min in 100% Xylol (The Geyer GmbH, Renningen, Germany) followed by decreased
ethanol series (3X 5 min in ethanol 99% followed by 5 min in each of the following con-
centrations 95%, 80% and 50%). After that, the slides were dipped in wash buffer (WB)
containing 20 mM Tris-HCl (pH 7.8) (Invitrogen, Carlsbad, CA, USA) for 1 min followed
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by incubation in 0.2M HCL in WB for 10 min at RT and washing for 1 min again in WB.
Permeabilization was done by dipping the glass slides containing tissue sections sequen-
tially in Proteinase K (Sigma-Aldrich, St. Louise, Missouri, USA) (10 µg mL-1) in 0.01M
Tris-HCL (pH=7.8), 0.05 EDTA (pH=8), 0.5% SDS buffer, Lysozyme (Sigma-Aldrich,
St. Louise, Missouri, USA) (10 µg mL-1) in 0.1M Tris-HCL (pH=7.8) and 0.05M EDTA
(pH=8) buffer and Achromopeptidase (Sigma-Aldrich) (60U mL-1) in 0.01M Tris-HCL,
0.01M NaCL each for 5 min at 37oC with washing steps of 1 min at RT in WB in be-
tween enzymatic treatments. The slides were air dried and the sections were circled using
Pap-pen and were prepared for the hybridization step.
The sections were hybridized for 3 h at 46°C in a pre-warmed hybridization chamber (made
out of a 50 mL Falcon tube, in a humid environment created by soaking a paper tissue
with 35% formamide in ultrapure water and place it at the bottom of the tube) using pre-
warmed hybridization buffer containing 0.9M NaCl, 20mM Tris-HCl (pH=7.5), 10% (w/v)
dextran sulfate, 0.02% (w/v) SDS, 35% (v/v) formamide (Fluka, Waltham, USA) and 1%
(w/v) blockingreagent (Boehringer, Mannheim Germany). The HRP-labelled probe con-
centration was 0.166 ng mL-1 (HRP-probe stock solution of 50 ng mL-1 diluted 1:300
v/v in hybridization buffer). Following hybridization, glass slides containing sections were
incubated in 50 mL of pre-warmed WB containing 70mM NaCl, 5mM EDTA (pH=8.0),
20mM Tris-HCl (pH=7.5), and 0.01% SDS for 15 min at 48°C. After washing, filters
were incubated for 15 min at RT in 1x PBS (pH=7.6) to equilibrate the HRP-labeled
probe. Subsequently, CARD-FISH was performed by incubating the sections for 20 min
at 46°C in the dark in amplification buffer containing 1x PBS, 2M NaCl, 0.1% (w/v)
blocking reagent, 10% (w/v) dextran sulfate, 0.0015% (v/v) H2O2, and 1 µg mL-1 Alexa
594-labeled tyramides (ThermoFisherScientific, Waltham, Massachusetts, USA). After-
wards, the slides containing sections were rinsed in 1x PBS for 10 min at RT followed by
staining with 4’,6-diamidino-2-phenylindole (DAPI) 1µg mL-1 for 10 min at RT, washing
in ultrapure water, air dried and embedded in mounting medium (a mixture of low fluo-
rescence glycerol mountant (Citifluor AF1, Citifluor, London) and mounting fluid Vecta
Shield (Vecta Laboratories Burlingame, CA) in a 4:1 v/v ratio and stored at -20°C prior
to imaging. For the CARD-FISH a mixture of HRP-labelled EUB338 I, II and III probes
and the HRP-labelled NON338 probe were used.
All the steps performed with the glass slides containing paraffin sections were performed
under sterile conditions. All the glass jars used for the above treatments were auto-
claved, MQ water was autoclaved and filter sterilized, using 0.2µm PC Isopore Membrane
(MERCK, Darmstadt, Germany) and used to prepare all buffers. The buffers were al-
ways prepared just before usage. The hybridization, washing and amplification buffers
were prepared with molecular grade DNase-, RNase-free solutions and autoclaved, filter
sterilized MQ water. In addition, we have performed controls to verify the sterility of all
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Figure 5.5: Expression of pro-inflammatory genes in subcutaneous adipose tissue
cells after treatment with E. coli DNA; A) Time-course, B) Replication of four hour
incubation
solutions. An empty polylisine coated slide was used together with the slides containing
tissue sections following steps above e.g. paraffin removing, washing and CARD-FISH.
Besides, a second control was made, a 500 µL of HB containing probe was incubated at
46°C for 3 h and further filtered on the 0.2 µm pore size GTTP type polycarbonate filter
and run for the tyramide amplification reaction being further imaged under fluorescence
microscope. NONEUB probe was used to detect the potential false positive signals on the
hybridized tissue sections.
5.3.3 Results
Bacterial DNA in the range of pg is sufficient to induce inflammation in human
AT cells
Very low amounts of bacterial DNA (E. coli) were sufficient to induce a pro-inflammatory
response in immortalized human subcutaneous adipocytes and the observed effect was
dose-dependent (see Figure 5.5 A and B). 1.4 ng of bacterial DNA, which would equate
to roughly equal amounts of bacterial and human cells, increased expression of both
TNFA and IL6 between 15 to 40-fold after 4 hours, showing a reduced effect after 24
hours and rarely any effect after 72 h (see Figure 5.5 A). After four hours, about 1.5-
fold increase in both TNFA and IL6 could be observed upon stimulation with 0.014 ng
of bacterial DNA and expression of these genes increased up to 100-fold when treated
with 14 ng bacterial DNA. Expression of IL1B and NFKB was also increased, but on
a smaller scale. No changes were observed for the NLRP3 inflammasome related gene
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human genomic DNA dilutions Enriched patient DNA
conc. [ng] FC St.dev. Patient group FC St.dev
14 0.85 0.06 IS 0.83 0.06
1.4 1.00 0.14 IR 0.89 0.06
0.14 0.86 0.06 p-value: 0.0002IL6
0.014 0.93 0.05
14 1.11 0.17 IS 0.94 0.10
1.4 1.30 0.11 IR 0.96 0.12
0.14 1.15 0.11 p-value: 0.35TNFA
0.014 1.06 0.15
14 0.99 0.02 IS 1.08 0.07
1.4 1.04 0.09 IR 1.04 0.07
0.14 1.03 0.07 p-value: 0.06IL1B
0.014 1.04 0.06
14 0.96 0.06 IS 0.95 0.07
1.4 1.03 0.07 IR 0.93 0.04
0.14 0.88 0.04 p-value: 0.12NFKB
0.014 0.91 0.04
14 0.86 0.14 IS 0.83 0.13
1.4 0.96 0.09 IR 0.89 0.10
0.14 0.82 0.12 p-value: 0.08CASP1
0.014 1.10 0.19
Table 5.2: Treatment of immortalized subcutaneous cells with human genomic DNA di-
lutions and enriched patient DNA
CASP1 (see Figure 5.5 B). Immortalized subcutaneous adipocytes were further stimulated
with varying concentration of genomic human DNA as well as enriched patient DNA as
described in the Methods section . I could not observe major effects of genomic DNA on
the cell line, if at all, expression of proinflammatory genes was reduced (Table 5.2).
Similarly, treatment with enriched patient DNA had barely an effect, but reflected the
results obtained by treatment with high concentrations of genomic DNA. Again, treatment
seemed to have a weak beneficial effect. I could not observe differences between the patient
groups apart from a significantly different TNFA expression (p=0.0002) (Table 5.2).
Visualization of bacterial cells in subcutaneous AT using CARD-FISH
In order to verify the presence of living bacteria in adipose tissue CARD-FISH using
general eubacterial probes was employed. CARD-FISH on 30 different consecutive and
randomly selected sections (at 60 µm interval) from subcutaneous adipose tissue samples
collected from three different patients was performed. The patients were selected according
to the qPCR results as belonging to the high, medium and low quantity of bacterial
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DNA. Between none and 93 EUB hybridized bacterial cells per tissue section (containing
approximately 900 adipocytes) in patient A, 5 to 12 hybridized cells in patient B and 3 to
33 cells in patient C were visualized. The hybridized cells were usually observed as single
or 2 cells together (Figure 5.6 1, C-F), rarely in a cluster of more cells (Figure 5.6, G &H).
The cell numbers were highly heterogeneous within the consecutive sections and sections of
the same patient. The positively hybridized cells were constantly observed in independent
hybridization events using EUB338I-III, in all hybridized sections of all three patients.
Hybridizations with nonsense probe (NONEUB) showed no hybridized cells (Figure 5.7,
A& C& E), although microbial cells could be observed by DAPI staining (Figure 5.7, B&
D& F).
Proper care was taken to avoid any type of contamination during tissue sample processing
and CARD-FISH. Several controls were run to check the sterility of the solutions used
(see Methods), probe specificity and potential false positive signals using nonsense probe
(NONEUB) and tyramide amplification steps without prior hybridizations (i.e. incubation
with HRP-labelled probe).
5.3.4 Discussion
To address the shortcomings of the above-mentioned manuscript I analyzed inflammatory
consequences of low concentrations of bacterial DNA on adipocytes. I could demonstrate
that DNA representing about one bacterial cell per 100 human cells is sufficient to re-
peatedly induce an inflammatory response. This response increased in a dose-dependent
manner. These results further highlight the role of adipose tissue derived bacteria in
metabolic disease. The response was strongest for IL6 and TNFA, two adipocytokines
which are expressed by adipocytes and are closely linked to an adverse metabolic pheno-
type.
Furthermore, CARD-FISH data provides qualitative information on the presence and dis-
tribution of bacterial cells in adipose tissue. The data suggests that living bacteria are
present in adipose tissue and that they are possibly in a dormant state, which is indi-
cated by their elongated shape. Due to the extremely high heterogeneity of bacterial cells
Figure 5.6 (preceding page): Representative epifluorescence micrographs obtained
by CARD-FISH using HRP-labelled EUB338 I-III probe mixture (in red) and
DAPI staining (in blue); showing the presence and distribution of hybridized bacterial
cells in the Subcutaneous Adipose Tissue (Sc AT) cross-sections. (A-B) Overview image of
Sc AT cross section (DAPI-blue) with hybridized cells (Alexa594-red). (C-F) Distribution
of single bacterial cells within the cross-section adipocyte. (G-H) Single cells cluster of
hybridized bacteria (red) and adipose tissue (purple).




Figure 5.7: Representative epifluorescence micrographs obtained by CARD-
FISH using HRP-labelled Non338 probe mixture (in red) and DAPI staining
(in blue); There was no hybridized bacteria cell to observe.
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abundances within the tissue, a CARD-FISH quantification would be possible, only if the
whole tissue sample would be sliced and visualized (e.g. approximately 1000 sections of 6
µm thickness) and a larger number of patients e.g. at least a quarter of the whole cohort
analyzed by imaging.
Still, these findings strongly support the data in the above-mentioned manuscript by show-
ing viability of adipose tissue bacteria and possible metabolic consequences. These results
also strengthen the finding that both quantity of bacterial DNA and kind of observed
bacterial genera are associated with adipose tissue specific inflammatory markers as well
as markers of insulin resistance.
Chapter 6
Identification of MHC-II alleles
contributing to the development of
type 2 diabetes
6.1 Rationale
As mentioned above, chronic low-grade inflammation in adipose tissue is one of the hall-
marks of an obesity-induced insulin resistance [215] as also supported by the results pre-
sented in the previous chapters. However, the exact mechanisms have yet to be understood.
Apart from macrophages, which were also analyzed in the preceding chapters and which
are currently one of the main research targets in obesity-induced inflammation (see Chap-
ter 4 and 5), adipose tissue harbors a wide range of other immune cells such as neutrophils,
T and B cells [216–218]. A novel mechanism in initiating obesity-associated inflammation
was presented in 2013 by Deng et al. [145] who reported that primary mouse and human
adipocytes had an enhanced expression of the genes in the major histocompatibility com-
plex II (MHCII) in obesity. Furthermore, they observed that MHCII knockout mice on
high-fat diet developed less adipose tissue inflammation and insulin resistance compared
to high-fat diet fed wild type mice with similar levels of adiposity. They concluded that
adaptive immune mechanisms could be essential to obesity-induced adipose tissue inflam-
mation [145].
Recent advances in both sequencing and bioinformatics-computational techniques allowed
the imputation of the MHCII (or human leucocyte antigen, HLA) genes based on SNP
genotyping results [219, 220]. Given the fact that previous association studies between
HLA subtypes and type 2 diabetes state lacked sufficient sample size and statistical con-
trols (i.e. no minor allele frequency or correction for multiple testing used), in the present
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study I aimed to test whether HLA class II alleles contribute to type 2 diabetes de-
velopment using SNP-imputed data and a meta-analysis approach with state of the art
statistical methods in three large population-based cohorts (the LIFE Adult [221], LIFE
Heart [222] and Sorbs cohort [223]).
The present work on HLA subtypes and type 2 diabetes was published in the Journal
of Clinical Endocrinology & Metabolism [138].
6.2 Publication
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C L I N I C A L  R E S E A R C H  A R T I C L E
HLA Class II Allele Analyses Implicate Common Genetic 
Components in Type 1 and Non–Insulin-Treated Type 2 
Diabetes
Thomas Jacobi,1,* Lucas Massier,1,* Nora Klöting,1 Katrin Horn,2,3  
Alexander Schuch,2 Peter Ahnert,2 Christoph Engel,2 Markus  Löffler,2  
Ralph Burkhardt,3,4 Joachim Thiery,3,5 Anke Tönjes,6 Michael Stumvoll,1,6  
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Department III – Endocrinology, Nephrology, Rheumatology, University of Leipzig Medical Center, 
Germany; and 7 Institute for Transfusion Medicine, University Hospital of Leipzig, Leipzig, Germany
ORCiD number: 0000-0002-0290-5423 (P. Kovacs).
Context: Common genetic susceptibility may underlie the frequently observed co-occurrence 
of type 1 and type 2 diabetes in families. Given the role of HLA class II genes in the 
pathophysiology of type 1 diabetes, the aim of the present study was to test the association of 
high density imputed human leukocyte antigen (HLA) genotypes with type 2 diabetes.
Objectives and Design: Three cohorts (Ntotal = 10 413) from Leipzig, Germany were included in 
this study: LIFE-Adult (N = 4649), LIFE-Heart (N = 4815) and the Sorbs (N = 949) cohort. Detailed 
metabolic phenotyping and genome-wide single nucleotide polymorphism (SNP) data were 
available for all subjects. Using 1000 Genome imputation data, HLA genotypes were imputed on 
4-digit level and association tests for type 2 diabetes, and related metabolic traits were conducted.
Results: In a meta-analysis including all 3 cohorts, the absence of HLA-DRB5 was associated with 
increased risk of type 2 diabetes (P = 0.001). In contrast, HLA-DQB*06:02 and HLA-DQA*01:02 
had a protective effect on type 2 diabetes (P = 0.005 and 0.003, respectively). Both alleles are 
part of the well-established type 1 diabetes protective haplotype DRB1*15:01~DQA1*01:02~D
QB1*06:02, which was also associated with reduced risk of type 2 diabetes (OR 0.84; P = 0.005). 
On the contrary, the DRB1*07:01~DQA1*02:01~DQB1*03:03 was identified as a risk haplotype 
in non–insulin-treated diabetes (OR 1.37; P = 0.002).
Conclusions: Genetic variation in the HLA class II locus exerts risk and protective effects on 
non–insulin-treated type 2 diabetes. Our data suggest that the genetic architecture of type 1 
diabetes and type 2 diabetes might share common components on the HLA class II locus. (J Clin 
Endocrinol Metab XX: 0–0, 2020)
Key Words:  HLA class II, single nucleotide polymorphism, genotype imputation, haplotype, 
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Human leukocyte antigen (HLA) is a well-known entity of adapted immune response and inflam-
mation. All mammals carry a homologous gene locus, 
known as the major histocompatibility complex 
(MHC). In humans, the HLA locus maps on chromo-
some 6 and consists of 3 groups: HLA class  I  and II 
engage in the presentation of cell intrinsic or extrinsic 
peptides respectively, while HLA class III consists of im-
mune signaling molecules such as the tumor necrosis 
factor (TNF) family. HLA class  I  and II antigens are 
constructed of 1 or 2 polymorphic chains, respectively. 
These chains show strong conservation in areas such 
as transmembrane anchors, but their peptide binding 
groove manifests an astonishingly high polymorphism, 
despite its low recombination rate. This diversity re-
sults in different binding specificity to various antigens, 
leading to heterogeneity in immune responses (1).
In the 1980s, HLA, especially the multigene haplo-
types DR3/DQ2 and DR4/DQ8, were shown to play 
a vital role in pancreas inflammation and islet cell de-
struction in type 1 diabetes (T1D) and latent-onset 
autoimmune diabetes in adults (LADA) (2, 3). Given 
the role of HLA class II in the pathophysiology of T1D, 
it seems plausible that genetic variation at HLA might 
be relevant in individuals with T2D as well. As dem-
onstrated in experimental models, a high-fat diet leads 
to increased MHC class II expression in adipose tissue 
macrophages and adipocytes in mice (4). This shift ap-
peared consecutively to the massive leptin release due 
to the diet and prior to leukocyte invasion of adipose 
tissue, thus even before inflammation occurred on a cel-
lular level. Cho et  al further showed an amelioration 
of insulin resistance and a decrease of blood glucose in 
adipose tissue–specific MHC knock-out mouse models 
on a high-fat diet, indicating a role of MHC genes in the 
development of T2D (5).
In addition, the classification of individuals into T1D 
and T2D has been recently challenged by the identi-
fication of 5 novel clusters for diabetes phenotypes 
that are associated with distinct genetic signatures (6). 
Moreover, a mixed family background for both T1D 
and T2D seems to be associated with intermediate T1D/
T2D phenotypes characterized by insulin resistance 
in T1D, and lower body mass index (BMI) and lower 
C-peptide concentrations in T2D patients (7).
However, initial genetic association studies were 
characterized by small sample sizes, resulting in a 
limited statistical power and inconsistent results. Some 
studies in populations with European ancestry reported 
moderate associations of T2D (8, 9) and its early onset 
(10) with DR3 and DR4. However, in addition to the 
small cohort sizes, these studies also analyzed serotypes 
and haplotypes with a low abundance and did usually 
not adjust for multiple testing, which negatively affected 
the reproducibility and robustness of their findings. 
Nevertheless, a more recent meta-analysis by Guo et al 
showed Bonferroni-adjusted significant associations of 
DQB1*02, DQB1*06:02, and DRB1*13:02 with the 
risk of gestational diabetes, which in turn increased the 
lifetime risk of T2D in a population of 3122 cases and 
3439 controls (11). Furthermore, with the progress of 
genome-wide association studies (GWAS), various SNPs 
in the HLA region have been shown to be associated 
with T2D (12–14). HLA-related studies were further fa-
cilitated by tools allowing imputation of HLA genotypes 
from SNP data, based on a genetic map of the HLA 
locus published in 2006 by Bakker et al (15, 16). The 
imputed genotypes significantly increased the coverage 
of genetic variation within the HLA locus, allowing 
identification of numerous alleles. This provides an ex-
cellent tool for uncovering novel genotype-phenotype 
associations. Therefore, the aim of the present study was 
to associate high-density imputed HLA class  II geno-
types with T2D in 3 independent German cohorts, and 
to test the hypothesis that established T1D HLA genes 
could be associated with T2D as well. To diminish the 
risk of including patients potentially misdiagnosed for 




Three cohorts, described in more detail below, were in-
cluded in this study. A  summary of cohort characteristics is 
provided in Table 1. A schematic overview outlining the study 
design is illustrated in Fig. 1.
LIFE-Adult and LIFE-Heart cohort
The LIFE-Adult cohort is a large population-based cohort 
of 10 000 inhabitants of the city of Leipzig, Germany (17). 
For the present analysis, 4986 randomly selected individuals 
with genotypes were available. LIFE-Heart is a cohort of 7000 
patients with suspected or confirmed coronary artery disease, 
of whom 5698 with genetic data are available (18). Being 
part of the LIFE Research Center for Civilization Diseases, 
both studies meet the ethical standards of the Declaration 
of Helsinki and are approved by the ethics committee of 
the University of Leipzig (LIFE-Adult: Reg. No 263-2009-
14122009, LIFE-Heart: Reg. No 276e2005). All subjects gave 
written informed consent including an agreement for genetic 
analyses before taking part in the study. LIFE-Heart is regis-
tered at ClinicalTrials.gov (NCT00497887).
All subjects underwent extensive clinical phenotyping, 
including measurements of BMI, waist-to-hip ratio, labora-
tory parameters (e.g., glycated hemoglobin A1c [HbA1c], 
blood glucose). Extensive metabolic characterization included 
standardized questionnaires to assess past medical history and 
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family history which comprised self-reported diabetes status. 
Assessment of medication and clinical phenotyping were per-
formed by trained personnel. Participants’ DNA was extracted 
from blood and genotyped using the Affymetrix AXIOM-CEU 
genome-wide SNP array or AXIOM-CEU CADLIFE which in 
principle contains the AXIOM-CEU as genome-wide back-
bone (Affymetrix, Santa Clara, CA) (19). After excluding pa-
tients with T1D, patients with missing information on diabetic 
state as well as those treated with insulin, 4649 (93.2% of 
the original cohort) individuals from LIFE-Adult and 4815 
(84.5%) individuals from LIFE-Heart were included in the 
present study (Table 1).
Sorbs cohort
The Sorbian people are a self-contained Slavic popula-
tion in Eastern Germany. Study subjects were recruited as 
described elsewhere (20, 21). Briefly, the participants were ex-
tensively characterized by trained personal using standardized 
questionnaires, measuring anthropometric parameters (age, 
sex, height, weight, waist and hip circumference) and param-
eters of glucose metabolism including plasma insulin and 
blood glucose levels before and after an oral glucose tolerance 
test (oGTT). Impaired glucose tolerance and T2D were de-
fined according to the ADA (American Diabetes Association) 
criteria (22). The study participants were genotyped either by 
500K Affymetrix GeneChip or by Affymetrix Genome-Wide 
Human SNP Array 6.0. All methods, including quality filtering 
and 1000 Genome imputation, are described elsewhere (23). 
After quality filtering and excluding all subjects lacking data 
on oGTT, diabetic state, and insulin treatment, 949 individ-
uals were enrolled in the present study (Table 1).
The study was approved by the ethics committee of the 
University of Leipzig and all subjects gave written informed 
consent before taking part in the study.
HLA genotype imputation
Using 1000 Genome phase 3 imputation data of both the 
LIFE cohorts and Sorb cohort, HLA genotypes were imputed 
on 4-digit level using Affymetrix Axiom HLA Analysis v1.1 
based on HLA-IMP2 (24). Genotyped or imputed SNPs of 
chromosome 6 (base position in hg19 25392022-34775445) 
with an info score of at least 0.3 and a valid Affymetrix SNP 
ID were used for this purpose. Best-guess genotypes were cal-
culated with threshold posterior probability >0.9. Maximum 
missingness per SNP was set to 3%. A total of 20 855 (LIFE-
Adult), 20 636 (LIFE-Heart), and 16 876 (Sorbs) SNPs were 
used for HLA genotype imputation.
Statistics
Statistical analyses were performed in R 3.5.1 (25) and 
SPSS 24 (IBM, Armonk). Only alleles with a minimum allele 
frequency of 5% in all 3 cohorts were considered.
To classify and compare HLA frequencies, the genetic 
distance between study cohorts and publicly available data 
from the Allele Frequency Net Database (Germany, Romania, 
Czech Republic, Slovakia, Russia–Moscow, Russia–Samara, 
Poland) (26) was calculated and visualized in a dendrogram. 
Allele frequencies of LIFE-Adult, LIFE-Heart and Sorbs co-
hort were calculated by the formula Allele/2n in equivalence to 
the Allele Frequency Net Database. For the compilation of the 

































































































































































































































































































































































































































































































































































































6 Identification of MHC-II alleles contributing to the development of type 2 diabetes 113
were used and compared by Nei’s distance (27) as calculated 
by the R package poppr (28). The genetic distance matrix was 
assembled using the R package ape (29) and the phylogram 
was visualized by FigTree (https://github.com/rambaut/
figtree/).
For statistical tests on HLA alleles, the R-package HIBAG 
ver. 3.4.0 was used (30). HLA genotypes were, if applic-
able, analyzed for associations with diabetes state, fasting 
plasma glucose, HbA1c, homeostatic model assessment for 
insulin resistance (HOMA-IR), homeostatic model assess-
ment of β-cell function (HOMA-B) (31), Stumvoll index (32) 
and age of onset, applying logistic regression for categorical 
endpoints and linear regression for continuous endpoints. 
Diabetes state was treated as a dichotomous trait. All regres-
sion analyses were adjusted for age, sex, and BMI and were 
conducted in an additive mode of inheritance. Benjamini-
Hochberg false discovery rate (FDR) correction for multiple 
testing was employed for the number of tested alleles or 
haplotypes.
To combine the 3 studies, a meta-analysis for all al-
leles complying with the above mentioned criteria was car-
ried out using the metafor v2.0-0 (33) as well as the meta 
v4.9-4 (34) package in R in a random effects model using 
DerSimonian-Laird estimate (35). Heterogeneity was as-
sessed by I2 according to Higgins and Thompson (36). DRB1-
DQA1-DQB1-haplotypes were analyzed using the BIGDAWG 
package v2.1 in R, which applies a χ 2 test in regard to diabetes 
status. Additionally, epitope correlations were analyzed using 
the BIGDAWG package (37).
Results
Population specific distribution of HLA 
genotypes
For a better understanding of the observed frequen-
cies of the analyzed subjects, frequency and genetic 
distance was compared between the 3 cohorts and pub-
licly available data from other populations. Both LIFE 
cohorts showed a high concordance in the frequency of 
MHC II alleles (Fig. 2B and 2C) and were very similar 
to the overall German population based on frequency 
data of 11  407 subjects (Nei’s distance: 0.0016). The 
Sorbs cohort however showed diverging frequencies and 
the calculated Nei’s distance, placing them between the 
LIFE and a Czech cohort, with an increased distance to 
other East European cohorts such as Polish or Russian 
(Fig. 2A and 2C).
Associations of HLA alleles with T2D and related 
metabolic traits
Since HLA class 2 alleles are well known to play a 
role in T1D pathophysiology, only this region was con-
sidered in the present study. All alleles with a minimum 
frequency of 5% in all imputed cohorts were considered 
for genetic association analyses (in total M = 34 alleles). 
Sorbs LAD LHE
N=974 N=4986 N=5698 Available participants with imputed
SNP data and HLA imputation




glucose, HOMA-IR, Stumvoll 
index
Meta analysis N=10,413 for 
diabetes
DRB1-DQA1-DQB1 haplotype
and amino acid association







Excluding patients with insulin
treatmentN=949 N=4649 N=4815
Figure 1. Study design. Abbreviations: LAD, LIFE Adult; LHE, LIFE Heart; T1D, type 1 diabetes; SNP, single nucleotide polymorphism; HOMA-IR, 
homeostatic model assessment of insulin resistance.
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Considering a threshold of 0.05 for FDR, 4 alleles were 
found to be associated with diabetes related traits. 
HLA-DQB*05:01 (3.0 × 10-3, ß = 0.21) was associated 
with fasting plasma glucose and HLA-DRB1*01:01 
with fasting plasma glucose and HOMA-IR (4.2 × 10-
4, ß  =  0.28 and 2.0 × 10-3, ß  =  0.30, respectively) in 
the Sorbs cohort. Furthermore, HLA-DQB*03:02 and 
HLA-DRB4*01:03 were significantly correlated with 
HbA1c in the LIFE Adult cohort (2.8 × 10-3, ß = 0.01 
and 1.6 × 10-3, ß = 0.01, respectively). No significant as-
sociations were observed for Stumvoll index, HOMA-B 
and age of onset (data not shown).
Albeit not significant after FDR correction in a single co-
hort, several HLA class II alleles showed nominal P values 
below 0.05 in 2 or all 3 cohorts (Fig. 3). Consequently, a 
meta-analysis was carried out for all alleles.
Meta-analysis
A meta-analysis of associations with T2D was per-
formed for all alleles with a frequency of more than 
5% in all cohorts. Except a few cases with negligible 
effects, effect direction was the same in all cohorts (data 
not shown). The most prominent effect was observed 
for the absence of DRB5 (noncoding variant, average 
frequency: 81.6%, shown as DRB5*99:01), which was 
associated with increased risk of diabetes (PFDR = 0.03, 
combined odds ratio [OR] = 1.19). Similarly, with 
a frequency of 14.5%, the most frequent DRB5 al-
lele DRB5*01:01 rendered protective effects on T2D 
(PFDR  =  0.03, combined OR = 0.83). Additionally, 3 
more alleles reached statistical significance levels after 
FDR correction in the meta-analysis: HLA-DQA*01:02 
(PFDR  =  0.03), HLA-DQB*06:02 (PFDR  =  0.04), and 
HLA-DRB1*15:01 (PFDR  =  0.04), which all rendered 
protective effects (Fig. 4).
DRB1-DQA1-DQB1 haplotype analysis
DRB1*15:01, DQA1*01:02 and DQB1*06:02 al-
leles which conveyed the strongest association with 
T2D in the meta-analysis are known to be part of a 
highly protective haplotype (DR2) in T1D (38). For 
validation, haplotype analysis was performed in regard 
to their effects on T2D and a meta-analysis was con-
ducted including all study cohorts. The DR2 haplotype 
DRB1*15:01-DQA1*01:02-DQB1*06:02 was asso-
ciated with reduced risk of non–insulin-treated T2D 
(OR = 0.87; PFDR = 0.021, I
2 = 0%; Fig. 5A). In con-
trast, DRB1*07:01-DQA1*02:01-DQB1*03:03 con-
ferred a higher risk for T2D (OR = 1.37; PFDR = 0.016, 
I2 = 6%, Fig. 5B).
Associations of HLA amino acids with T2D
Utilizing the R package “BIGDAWG”, amino acid 
correlations for the DRB1, DQA1, and DQB1 locus 
were performed and compared with data from a recent 
publication by Roark et al, who analyzed HLA epitopes 
in the context of T1D (39). After performing a meta-
analysis, significant associations with the same direction 
as in Roark et al were found for 2 epitopes (39): DRB1 
R13 (P = 0.003) and A71 (P = 0.02) were protective 
(OR = 0.86 and 0.87, respectively) for T2D. For K71, a 
T1D risk epitope, we could confirm the effect direction 
(OR = 1.10; P = 0.07). Although other epitopes did not 
show significant associations in our study, effect direc-
tions were consistent in all cases with those reported for 
T1D by Roark et al (39) (data not shown).
Discussion
Considering an emerging evidence for the role of HLA 





































































Nei distance based on HLA-A, -B, -DRB1
Figure 2. Cohort comparison based on HLA frequency with minor allele frequency above 5%. MHC II allele compared between LIFE-Adult and 
Sorbs (A) and LIFE-Adult and Heart (B); (C) Genetic distance (Nei’s) between study cohorts and publicly available frequency data based on HLA-A, -B 
and –DRB1.
























6 Identification of MHC-II alleles contributing to the development of type 2 diabetes 115
inconsistent findings in genetic association studies (40, 
41, 13, 14), we tested the association between high 
density imputed HLA genotypes with T2D in 3 German 
cohorts comprising a total of 10 413 subjects.
T2D diabetes is a disease with highly complex 
pathophysiology. With advanced knowledge about the 
underlying mechanisms, novel classifications (6) are 
emerging which may uncover previously misdiagnosed 
T2D (42). Yet, even a profound antibody characteriza-
tion of the study cohort would not elicit all known auto-
immune aspects of T2D, since autoreactive T cells can 
even be found in autoantibody negative patients with 
diabetes, indicating an influence of autoimmune signals 
on the pathogenesis of T2D (43, 44). These findings led 
to the proposition of a more continuous reception of 
the known diabetes types (45), which was further sup-
ported by studies suggesting pancreatic fat content as a 
potential classifier of diabetic states (46, 47). Moreover, 
inflammation of the pancreas is prevalent in T2D (48, 
49) and occurs prior to the first diabetes-driven meta-
bolic changes (48). To minimize the risk of including 
patients with other diabetes forms such as LADA, which 
might substantially affect the statistical analyses, we ex-
cluded all patients with insulin treatment.
We hypothesized that part of the reported inflamma-
tion in T2D is driven by HLA genotype even in non–
insulin-treated subjects with T2D. It is noteworthy that 
we performed all analyses also with the complete un-
restricted dataset including all patients with T2D (i.e., 
also insulin-treated); however, effect size and direction 
of observed associations remained materially unchanged 
(data not shown but provided in [repository]).
Taking into account all alleles with a minimum fre-
quency of 5% in all 3 cohorts, HLA-DQB*05:01 and 
HLA-DRB1*01:01 alleles were found to be significantly 
associated with fasting plasma glucose in the Sorbs co-
hort, and HLA-DQB*03:02 and HLA-DRB4*01:03 
were positively associated with HbA1c in the LIFE-
Adult cohort. After adjusting for age, sex, and BMI, as 
well as correcting for FDR in a meta-analysis in all 3 
cohorts, 5 significant association hits rendering mod-
































































































































HLA-DQA HLA-DQB HLA-DRB1 HLA-DRB3-5
Figure 3. Significance plot for associations between HLA genotype and diabetes and related traits. Abbreviations: LAD, LIFE Adult; LHE, LIFE Heart; 
HbA1c, glycated hemoglobin A1c; HOMA-IR, homeostatic model assessment of insulin resistance.
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considering the polygenic nature of T2D. The strongest 
effect was observed for the DRB5 gene, whose allele 
01:01 appeared to reduce the susceptibility to T2D 
but its absence (i.e., noncoding gene variant) in con-
trast increased the risk for T2D. DRB5 is a beta chain 
paralogue to DRB1, which means that DR-receptor 
dimers are formed by a HLA-DRA alpha chain and 
DRB1, 3, 4 or 5 ß-chain. However, apart from DRB1, 
the other DRB genes are not present in all individuals. 
Recently, 2 SNPs, a missense variant (rs701884) and a 
noncoding variant (rs2050188), in the DRB5 gene were 
reported to be associated with T2D (OR = 1.27 and 
1.06, respectively) in a large-scale GWAS (N = 48 437) 
(14), which is in line with our findings on the absence of 
DRB5. It is also suggested, that DRB3, 4, and 5 alleles 
are independently associated with the presence of islet 
autoantibodies (50).
Three more alleles, DQA*01:02, DQB*06:02, and 
DRB1*15:01 were negatively associated with T2D 
status in our study. Interestingly, these genes are building 
the DR2 haplotype known to be protective for T1D 
(38). Additionally, DRB1*15:01 and DRB5*01:01 form 
a haplotype that increases the risk for multiple sclerosis 
(51). Although Tuomi et al did not observe protective ef-
fects of DR2 and DQB*06:02 in a small Finnish cohort 
(n = 540) (52), considering larger sample size, different 
population, and advanced HLA typing and statistical 
methods, we believe that the protective effect found in 
our study is statistically sound and worth pursuing in 
the future. It has to be acknowledged that the protective 
effect of the DR2 haplotype on T2D was also evident in 
the meta-analysis after correction for FDR and addition-
ally, amino acid correlations in the DR and DQ region 
are in line with a previously published study on T1D 
(39). However, another well-established haplotype with 
protective effects on T1D, DRB1*07:01-DQA1*02:01-
DQB1*03:03 (53), significantly increased the risk of 
non–insulin-treated diabetes in our cohorts (OR = 1.37). 
Seemingly, although subjects carrying this haplotype are 






















































































Figure 4. Meta-analysis of the HLA class genes for type 2 diabetes; minor allele frequency above 5%, all results with FDR adjusted significance are 
shown. Abbreviations: OR, odds ratio; RE, random effects model.























































Figure 5. Meta-analysis of the DRB1~DQA1~DQB1 haplotype with type 2 diabetes, all results with FDR adjusted significance are shown.
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require insulin treatment in the course of their lives. In 
summary, our data suggest that both T1D and (non–
insulin-treated) T2D share common underlying mech-
anism for some of the HLA alleles, whereas others 
exhibit different effects.
Nevertheless, it has to be acknowledged that even 
in T1D, the underlying mechanisms of the established 
haplotypes, including the protective effect of haplotype 
DR2/DQ6, are not well understood; consequently, we 
can only speculate about their potential role in T2D. 
Functional interpretation of the binding properties of 
the respective diabetes susceptibility and protective al-
leles would be the ultimate goal of association studies 
like ours. This is definitely one of the major challenges 
as documented by recent and previous research in the 
field. It is well recognized that the affinity of epitopes for 
MHC molecules during antigen processing would deter-
mine whether a “diabetogenic” or “non-diabetogenic” 
epitope is presented on the antigen presenting cell sur-
face. One prediction from these models is that per-
missive and protective MHC molecules should vary 
measurably in their ability to bind disease-related pep-
tide epitopes. However, only a few such epitopes have 
been identified with certainty in humans (54). For ex-
ample, ADAMTS13, a novel risk factor for T2D (55), 
was recently identified as a binding partner of HLA-DR 
and DQ alleles (56).
In the context of our findings, both DRB1*15:01 
and DRB1*07:01 belong to the same HLA class  II 
supertype and have a similar amino acid binding 
repertoire (1). For instance, they both prefer bulky 
hydrophobic and aromatic amino acids at the P1 core 
position, small noncharged amino acids at the P6 posi-
tions and positively charged amino acids at position 8 
and 9 (51, 57–60). DRB1*15:01 and DRB5*01:01 are 
forming the commonly observed haplotype DR2 (51), 
and they present complementary peptide repertoires 
with DRB5*01:01, preferring aliphatic amino acids at 
position 1 (51). Taking into account these similarities, 
the observed differences between risk and protective 
alleles are likely to stem from the respective DQA1 and 
DQB1 alleles or further interactions. DQB1*06:02 
belongs to the DQ7 supertype (1) and DQB1*03:03 
to the DQ9 supertype (61), both binding peptides 
without type 1–like anchor residues (61). However, 
the protective DQ alleles show an increased binding 
of proinsulin, which is a well-known autoantigen in 
diabetes development (62). Moreover, mice expressing 
human HLA-DR4, a strong T1D-risk haplotype, de-
veloped diabetes after proinsulin treatment. In general, 
proinsulin induces antigen-specific regulatory T cells 
(63) and represents a highly specific marker for insulin 
resistance also in patients with T2D (64). It is possible, 
that better proinsulin binding results in faster clear-
ance of proinsulin from the circulation thus effectively 
ameliorating insulin resistance.
Furthermore, it was reported that DQ6 might pre-
vent the development of T1D through epitope stealing 
and it was shown, that the binding of addressed epitopes 
did not lead to a proinflammatory shift in CD4+-T-cells 
(65). Carriers of DQ6 could thus be protected from 
pancreatic autoimmunity, which is known to be an ag-
gravating factor in the progress of diabetes in general 
and in a decline of β-cell content in particular. Although 
this may provide one plausible explanation of the pro-
tecting role of DQ6, further experiments are warranted 
to better understand its mode of action.
In conclusion, the present study shows that genetic 
variation in the HLA class II locus exert both protective 
and enhancing effects on T2D. Our data also suggest 
that the genetic architecture of T1D and T2D might 
share common components on the HLA class II locus.
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Chapter 7
Conclusion and Outlook
With my work on the subject of “Bacterial translocation to adipose tissue in metabolic
disease” I support data from previous animal studies [131] and provide first evidence in
humans for the contribution of bacterial DNA to adipose tissue inflammation and insulin
resistance. As the tissue microbiome is currently one of the most novel studied topics
in the metabolic research field [127], further evidence from independent researchers is
essential and will definitely emerge in the near future. Especially further well-controlled
studies and functional experiments are needed to understand the importance and
role of a tissue microbiome in metabolic diseases. In my initial approaches I could
demonstrate that a very low concentration of 10 pg bacterial DNA is sufficient to induce
a pro-inflammatory response. However, it has to be acknowledged that I used bacterial
DNA as a measure of bacterial load and to test its effect on adipocytes; yet, further
bacterial components, toxins or metabolites might possibly have even larger consequences
on adipocyte biology, even at very low concentrations.
Additionally, longitudinal studies using better controls would be necessary to understand
if the observed process is acute or chronic and also happens in apparently healthy lean
subjects with a low BMI. Furthermore, for a better understanding of the increased
paracellular pathway via altered tight junction regulation, larger cohorts employing lac-
tulose/ mannitol or other reliable tests for intestinal permeability are needed. Although
biomarkers were reported and commonly used, correlations are often weak and not
correlated to gold standard measurements, rendering many results questionable [139].
Thus, increased efforts to identify novel circulating markers strongly associated with
elevated gut permeability are needed, as the measurement of biomarkes is more feasible
in large cohorts compared to gold standard methods like the lactulose/ mannitol test.
With my work I could further identify epiploic adipose tissue as a metabolically highly
active organ exhibiting distinct features clearly distinguishing patients with and without
insulin resistance. Unexpectedly, commonly measured markers of inflammation, such as
7 Conclusion and Outlook 122
TNF-α, IL-6 or adipose tissue macrophages were not increased in this colon-related fat
depot. Nonetheless, I observed an increased expression of caspase-1, IL-8 and various
other chemokine-signaling related molecules, which was supported by both transcriptome
and proteome data. This highlights the importance of identifying novel mechanisms
linking low grade adipose tissue inflammation and insulin resistance. Though not
mechanistically, I also provide data suggesting that the MHC class II proteins are crucial
in the development of insulin resistance, thus implying common molecular features
between type 1 and type 2 diabetes. Consequently, and to follow up initial results from
animal studies, further functional experiments are needed to determine the impact of
MHC molecules and the adaptive immune system on adipose tissue inflammation.
In conclusion, I could, to the best of my knowledge, provide the first contaminant-
aware evidence for the presence of bacterial DNA in human adipose tissue and highlight
the importance of investigating novel adipose tissue depots by demonstrating that
fat of the appendices epiploicae, previously only considered as a mechanic cushion, is
metabolically active and most likely involved in the development of insulin resistance.
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Alterations in composition and function of human gut microbiota can affect phys-
iological processes and are known to be associated with many diseases including
inflammatory bowel disease, hypertension, asthma and colon cancer [15, 17, 42, 167,
171]. Complex interactions between gut microbiota, environmental toxins, nutrients
and host genetics may result in an increased permeability of the gut, which is closely
linked to the presence of adverse metabolic conditions [127, 131, 139]. As a consequence,
translocation of bacterial DNA into the blood circulation increases in patients with
obesity [128-130]. Obesity is a growing health problem worldwide and often paired with
severe secondary complications, such as type 2 diabetes or cardiovascular problems [68].
A main feature of disease progression is a chronic low-grade inflammation of adipose
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tissue which contributes to the development and aggravation of insulin resistance and
many of the underlying mechanisms are still unknown [106-108]. Although data from
mice studies suggest that the presence of bacterial components in adipose tissue can
support these processes, human studies on this subject are lacking [131].
In my thesis entitled “Bacterial translocation to adipose tissue in metabolic diseas”
I provide evidence supporting the initial hypothesis, namely that bacterial DNA is
present in adipose tissue, even after stringent controlling for contaminants. To this
end, I established a wet lab routine protocol to eliminate contamination as well as a
bioinformatics pipeline accounting for contamination by subtracting negative controls.
Briefly, this included the use of lab ware and reagents UV-treated for at least 90
minutes, the use of breath protection, extra-long gloves and single-use lab coats as well
as working under a sterile laminar flood hood in a clean lab free of any PCR products.
The bioinformatics pipeline employed commonly used 16S rRNA gene analysis tools
including qiime2 [224], phyloseq [225] and DESeq2 [226] as well as decontam, a novel
tool to extract negative controls [214]. Observed quantity of bacterial DNA was in the
range of 1 to 10 pg/µg total isolated genomic DNA, which is equivalent to about 0.01 to
0.7% of bacterial cells per human cell. The highest quantity was present in subcutaneous
adipose tissue, followed by mesenteric adipose tissue. Bacterial amount correlated with
adipose tissue macrophages and PPARG expression in omental and with IL1B and TNF
expression in subcutaneous adipose tissue. Mesenteric adipose tissue showed the highest
diversity of the observed genera. The most commonly observed phyla in all tissues were
Proteobacteria and Firmicutes, which is in line with previously published data on blood
bacterial DNA [128]. Still, many genera were predominantly found in specific tissues,
e.g. Enterobacter in subcutaneous and Acinetobacter in omental adipose tissue. I further
showed that the distribution of observed features could partially be explained by markers
of insulin resistance (HOMA-IR, HbA1c) and inflammation (IL-6, TNF-α, macrophages)
and that certain genera, such as Rhodoferax or Lactobacillus are associated with type
2 diabetes status. In first functional approaches I demonstrated that concentrations of
bacterial DNA in the observed range are sufficient to stimulate an inflammatory response
in immortalized subcutaneous adipocytes derived from a healthy donor. The effect was
most prominent after four hours of treatment and increased in a dose-dependent matter
(see Chapter 5).
One of the aims in the present study was to determine levels of gut leakage by measuring
zonulin, the most commonly used biomarker for intestinal permeability in humans [139,
141], and analyze possible associations with adipose tissue bacterial signature. As there
are few well-conducted studies on circulating zonulin levels in patients with metabolic
diseases [142-144], I first performed a correlation study in the available and metabolically
well-characterized Sorbs cohort. Circulating zonulin correlated significantly positive with
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BMI, fasting glucose, triglycerides and cholesterol and negatively with HOMA-IS, high
density lipoprotein and circulating adiponectin levels. Albeit these strong correlations
with markers of glucose and lipid metabolism supported previously reported findings,
the results pointed to some inconsistencies. As zonulin is reported to be pre-haptoglobin
2 (preHP2), and about 15% percent of a typical western European population are
homozygous for haptoglobin 1, they should not express zonulin at all [117, 155]. I
confirmed in the Sorbs cohort previously reported distributions of haptoglobin genotypes
and showed that the target of the only commercially available zonulin ELISA kit was not
related to haptoglobin genotype, therefore presumably not measuring zonulin/ preHP2.
Subsequently, I identified properdin as a possible target by employing mass spectrometry
approaches. Properdin is structurally related to haptoglobin, as both proteins belong to
the mannose-associated serine protease family, however further experiments are needed
to validate a possible functional resemblance [134] (see Chapter 3).
In regard to bacterial translocation two adipose tissue depots were of notable interest
due to their close proximity to the gastrointestinal tract. Mesenteric adipose tissue is
located around the small intestine and the adipose tissue of the appendices epiploicae,
small chunks of fat also called epiploic adipose tissue, are directly attached to the colon.
After a thorough literature research I could also assert that both adipose tissues were
rarely analyzed in the context of obesity [164-166]. Therefore they were extensively
investigated by measuring gene expression of adipo(cyto)kines, circulating inflammatory
markers and analyzing adipocyte size and adipose tissue macrophages. Furthermore,
a “multiomics” characterization was conducted and by analyzing transcriptome and
methylome data I could identify epiploic adipose tissue as a tissue of interest in regard
to type 2 diabetes and insulin resistance, which was further confirmed by untargeted
proteomics data. Contrary to initial assumptions, I observed only a slight increase in
translocation of bacterial DNA and no increased inflammation, as measured by tissue
specific TNF and IL6 expression as well as adipose tissue macrophage infiltration.
However, both transcriptome and proteome profiles allowed a clear discrimination of
patients with and without insulin resistance which was most distinct in epiploic adipose
tissue. Compared to other fat depots, epiploic adipose tissue exhibited a discriminable
metabolic profile whereas mesenteric adipose tissue was more similar to omental-visceral
adipose tissue. Most strikingly, epiploic adipose tissue showed a strong increase in leptin
expression and, in general, the upregulation of various metabolic pathways involved in
sugar, amino acid or sphingolipid metabolism. In accord with the leaky gut hypothesis
high expression of lipopolysaccharide binding protein and various pathways involved in
chemokine signaling were observed. In summary, I did not observe an increase in bacterial
DNA or adipose tissue macrophages, but demonstrated elevated inflammatory signals
such as increased chemokine or IL-8 signaling which are linked with an overall increase of
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metabolic processes and an increased expression of various adipokines. Epiploic adipose
tissue might have a watch dog function by being the first adipose tissue sensing and
forwarding certain (microbial) stimuli from the large intestine to the host (see Chapter
4).
In the last part of my thesis I addressed a possible role of the HLA genomic region on the
development of type 2 diabetes. The influence of HLA genetics on type 2 diabetes has
been under debate for several decades, since HLA was recognized to largely contribute to
type 1 diabetes heritability [227]. However, studies remained inconclusive due to lacking
cohorts with sample sizes providing sufficient statistical power for association analyses
[138]. More recently, animal studies suggested MHC class II proteins as crucial factors
mediating adipose tissue inflammation and insulin resistance [145]. The sample size of
the leaky gut cohort was insufficient to determine any correlation between HLA class II
genotypes and the presence or type of bacteria in adipose tissue due to the high variability
in the observed genomic region. Yet, I had access to three large population-based cohorts
which allowed me to analyze associations between HLA class II alleles and type 2
diabetes. Therefore HLA genotypes of the LIFE-Adult (N=4649), LIFE-Heart (N=4815)
and Sorbs (N=949) cohort were imputed from SNP genotyping data and analyzed
for association with type 2 diabetes. In a meta-analysis including all three cohorts, I
identified a protective effect for the well-established type 1 diabetes protective haplotype
DRB1*15:01 ˜ DQA1*01:02 ˜ DQB1*06:02 and confirmed DRB1*07:01 ˜ DQA1*02:01
˜ DQB1*03:03 as a risk haplotype in non-insulin treated diabetes. These results suggest
that the genetic foundation of both type 1 and 2 diabetes shares common elements
involving the HLA class II locus (Chapter 6).
In conclusion, to the best of my knowledge, I provide in my work the first contaminant-
aware identification of bacterial DNA in human adipose tissue and highlight the
importance of analyzing novel adipose tissue depots by showing that fat of the appen-
dices epiploicae, previously only considered to have a cushioning function, is metabolically
active and possibly involved in the development of insulin resistance.
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A.1 Supplements Chapter 4
Supplementary Tables 
Table S1: 24 subject – cohort characteristics 
  No T2D n T2D n p 
Age [years] 44.8 ± 11.5 9 45.3 ± 9.3 15 0.90 
Sex [female/male] 7/2 9 10/5 15 0.56+ 
BMI [kg/m²] 46.6 ± 5.3 9 48.2 ± 6.8 15 0.55 
FPG [mmol/l] 5.0 ± 0.4 9 8.2 ± 2.5 15 1.7E-4 
FPI [pmol/l] 51.2 ± 26.2 9 243.1 ± 170.4 15 6.5E-4 
HOMA-IR 1.6 ± 0.7 9 13.8 ± 14.5 15 0.006 
HbA1c [%] 5.2 ± 0.3 9 6.9 ± 1.0 15 2.2E-5 
Lipid markers           
HDL [mmol/l] 1.3 ± 0.5 9 1.0 ± 0.3 15 0.15 
LDL [mmol/l] 2.7 ± 0.7 9 2.3 ± 0.8 15 0.33 
Triglycerides [mmol/l] 1.0 ± 0.4 9 2.3 ± 2.5 15 0.16 
Body fat [%] 48.8 ± 9.4 9 44.1 ± 9.9 12 0.29 
Blood cells           
Leucocytes [Gpt/l] 7.4 ± 2.7 9 8.4 ± 2.5 15 0.38 
Erythrocytes [Tpt/l] 4.9 ± 0.4 9 4.8 ± 0.4 15 0.68 
Thrombocytes [Gpt/l] 258.2 ± 80.2 9 267.1 ± 67.5 15 0.77 
Inflammation           
LBP [µg/ml] 10.0 ± 4.0 7 13.5 ± 4.0 15 0.07 
TNF-? [pg/ml] 1.5 ± 0.6 7 1.8 ± 0.9 15 0.44 
IL-6 [pg/ml] 2.7 ± 1.8 7 5.6 ± 4.7 15 0.13 
CRP [mg/l] 8.9 ± 7.1 9 11.6 ± 9.6 15 0.48 
Life style           
Tobacco [ever/never] 3/3 6 5/0 5 0.06+ 
Alcohol [yes/no] 3/3 6 2/2 4 1.00+ 
 
Table S2: 18 subject – cohort characteristics 
  No T2D n T2D n p 
Age [years] 44.8 ± 11.5 9 44.9 ± 10.6 9 0.98 
Sex [female/male] 7/2 9 5/4 9 0.32 
BMI [kg/m²] 46.6 ± 5.3 9 47.3 ± 5.1 9 0.78 
FPG [mmol/l] 5.0 ± 0.4 9 7.9 ± 2.6 9 0.01 
FPI [pmol/l] 51.2 ± 26.2 9 254.6 ± 189.5 9 0.01 
HOMA-IR 1.6 ± 0.7 9 14.4 ± 17.6 9 0.06 
HbA1c [%] 5.2 ± 0.3 9 6.7 ± 0.7 9 2.3 x E-4 
Lipid markers           
HDL [mmol/l] 1.0 ± 0.5 9 1.0 ± 0.3 9 0.16 
LDL [mmol/l] 2.7 ± 0.7 9 2.3 ± 0.9 9 0.34 
Triglycerides [mmol/l] 1.0 ± 0.4 9 2.6 ± 3.2 9 0.15 
Body fat [%] 48.8 ± 9.4 9 42.5 ± 12.0 9 0.25 
Blood cells           
Leucocytes [Gpt/l] 7.4 ± 2.7 9 8.8 ± 2.7 9 0.28 
Erythrocytes [Tpt/l] 4.9 ± 0.4 9 5.0 ± 0.3 9 0.51 
Thrombocytes [Gpt/l] 258.2 ± 80.2 9 257.9 ± 70.0 9 0.99 
Inflammation           
LBP [µg/ml] 10.0 ± 4.0 7 13.3 ± 4.2 9 0.14 
TNF-alpha [pg/ml] 1.0 ± 0.6 7 2.0 ± 1.1 9 0.26 
IL-6 [pg/ml] 2.7 ± 1.8 7 6.0 ± 5.2 9 0.14 
A Supplementary Material II
CRP [mg/l] 8.9 ± 7.1 9 7.0 ± 5.5 9 0.53 
Life style           
Tobacco [ever/never] 3/3 6 2/0 2 0.21 
Alcohol [yes/no] 3/3 6 1/1 2 1.00 
 
Table S3: Gene expression; tissue comparison 
Gene Mean values [AU] Statistics 







ADIPOQ 3.8E+00 ± 2.8E+00 3.2E+00 ± 2.1E+00 2.2E+00 ± 1.5E+00 2.8E+00 ±1.8E+00 1.1E-02 1.6E-07 4.7E-03 
CASP1 2.1E-01 ± 9.1E-02 1.3E-01 ± 5.8E-02 1.3E-01 ± 4.2E-02 1.0E-01 ±5.4E-02 6.8E-09 4.1E-10 8.4E-12 
CCL2 6.3E-02 ± 5.0E-02 6.6E-02 ± 1.3E-01 8.4E-02 ± 6.9E-02 9.0E-02 ±1.2E-01 5.0E-02 1.3E-01 1.1E-01 
CEBPA 6.7E-01 ± 2.6E-01 4.6E-01 ± 1.7E-01 3.7E-01 ± 1.8E-01 4.8E-01 ±2.7E-01 1.0E-08 5.6E-11 1.6E-06 
GRN 9.3E-01 ± 2.9E-01 5.9E-01 ± 2.2E-01 4.8E-01 ± 2.1E-01 6.0E-01 ±3.2E-01 1.1E-10 4.7E-12 8.5E-10 
IL1B 8.4E-03 ± 8.6E-03 8.1E-03 ± 1.9E-02 9.1E-03 ± 7.4E-03 7.4E-03 ±6.8E-03 1.4E-02 5.8E-01 2.5E-01 
IL6 1.5E-02 ± 1.2E-02 1.8E-02 ± 4.0E-02 2.4E-02 ± 4.3E-02 1.6E-02 ±2.8E-02 2.9E-01 3.8E-01 2.1E-02 
INFG 7.7E-05 ± 7.5E-05 6.1E-05 ± 1.2E-04 6.7E-05 ± 7.3E-05 4.0E-05 ±3.6E-05 2.6E-03 4.9E-02 9.4E-06 
LEP 1.9E+00 ± 1.1E+00 3.5E-01 ± 5.8E-01 6.7E-02 ± 4.7E-02 2.4E-02 ±2.8E-02 1.9E-11 5.2E-13 5.2E-13 
LEPR 7.0E-01 ± 3.2E-01 6.0E-01 ± 5.0E-01 3.8E-01 ± 3.0E-01 6.1E-01 ±4.5E-01 2.8E-03 6.4E-08 1.3E-01 
NLRP3 1.3E-01 ± 6.0E-02 2.4E-01 ± 6.6E-01 1.6E-01 ± 1.1E-01 1.4E-01 ±1.2E-01 6.5E-03 1.5E-01 1.4E-01 
PGC1A 3.7E-02 ± 1.4E-02 3.1E-02 ± 2.1E-02 3.8E-02 ± 2.1E-02 2.4E-02 ±1.8E-02 1.2E-03 8.2E-01 2.7E-06 
PPARG 3.4E-01 ± 1.0E-01 2.2E-01 ± 7.4E-02 2.0E-01 ± 8.6E-02 1.9E-01 ±8.5E-02 1.3E-10 1.9E-11 1.8E-12 
PYCARD 7.6E-02 ± 3.5E-02 1.1E-01 ± 2.0E-01 9.6E-02 ± 2.9E-02 7.5E-02 ±5.1E-02 6.2E-02 2.5E-04 4.6E-01 
RARRES2 4.3E+00 ± 1.7E+00 2.5E+00 ± 8.8E-01 2.5E+00 ± 8.6E-01 2.1E+00 ±1.1E+00 8.4E-12 2.3E-12 3.6E-12 
SREBP1C 1.2E-01 ± 7.2E-02 1.2E-01 ± 7.9E-02 7.4E-02 ± 3.8E-02 1.1E-01 ±7.9E-02 3.8E-01 6.6E-08 2.4E-01 
TLR2 2.9E-02 ± 1.2E-02 2.9E-02 ± 5.9E-02 2.5E-02 ± 2.2E-02 1.6E-02 ±1.2E-02 7.7E-05 2.6E-03 2.6E-08 
TLR4 9.1E-02 ± 3.6E-02 1.1E-01 ± 2.1E-01 8.0E-02 ± 3.7E-02 7.4E-02 ±1.0E-01 9.3E-01 3.1E-02 3.8E-08 
TLR9 1.0E-02 ± 6.3E-03 6.7E-03 ± 1.3E-02 4.2E-03 ± 2.4E-03 4.0E-03 ±3.2E-03 1.6E-06 3.6E-09 1.6E-09 
TNFA 4.6E-03 ± 3.0E-03 5.9E-03 ± 1.4E-02 4.0E-03 ± 2.4E-03 4.9E-03 ±3.3E-03 4.3E-01 4.4E-02 5.8E-01 
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Figure A.1: Alpha diversity between patients with and without T2D per tissue
Tables
Supplementary Tables  
Supplementary Table 1: Statistics for fit of db-RDA per tissue; 1000 permutations 
 dbRDA1 dbRDA2 R² P(r) 
Mesenteric  
LBP 0.24 -0.97 0.07 0.20 
TNFA 0.94 0.35 0.03 0.51 
IL6 -0.20 -0.98 0.16 0.04 
age -0.94 -0.35 0.02 0.60 
BMI -0.46 -0.89 0.15 0.03 
CRP -0.22 -0.98 0.09 0.09 
HOMA 0.81 -0.59 0.88 0.001 
HbA1c 0.24 -0.97 0.12 0.06 
Bact load 0.98 0.18 0.82 0.001 
Omental  
LBP 0.35364 -0.93538 0.28 0.003 
TNFA_Serum 0.68956 0.72423 0.17 0.017 
IL6_Serum 0.42405 -0.90564 0.07 0.203 
age -0.99998 0.00672 0.06 0.287 
BMI -0.13176 0.99128 0.13 0.053 
CRP -0.72075 -0.69319 0.06 0.235 
HOMA 0.99839 -0.05671 0.57 0.001 
HbA1c 0.68907 -0.7247 0.1 0.095 
Adipocyte_size 0.27558 -0.96128 0.02 0.665 
ATM 0.61315 -0.78997 0.01 0.734 
bact_load 0.99873 -0.0504 0.22 0.007 
Subcutaneous  
LBP 0.94998 -0.31232 0.08 0.177 
TNFA_Serum -0.19994 0.97981 0.28 0.003 
IL6_Serum -0.60836 -0.79366 0.1 0.089 
age 0.45129 -0.89238 0.06 0.254 
BMI 0.67544 -0.73742 0 0.932 
CRP 0.91348 -0.40689 0.47 0.001 
HOMA 0.93652 0.35061 0.11 0.08 
HbA1c -0.21669 0.97624 0.14 0.037 
Adipocyte_size -0.99888 -0.04723 0.01 0.779 
ATM -0.78253 0.62261 0.16 0.024 
bact_load 0.84125 0.54065 0.29 0.005 
Blood  
LBP -0.98464 -0.17461 0.19 0.008 
TNFA_Serum -0.14505 0.98942 0.44 0.001 
IL6_Serum -0.97247 -0.23301 0.49 0.001 
age -0.93292 0.36009 0.27 0.001 
BMI 0.92286 0.38513 0.02 0.564 
CRP -0.63027 0.77638 0.33 0.001 
HOMA 0.59456 0.80405 0.01 0.708 
HbA1c -0.1643 0.98641 0.11 0.066 
bact_load 0.71806 -0.69599 0.08 0.117 
 
  
A Supplementary Material V
Supplementary Table 2: Statistics differential abundance (DESeq2) 
Phylum Level 
baseMean log2FC lfcSE stat pvalue padj Phylum 
 
omental vs blood 
2.18 -2.49 2.37 -1.05 2.9E-01 8.3E-01 Patescibacteria 
 
0.20 -1.62 2.90 -0.56 5.8E-01 8.3E-01 Armatimonadetes 
 
41.46 -13.11 2.90 -4.53 6.0E-06 3.9E-05 Chloroflexi 
 
10.03 -27.62 2.90 -9.53 1.6E-21 2.1E-20 Planctomycetes 
 
11.72 1.72 1.83 0.94 3.5E-01 8.3E-01 Actinobacteria 
 
0.00 -0.50 1.21 -0.41 6.8E-01 8.9E-01 Gemmatimonadetes 
 
1395.24 1.98 0.68 2.92 3.5E-03 1.5E-02 Firmicutes 
 
0.40 -2.10 2.90 -0.72 4.7E-01 8.3E-01 Tenericutes 
 
0.28 -1.82 2.90 -0.63 5.3E-01 8.3E-01 Bacteroidetes 
 
16481.48 0.37 0.61 0.61 5.4E-01 8.3E-01 Proteobacteria 
 
mesenteric vs blood 
15.05 7.12 2.89 2.46 1.4E-02 2.9E-02 Cyanobacteria 
 
0.22 -2.90 2.90 -1.00 3.2E-01 3.9E-01 Armatimonadetes 
 
42.73 -6.82 2.75 -2.48 1.3E-02 2.9E-02 Chloroflexi 
 
10.68 -27.31 2.90 -9.42 4.4E-21 5.7E-20 Planctomycetes 
 
1322.63 9.72 2.18 4.46 8.3E-06 5.4E-05 Actinobacteria 
 
10.30 7.65 2.57 2.97 3.0E-03 1.3E-02 Elusimicrobia 
 
0.05 -1.20 2.90 -0.42 6.8E-01 7.3E-01 Gemmatimonadetes 
 
1422.09 1.73 0.60 2.88 4.0E-03 1.3E-02 Firmicutes 
 
0.40 -2.83 2.90 -0.98 3.3E-01 3.9E-01 Tenericutes 
 
0.93 -0.58 2.34 -0.25 8.0E-01 8.0E-01 Fusobacteria 
 
0.32 -3.15 2.90 -1.09 2.8E-01 3.9E-01 Bacteroidetes 
 
30.30 3.16 1.31 2.42 1.6E-02 2.9E-02 Patescibacteria 
 
15691.88 1.09 0.56 1.94 5.2E-02 8.4E-02 Proteobacteria 
 
subcutaneous vs blood 
0.20 -2.27 2.53 -0.90 3.7E-01 4.6E-01 Cyanobacteria 
 
0.25 -3.56 2.86 -1.24 2.1E-01 3.2E-01 Armatimonadetes 
 
57.73 -13.79 2.89 -4.76 1.9E-06 2.3E-05 Chloroflexi 
 
18.58 -4.15 2.89 -1.44 1.5E-01 3.1E-01 Planctomycetes 
 
29.27 3.63 1.70 2.14 3.3E-02 1.4E-01 Actinobacteria 
 
0.78 0.47 2.89 0.16 8.7E-01 8.7E-01 Elusimicrobia 
 
2423.65 0.55 0.63 0.87 3.9E-01 4.6E-01 Firmicutes 
 
0.57 -4.13 2.90 -1.43 1.5E-01 3.1E-01 Tenericutes 
 
25.28 4.44 2.57 1.73 8.4E-02 2.5E-01 Fusobacteria 
 
1.13 -3.64 2.90 -1.26 2.1E-01 3.2E-01 Bacteroidetes 
 
41.68 3.48 1.65 2.12 3.4E-02 1.4E-01 Patescibacteria 
 
16250.03 0.47 0.61 0.77 4.4E-01 4.8E-01 Proteobacteria 
 
omental vs mesenteric 
13.82 -7.55 2.90 -2.61 9.1E-03 2.3E-02 Cyanobacteria 
 
3.54 -3.33 2.83 -1.18 2.4E-01 3.0E-01 Chloroflexi 
 
1265.84 -6.63 1.74 -3.81 1.4E-04 6.1E-04 Actinobacteria 
 
9.66 -9.75 2.61 -3.74 1.8E-04 6.1E-04 Elusimicrobia 
 
0.04 1.02 0.86 1.18 2.4E-01 3.0E-01 Gemmatimonadetes 
 
2535.17 0.91 0.61 1.49 1.4E-01 2.3E-01 Firmicutes 
 
0.04 1.15 0.69 1.67 9.5E-02 1.9E-01 Tenericutes 
 
0.34 0.33 1.42 0.23 8.2E-01 8.2E-01 Fusobacteria 
 
24.21 -6.98 1.59 -4.39 1.2E-05 1.2E-04 Patescibacteria 
 
24708.17 0.12 0.49 0.25 8.0E-01 8.2E-01 Proteobacteria 
 
omental vs subcutaneous 
1.15 3.74 2.90 1.29 2.0E-01 4.3E-01 Cyanobacteria 
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0.01 2.15 0.94 2.27 2.3E-02 6.3E-02 Chloroflexi 
 
0.64 -0.82 2.89 -0.28 7.8E-01 8.2E-01 Planctomycetes 
 
46.03 -0.57 1.61 -0.35 7.2E-01 8.2E-01 Actinobacteria 
 
0.59 -0.65 2.89 -0.22 8.2E-01 8.2E-01 Elusimicrobia 
 
0.01 2.22 0.94 2.36 1.8E-02 6.3E-02 Gemmatimonadetes 
 
4147.83 0.39 0.62 0.63 5.3E-01 7.3E-01 Firmicutes 
 
14.06 -7.00 2.75 -2.54 1.1E-02 6.0E-02 Fusobacteria 
 
0.55 2.10 2.90 0.72 4.7E-01 7.3E-01 Bacteroidetes 
 
36.89 -7.40 1.82 -4.07 4.7E-05 5.2E-04 Patescibacteria 
 
29047.32 0.53 0.52 1.01 3.1E-01 5.7E-01 Proteobacteria 
 
subcutaneous vs mesenteric 
1.64 -3.21 2.90 -1.11 2.7E-01 5.3E-01 Cyanobacteria 
 
2732.19 -6.49 1.72 -3.77 1.6E-04 2.0E-03 Actinobacteria 
 
21.42 -4.90 2.49 -1.96 5.0E-02 1.6E-01 Elusimicrobia 
 
5.60 -5.57 2.89 -1.92 5.4E-02 1.6E-01 Chloroflexi 
 
15.48 5.11 2.17 2.36 1.8E-02 1.1E-01 Fusobacteria 
 
32540.68 -0.69 0.49 -1.42 1.6E-01 3.7E-01 Proteobacteria 
 
Genus level 
baseMean log2FC lfcSE stat pvalue padj Phylum 
 
omental vs blood 
36.55 -29.09 2.90 -10.04 1.0E-23 3.9E-22 Chloroflexi UTCFX1 
6.80 -5.90 2.32 -2.55 1.1E-02 4.6E-02 Firmicutes Lactococcus 
2348.03 3.99 1.05 3.79 1.5E-04 8.2E-04 Firmicutes Streptococcus 
1.96 -26.57 2.90 -9.16 5.1E-20 3.2E-19 Proteobacteria 
 
12.94 -27.61 2.82 -9.79 1.3E-22 1.6E-21 Proteobacteria Bdellovibrio 
4.09 -8.15 2.90 -2.81 4.9E-03 2.3E-02 Proteobacteria Tahibacter 
67639.97 9.36 1.02 9.22 2.9E-20 2.2E-19 Proteobacteria Acinetobacter 
7.49 -28.39 2.90 -9.79 1.2E-22 1.6E-21 Proteobacteria Sutterella 
5.14 -27.88 2.90 -9.62 6.7E-22 6.4E-21 Proteobacteria Delftia 
mesenteric vs blood 
54.05 -9.39 2.89 -3.25 1.2E-03 4.8E-03 Chloroflexi UTCFX1 
2.41 -25.61 2.90 -8.83 1.0E-18 5.5E-18 Proteobacteria 
 
48.03 30.00 2.90 10.36 4.0E-25 1.5E-23 Proteobacteria Pseudochrobactrum 
16.91 -28.21 2.90 -9.74 2.1E-22 3.9E-21 Proteobacteria Methylocystis 
5.92 -26.82 2.90 -9.25 2.2E-20 1.7E-19 Proteobacteria Tahibacter 
3.58 26.16 2.90 9.02 1.8E-19 1.1E-18 Proteobacteria Escherichia-Shigella 
5259.91 5.84 0.89 6.53 6.4E-11 3.0E-10 Proteobacteria Acinetobacter 
9.91 27.84 2.90 9.61 7.5E-22 9.2E-21 Proteobacteria Thauera 
6.38 -26.92 2.90 -9.29 1.6E-20 1.5E-19 Proteobacteria Delftia 
442.50 6.70 2.47 2.71 6.7E-03 2.5E-02 Proteobacteria Rhodoferax 
subcutaneous vs blood 
43.25 -13.24 2.90 -4.57 4.9E-06 1.6E-05 Chloroflexi UTCFX1 
13.20 28.12 2.51 11.19 4.6E-29 1.5E-27 Firmicutes Gemella 
719.71 -8.26 2.89 -2.86 4.2E-03 1.1E-02 Firmicutes Lactobacillus 
2098.89 3.03 0.93 3.26 1.1E-03 3.2E-03 Firmicutes Streptococcus 
2.29 -26.24 2.90 -9.05 1.5E-19 5.9E-19 Proteobacteria 
 
16.13 -28.88 2.90 -9.97 2.1E-23 2.3E-22 Proteobacteria Methylocystis 
15.99 -28.87 2.79 -10.34 4.6E-25 7.3E-24 Proteobacteria Bdellovibrio 
7.85 27.55 2.90 9.51 1.9E-21 1.2E-20 Patescibacteria 
uncultured 
bacterium 
4.82 -27.24 2.90 -9.40 5.7E-21 3.1E-20 Proteobacteria Tahibacter 
5.33 26.51 2.90 9.15 5.9E-20 2.7E-19 Proteobacteria Enterobacter 
2664.98 4.90 0.87 5.62 1.9E-08 6.7E-08 Proteobacteria Acinetobacter 
11.56 -28.43 2.90 -9.81 1.0E-22 8.3E-22 Proteobacteria Sutterella 
omental vs mesenteric 
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178.70 -30.00 2.90 -10.35 4.0E-25 3.7E-23 Proteobacteria Pseudochrobactrum 
6.08 -28.18 2.90 -9.72 2.5E-22 7.7E-21 Proteobacteria Thauera 
8.92 -28.68 2.90 -9.90 4.3E-23 2.0E-21 Proteobacteria Deefgea 
3.81 -27.53 2.90 -9.49 2.2E-21 5.2E-20 Proteobacteria uncultured 
omental vs subcutaneous 
2.66 -27.03 2.90 -9.32 1.1E-20 2.6E-19 Elusimicrobia 
uncultured 
bacterium 
5.07 -27.91 2.90 -9.63 6.0E-22 1.9E-20 Patescibacteria 
uncultured 
bacterium 
21.46 -29.90 2.90 -10.32 5.7E-25 2.8E-23 Proteobacteria Enterobacter 
63369.91 2.50 0.83 3.02 2.5E-03 4.6E-02 Proteobacteria Acinetobacter 
25.22 -29.88 2.90 -10.32 6.0E-25 2.8E-23 Proteobacteria uncultured 
subcutaneous vs mesenteric 
2.28 -26.26 2.90 -9.05 1.4E-19 2.5E-18 Firmicutes Nosocomiicoccus 
11.03 25.00 2.49 10.04 9.9E-24 3.6E-22 Firmicutes Gemella 
26.07 -29.58 2.90 -10.21 1.8E-24 1.0E-22 Proteobacteria Sphingopyxis 
284.47 -30.00 2.90 -10.36 3.9E-25 4.3E-23 Proteobacteria Pseudochrobactrum 
6.57 25.97 2.90 8.96 3.2E-19 5.0E-18 Patescibacteria 
uncultured 
bacterium 
30.55 28.14 2.90 9.71 2.6E-22 5.7E-21 Proteobacteria Enterobacter 
11.56 -28.46 2.90 -9.82 9.2E-23 2.5E-21 Proteobacteria Deefgea 
 
Supplementary Table 3: Tested primers and amplification combinations thereof 
Name Sequence (5’-3’) Reference 
BAc08F agagtttgatcctggctcag (Baker et al., 2003; Salipante et al., 2013) 
V3-R attaccgcggctgctgg (Claesson et al., 2010) 
V3-F actcctacgggaggcagcag (Claesson et al., 2010) 
V4-F actgggcgtaaagcg (Claesson et al., 2010) 
V5-R ccgtcaattcctttgagttt (Claesson et al., 2010) 
V6-R cgacagccatgcagcacct (Claesson et al., 2010) 
R1492-R tacggttaccttgttacgactt (Baker et al., 2003) 
V6-F ttgacgggggcccgcac (Salipante et al., 2013) 
Uni1390-R gacgggcggtgtgtacaa (Siala et al., 2008) 
806-R ggactaccagggtatctaat (Bik et al., 2006) 
927-R cccgtcaattcatttgagtt (Bik et al., 2006) 
63-F gcaggcctaacacatgcaagtc (Claesson et al., 2010) 
355-R ctgctgcctcccgtaggagt (Claesson et al., 2010; Salipante et al., 2013) 
8-fw agagtttgatymtggctcag (Klindworth et al., 2012) 
357-rev ctgctgcctyccgta (Klindworth et al., 2012) 
341-fw cctacgggnggcwgcag (Klindworth et al., 2012) 
805-rev gactachvgggtatctaatcc (Klindworth et al., 2012) 
785-fw ggmttagatacccbdgta (Klindworth et al., 2012) 
1068-rev ctgacgrcrgccatgc (Klindworth et al., 2012) 
1053-fw gcatggcygycgtcag (Klindworth et al., 2012) 
1510-rev rgytaccttgttacgactt (Klindworth et al., 2012) 
564-fw aytgggydtaaagng (Klindworth et al., 2012) 
540-rev ctnygtmttaccgcggctgc (Klindworth et al., 2012) 
8-fw-short agagtttgatcmtggc (Klindworth et al., 2012) 
357-rev-long tgctgcctcccgtaggagt (Klindworth et al., 2012) 
V-region Results 
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V1-2 Additional but distinguishable human product 
V1-3 One band with human product 
V1-4 Only bacterial product, but low yield 
V1-5 Only bacterial product, but low yield 
V3 One band with human product 
V3-6 Only bacterial product, but low yield 
V4-5 Only bacterial product, good results 
V4-6 Only bacterial product, but low yield 
V4-9 Only bacterial product, but low yield 
V6 Two bands with human products 
V6-8 Only bacterial product, good results 
V6-9 Low yield 
 
Supplementary Table 4: Tested polymerases and results for low bacterial biomass samples 
Polymerase Results Supplier 
Taq DNA polymerase, recombinant 
5 U/µl 
No products ThermoFisher (#EP0402) 
Accuprime HS  No products ThermoFisher (#12339016) 
VitaTaq Only NC were amplified  Procomcure Biotech 
FastStart PCR master Good results, i.e. amplified 
samples and NC were clean 
Sigma-Aldrich 
Biozym Long Range PCR No products Biozym 
Phusion II (HS) Contaminated ThermoFisher (F549S) 
GoTaq Good results, i.e. amplified 
samples and NC were clean 
Promega 
Q5 high fidelity HS Good results, i.e. amplified 
samples and NC were clean 
NEB 
DreamTaq Some NC contaminated ThermoFisher 
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Hiermit erkläre ich, dass ich die vorliegende Arbeit selbstständig und ohne unzulässige
Hilfe oder Benutzung anderer als der angegebenen Hilfsmittel angefertigt habe. Ich
versichere, dass Dritte von mir weder unmittelbar noch mittelbar eine Vergütung oder
geldwerte Leistungen für Arbeiten erhalten haben, die im Zusammenhang mit dem Inhalt
der vorgelegten Dissertation stehen, und dass die vorgelegte Arbeit weder im Inland
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